<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430928</article-id><article-id pub-id-type="pmcid-ver">PMC12430928.1</article-id><article-id pub-id-type="pmcaid">12430928</article-id><article-id pub-id-type="pmcaiid">12430928</article-id><article-id pub-id-type="pmid">40549442</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002668</article-id><article-id pub-id-type="publisher-id">IJS-D-25-00547</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="L">Lingxia</given-names></name><degrees>MSc</degrees><email>clx20211008@126.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="Y">Yu</given-names></name><degrees>PhD</degrees><email>caoyu0709@139.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shihao</given-names></name><degrees>MSc</degrees><email>lancer001011@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="L">Lukai</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jianjun</given-names></name><degrees>MSc</degrees><email>267355869@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bao</surname><given-names initials="J">Ji</given-names></name><degrees>PhD</degrees><email>baoji@scu.edu.cn</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="G">Guan</given-names></name><degrees>PhD</degrees><email>guan8079@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="P">Ping</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Emergency Department, Zigong Fourth People&#8217;s Hospital, Sichuan, China</aff><aff id="aff2"><label>b</label>State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Sichuan, China</aff><aff id="aff3"><label>c</label>Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Sichuan, China</aff><aff id="aff4"><label>d</label>Institute of Medical Big Data, Zigong Academy of Artificial Intelligence and Big Data for Medical Science,Sichuan, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Sichuan, China. E-mail: <email>baoji@scu.edu.cn</email> (J. Bao); Emergency Department, Zigong Fourth People&#8217;s Hospital, Sichuan, China. E-mail: <email>guan8079@163.com</email> (G. Wang); Institute of Medical Big Data, Zigong Academy of Artificial Intelligence and Big Data for Medical Science, Sichuan, China. E-mail: <email>xp1657@126.com</email> (P. Xu).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6260</fpage><lpage>6289</lpage><history><date date-type="received"><day>25</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbysalicense">https://creativecommons.org/licenses/by-sa/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons Attribution-ShareAlike License 4.0</ext-link>, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6260.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6260.pdf"/><abstract><p>Sepsis is a life-threatening multi-organ dysfunction caused by the dysregulated systemic inflammatory and immune responses in the host to an infection. Despite continuous advances in the treatment of sepsis, its high morbidity and mortality seriously challenge global public health. Symptomatic treatments are currently applied to sepsis patients, while precise treatments acting on the individualized etiological and pathogenic factors are scant. To address the issue, the present review aims to illustrate the pathogenic mechanisms of Gram-negative bacteria, the immune imbalance of co-existing continuous inflammation and immunosuppression, and the increased susceptibility resulting from the imbalanced gut microbiota. Moreover, we summarized the therapeutic strategies for sepsis and the development of precise treatment acting on sepsis patients&#8217; individualized subphenotypes and immune statuses. From the perspectives of etiological factors, pathogenesis, and precision treatment, we provide new insights into the future treatment of sepsis.</p></abstract><kwd-group><kwd>Gram-negative bacteria</kwd><kwd>pathogenesis</kwd><kwd>precision treatment</kwd><kwd>sepsis</kwd><kwd>sepsis subtype</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In 1991, the definition of sepsis was established (sepsis 1.0), defined as the systemic inflammatory response syndrome (SIRS) triggered by infection. Within this framework, more severe cases are termed severe sepsis (sepsis with organ dysfunction) and septic shock (sepsis with refractory hypotension). Sepsis 3.0 was proposed in 2016 as a life-threatening organ dysfunction caused by a dysregulated host response to infections<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup>, and severe sepsis is no longer cited<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. Globally, there were 48.9 million patients who suffered from sepsis in 2017<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. The mortality of sepsis in any country may be seriously underreported, and its incidence is growing elevated as the population aging<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Although the mortality of sepsis decreased by 52.8% from 1990 to 2017, the 11 million sepsis-related deaths annually accounted for an astonishing 19.7% of global deaths<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. Moreover, recurrences, secondary damage, and sequelae of sepsis after discharge seriously harm human health<sup>[<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R9" ref-type="bibr">9</xref>]</sup>. It is reported that 31.5% of survivors of sepsis rely on nursing care after discharge, resulting in a huge medical expense of 29&#160;000 euros for each survivor within the 3&#160;years of onset. An estimated healthcare burden of global survivors of septic shock is inflated to $24 billion per year. Sepsis imposes a serious burden on society and families worldwide<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup>.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>Sepsis is a life threatening syndrome initiated by microorganisms, characterized by significant heterogeneity.</p></list-item><list-item><p>Understanding the mechanisms of bacterial infection, the host&#8217;s excessive inflammatory response and immune suppression, as well as the mechanisms by which dysregulation of the gut microbiota leads to susceptibility, is necessary.</p></list-item><list-item><p>&#8220;One-size-fits-all&#8221; strategies to treat sepsis are no longer satisfactory.</p></list-item><list-item><p>Host directed therapy (sepsis subtypes and immunotherapy) has potential roles in the treatment of sepsis.</p></list-item><list-item><p>It is hoped that from the perspective of pathogenic factors, pathogenesis, and personalized treatment, new insights can be provided for the clinical precision treatment and multimodal combination treatment of sepsis.</p></list-item></list></p></sec></boxed-text></p><p>Infection is the only cause of sepsis. The source of sepsis may come from any infected part of the body. Multiple pathogens can be detected in one hospitalized sepsis patient. In 2019, more than 6 million patients died from three infectious syndromes, including 2 million from lower respiratory tract and blood infections, and 6 million from peritoneal and intra-abdominal infections<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>. Particularly, 400&#160;000 deaths are attributable to and 1.5 million deaths are associated with lower respiratory tract infections<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>. The global impact of antimicrobial resistance (AMR) is profound. Computational predictive modeling for 2019 estimated that 1.27 million deaths were directly attributable to bacterial AMR globally, establishing AMR as the third leading underlying cause of death that year, following ischemic heart disease and stroke<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>. Furthermore, bacterial AMR was associated with an estimated 4.95 million deaths in the same period, underscoring its vast global health impact. Lower respiratory tract infections were a major contributor to this burden, accounting for over 1.5 million deaths associated with AMR in 2019. Pathogens such as <italic toggle="yes">Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii</italic>, and <italic toggle="yes">Pseudomonas aeruginosa</italic> have emerged as key contributors to these resistance-associated deaths, with <italic toggle="yes">E. coli</italic> being particularly predominant<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>. Given that sepsis is a common and life-threatening manifestation of severe infections, frequently complicated by AMR &#8211; the rise of antimicrobial resistance has critically escalated the challenge of managing septic patients and preventing sepsis-related mortality worldwide<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup>. Thus, antimicrobial resistance represents a rapidly aggravating global issue, with resistance-complicated sepsis at the forefront of this crisis.</p><p>Pathogens enter the human body through the skin, mucous membranes, or other routes, colonize at the site of infection, and may produce toxins or enzymes that destroy tissues and facilitate the spread of the pathogen. Throughout this process, after bacteria and toxins enter the body, they activate the host&#8217;s immune cells, producing and releasing a large amount of inflammatory mediators (such as TNF-&#945;, IL-1&#946;, IL-6, etc.), causing local or systemic inflammatory responses. If the immune system fails to control the infection, the body develops excessive inflammatory responses and shifts into a state of immunosuppression, leading to sepsis. As sepsis progresses, the initial hyperinflammatory response may transition into a state of immunosuppression. Excessive inflammatory responses and immunosuppression are not mutually exclusive; they can transform into each other during sepsis, forming a dynamic change in immune status. In the progression of sepsis, gut commensal microbes also play a significant role. Dysbiosis can lead to increased disease susceptibility. The disruption of the gut microbiota and the impairment of the intestinal barrier in sepsis patients can result in the translocation of opportunistic pathogens and their metabolic products, which can further affect the function of immune cells in the body, leading to or exacerbating immunological dysregulation.</p><p>In a study that included 8135 patients with suspected or confirmed infections, 67% had Gram-negative bacteria detected, making Gram-negative bacteria the main causative agent<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. This text focuses primarily on Gram-negative sepsis. A proper anti-inflammation against pathogen infections stimulates tissue repair and balances homeostasis<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>. An overwhelming inflammation, nevertheless, induces immune dysregulation and eventually organ dysfunction<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>. The intensity and extent of the inflammatory response vary according to the type, load, and virulence of the pathogen, as well as the underlying disease, immune status, age, and nutritional status of hosts<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Individualized conditions of pathogens and physical status result in the heterogeneity of sepsis. In response to infections, an inflammatory cascade alters coagulation, complement, and microbiome systems, causes extensive damage to endothelial cells, coagulation and fibrinolysis, and ultimately induces septic shock and disseminated intravascular coagulation (DIC). So far, a clear illustration of the heterogeneity of sepsis has not been fundamentally unveiled.</p><p>A one-size-fits-all approach is no longer satisfying the treatment of sepsis due to the heterogeneity. The current standard of care for treating sepsis involves managing the infection sites through drainage, administering antibiotics, providing fluid resuscitation, and providing supportive care for failing organs<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>. According to the statistics from more than 200 relevant randomized controlled trials (RCTs) within the past 3 decades, sepsis patients are poorly responsive to the treatment regimens.</p><p>A concept of sepsis bundle was proposed by the Surviving Sepsis Campaign (SSC) to act on the treatment of sepsis, but as understanding of sepsis continues to deepen, higher demands are placed on treatment<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>. Furthermore, to address the issue of sepsis heterogeneity, numerous scholars have utilized genomics, transcriptomics, proteomics, and other omics approaches along with clinical data to classify sepsis<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup>, dividing it into different subgroups based on treatment response, outcomes, shared clinical and laboratory features of two or more, or specific pathophysiological changes<sup>[<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref>]</sup>. A clear illustration of the pathogenesis of different subtypes of sepsis contributes to achieving the precise treatment. In the present article, we summarize infection mechanisms, immune dysregulation (persistent inflammatory response and immune suppression), and gut microbiota (increased susceptibility). Besides, conventional and newly emerging therapeutic strategies for sepsis were summarized, especially the individualized, precise treatment based on the subtype and immune status.</p></sec><sec><title>Materials</title><sec><title>Literature search strategy</title><p>This review aimed to comprehensively gather current research on the pathogenesis, precise interventions, and clinical perspectives of sepsis. A systematic search was conducted across multiple electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search period was defined from January 2000 to December 2024 to ensure the inclusion of both foundational studies and the latest advancements in the field.</p><p>The search strategy combined free-text terms and subject headings (e.g., MeSH terms in PubMed). Core search terms included, but were not limited to: &#8220;sepsis&#8221;, &#8220;septic shock&#8221;, &#8220;pathogenesis&#8221;, &#8220;etiology&#8221;, &#8220;Gram-negative bacteria&#8221;, &#8220;Escherichia coli&#8221;, &#8220;Klebsiella pneumoniae&#8221;, &#8220;Pseudomonas aeruginosa&#8221;, &#8220;Acinetobacter baumannii&#8221;, &#8220;immune response&#8221;, &#8220;immunosuppression&#8221;, &#8220;inflammation&#8221;, &#8220;cytokines&#8221;, &#8220;neutrophils&#8221;, &#8220;endothelial dysfunction&#8221;, &#8220;coagulation&#8221;, &#8220;complement system&#8221;, &#8220;gut microbiota&#8221;, &#8220;dysbiosis&#8221;, &#8220;precision medicine&#8221;, &#8220;sepsis subtypes&#8221;, &#8220;sepsis biomarkers&#8221;, &#8220;sepsis treatment&#8221;, and &#8220;immunotherapy&#8221;. These keywords were combined using Boolean operators (AND, OR) to optimize the specificity and sensitivity of the retrieved results.</p></sec><sec><title>Literature screening was based on the following criteria</title><p>Inclusion Criteria: Original research articles (both experimental and clinical studies), high-quality review articles, meta-analyses, and guidelines from recognized academic institutions and professional societies were primarily included. The focus was on literature relevant to the etiology, pathogenesis of sepsis (particularly concerning Gram-negative bacteria), immune dysregulation (such as the coexistence of persistent inflammation and immunosuppression), gut microbiota dysbiosis leading to increased susceptibility, clinical diagnosis, and therapeutic strategies (including individualized precision treatment based on subtypes and immune status).</p><p>Exclusion Criteria: Non-English language publications, duplicate articles, conference abstracts, letters to the editor, and articles not directly relevant to the scope of this review were excluded. Case reports were generally not included unless they were highly illustrative of a specific point.</p><p>Two investigators independently performed literature screening and data extraction. Initial screening was conducted by reviewing titles and abstracts, followed by a full-text assessment of potentially eligible articles to determine final inclusion. Any discrepancies were resolved through discussion or consultation with a third expert if necessary. Relevant data on pathogenic mechanisms, immune responses, organ dysfunction, diagnostic markers, existing and emerging therapeutic strategies (especially precision treatments and immunotherapies) were extracted and synthesized narratively.</p><p>Although this is primarily a narrative review, the principles of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were referred to during the literature search and selection process to enhance comprehensiveness and transparency. During the conception and writing of the review, no artificial intelligence assistance was used to avoid the loss of authenticity in the content<sup>[<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup>.</p></sec></sec><sec><title>Gram-negative</title><p>Sepsis can be caused by various pathogenic microorganisms like bacteria, fungi and parasites, of which bacterial infections are the predominant cause (&gt;90%). Bacterial infections are categorized into Gram-positive and Gram-negative, and the latter is more common (67%, <italic toggle="yes">n</italic> =&#160;3540)<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. The incidence of severe sepsis and relative levels of inflammatory factors (e.g., CRP, PCT, TNF-&#945;) are both higher in patients with Gram-negative sepsis than those of Gram-positive sepsis<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup>, alongside the higher prevalence<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup>, longer length of stay<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup>, higher mortality<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> and higher risk of drug resistance<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup>. Gram-negative sepsis has become a priority to be concerned about in clinical practice.</p><p>In an observational study involving 1150 centers, it was found that 67% of cultured microorganisms were Gram-negative bacteria, 37% were Gram-positive bacteria, and 16% were fungi<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. <italic toggle="yes">Staphylococcus aureus, E. coli, Streptococcus pneumoniae, K. pneumoniae</italic>, and <italic toggle="yes">P. aeruginosa</italic> isolated from the samples accounted for 54.9% of the fatal bacterial species<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup>. Clinical practice must pay attention to <italic toggle="yes">A. baumannii</italic>, which has a multidrug resistance rate as high as 71%<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</sup>. Drug resistance is a significant barrier to the clinical management of sepsis, increasing mortality. Gram-negative bacteria have become the most common pathogens causing sepsis. Among them, <italic toggle="yes">E. coli, K. pneumoniae</italic>, and <italic toggle="yes">P. aeruginosa</italic> are the main pathogens causing Gram-negative infections, ranking in p 10. <italic toggle="yes">A. baumannii</italic> has become a long-term challenge for clinicians due to its drug resistance. Therefore, this review summarizes the infection and antimicrobial resistance mechanisms of <italic toggle="yes">E. coli, K. pneumoniae, P. aeruginosa</italic>, and <italic toggle="yes">A. baumannii.</italic></p><sec><title>Escherichia coli: epidemiology and pathogenicity</title><p><italic toggle="yes">Escherichia coli</italic> strains are the most common causes of infection, and their case fatality rate ranges from 5% to 30%<sup>[<xref rid="R27" ref-type="bibr">27</xref>-<xref rid="R29" ref-type="bibr">29</xref>]</sup>. <italic toggle="yes">E. coli</italic> pathogens mainly cause urinary tract infections and gastrointestinal infections (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup>. Even though urinary tract infections serve as the leading cause, their mortality is lower than that caused by other sources of <italic toggle="yes">E. coli</italic> sepsis<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup>.<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Comparison of common Gram-negative bacteria in sepsis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Category</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic></th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">Klebsiella pneumoniae</italic></th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">Pseudomonas aeruginosa</italic></th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">Acinetobacter baumannii</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Common infection sites</td><td align="left" rowspan="1" colspan="1">Urinary tract, abdominal cavity, bloodstream</td><td align="left" rowspan="1" colspan="1">Pneumonia, urinary tract, sepsis</td><td align="left" rowspan="1" colspan="1">Hospital-acquired pneumonia, burn infections</td><td align="left" rowspan="1" colspan="1">ICU pneumonia, trauma infections, bloodstream</td></tr><tr><td align="left" rowspan="1" colspan="1">Major virulence factors</td><td align="left" rowspan="1" colspan="1">Adhesins, endotoxins</td><td align="left" rowspan="1" colspan="1">capsules, LPS, siderophores, pili and allantoin</td><td align="left" rowspan="1" colspan="1">Outer membrane proteins, toxins, biofilm</td><td align="left" rowspan="1" colspan="1">Biofilm formation, capsule</td></tr><tr><td align="left" rowspan="1" colspan="1">Resistance mechanisms</td><td align="left" rowspan="1" colspan="1">ESBLs, aminoglycoside-modifying enzymes</td><td align="left" rowspan="1" colspan="1">KPC, NDM, OXA-type enzymes, ESBLs, carbapenem</td><td align="left" rowspan="1" colspan="1">Outer membrane proteins, transcriptional regulators, efflux pumps, &#946;-lactamases, biofilms</td><td align="left" rowspan="1" colspan="1">Enzymes, increased efflux</td></tr><tr><td align="left" rowspan="1" colspan="1">Common resistance genes</td><td align="left" rowspan="1" colspan="1">blaCTX-M, blaTEM, blaSHV</td><td align="left" rowspan="1" colspan="1">blaKPC, blaNDM,</td><td align="left" rowspan="1" colspan="1">blaVIM, blaIMP, mexAB-oprM</td><td align="left" rowspan="1" colspan="1">adeABC efflux pump</td></tr><tr><td align="left" rowspan="1" colspan="1">Biofilm formation ability</td><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">Strong</td><td align="left" rowspan="1" colspan="1">Strong</td><td align="left" rowspan="1" colspan="1">Very strong</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical impact/risk</td><td align="left" rowspan="1" colspan="1">Common in community infections, ESBL producers linked to high mortality</td><td align="left" rowspan="1" colspan="1">High resistance rates, carbapenem-resistant strains increase nosocomial mortality</td><td align="left" rowspan="1" colspan="1">Difficult to treat, leads to chronic and recurrent infections</td><td align="left" rowspan="1" colspan="1">Extremely drug-resistant, limited treatment options, high ICU mortality</td></tr><tr><td align="left" rowspan="1" colspan="1">Resistance trend</td><td align="left" rowspan="1" colspan="1">Increasing ESBLs, declining carbapenem susceptibility</td><td align="left" rowspan="1" colspan="1">Rapid spread of carbapenemases like KPC and NDM</td><td align="left" rowspan="1" colspan="1">Inherently resistant, rising carbapenem resistance</td><td align="left" rowspan="1" colspan="1">Persistently high MDR, growing XDR prevalence</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ESBL, extended-spectrum &#946;-lactamase; ICU, intensive care unit; IMP, imipenem; LPS, lipopolysaccharide; KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; MDR, multidrug-resistant; XDR, extensively drug-resistant; NDM, New Delhi metallo-&#946;-lactamase; OXA, oxacillinase; VIM, Verona integron-encoded metallo-&#946;-lactamase.</p></fn></table-wrap-foot></table-wrap>
</p><p><italic toggle="yes">E. coli</italic> strains are grouped into four phylogenetic groups: A, B1, B2, and D. Group A represents commensalism and group B represents pathogenic clones<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>. More virulence factors, such as toxins, adhesins, and siderophores, that support initial site invasion, dissemination, and bloodstream survival are expressed by groups B2 and D<sup>[<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]</sup>. Capsular polysaccharide O-acetylation is engaged in the initial infection and immune evasion in the bloodstream by escaping Siglec-mediated innate immunity and lysosomal degradation<sup>[<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>]</sup>. The serine protease Pic secreted by <italic toggle="yes">E. coli</italic> is an important virulence factor that allows pathogens to colonize and survive in the bloodstream and multiple organs by directly cleaving the complement molecule C3/C3b. Serine protease is essential for the adaptability of pic-encoded <italic toggle="yes">E. coli</italic> strains. It triggers white cell migration via targeting leukocyte adhesion-associated factors (CD43, CD44, CD45, and CD93), suppresses the complement system activation, and induces the production of massive inflammatory mediators, eventually leading to infections or even deaths<sup>[<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Adhesins have a well-established role in the pathogenesis of <italic toggle="yes">E. coli</italic>. In mice with tail vein injection of <italic toggle="yes">E. coli</italic> strains, mutants lacking type I and P pili are outcompeted by the wild-type strains, indicating that pili adhesion contributes to local infection and systemic colonization<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. &#1056; pili expressed by uropathogenic <italic toggle="yes">E. coli</italic> bind to P antigens on red blood cells and play a potential role in the systemic transmission of bacteria<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>. A-hemolysin is an important pathogenic factor leading to urinary tract infection in a mouse model. It induces the release of pro-inflammatory factors (IL-1&#946;, TNF-&#945; and IL-6) by directly activating the immune system or indirectly activating it via stimulating the purinergic signaling pathway. Additionally, &#945;-hemolysin induces platelet activation through the engagement of P2Y12 and P2Y1 receptors, contributing to the development of severe sepsis<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>.</p><p>Poly-<italic toggle="yes">N</italic>-acetylglucosamine is an extracellular <italic toggle="yes">E. coli</italic> polysaccharide that contributes to biofilm formation and extracellular matrix binding. Extracellular <italic toggle="yes">E. coli</italic> polysaccharide poly-<italic toggle="yes">N</italic>-acetylglucosamine aids in the production of biofilms and the binding of extracellular matrix<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup>. By actively limiting iron bioavailability, the immune system of the host blocks pathogen growth. Siderophores are iron-chelating compounds to help the organism accumulate iron. In the isolated strains, the expression level of siderophores is significantly correlated with the pathogenicity of the B2 group isolates<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup>. Siderophores allow bacteria to acquire iron in the blood, and overexpressed siderophores in <italic toggle="yes">E. coli</italic> isolates are conducive to iron absorption and bacterial survival<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup>, making the host more susceptible to infection. The correlation between the genes required for P pili and the survival of <italic toggle="yes">E. coli</italic> remains controversial. PapC, papGII and/or papGIII that assemble P pili are protective factors<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup>. On the contrary, <italic toggle="yes">P pili</italic> are essential for infection<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup> and UTI<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup> in mouse models, which are responsible for triggering the immune response to eliminate pathogens by the TLRs signaling pathway<sup>[<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R44" ref-type="bibr">44</xref>]</sup>.</p><p>Currently, antimicrobial resistance is a major concern in the treatment of <italic toggle="yes">E. coli</italic> infection. In southern Sweden, the proportion of <italic toggle="yes">E. coli</italic> infections resistant to fluoroquinolones rises dramatically from 8.4% to 13.6%, and the proportion resistant to third-generation cephalosporins rises from 4.9% to 7.3%<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup>. A Finland study reported that the annual proportion of <italic toggle="yes">E. coli</italic> isolates producing extended-spectrum beta-lactamase (ESBL) in blood culture increases from 2.4% to 8.6%<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup>. <italic toggle="yes">E. coli</italic> isolates usually carry antimicrobial plasmids encoding &#946;-lactamase (bla), ESBL and carbapenemase<sup>[<xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref>]</sup>. <italic toggle="yes">E. coli</italic> sequence types (STs) 131, 193 and 410 are collectively responsible for a large proportion of <italic toggle="yes">E. coli</italic> infection<sup>[<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R49" ref-type="bibr">49</xref>]</sup>. Their isolates often carry plasmid-mediated resistance genes <italic toggle="yes">CTX-M-14, CTX-M-15, CTX-M-27, CTX-M-55</italic>, and <italic toggle="yes">CTX-M-65</italic> that transfer between bacteria through plasmids (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref>]</sup>. The annoying antimicrobial resistance greatly weakens the effectiveness of antibiotics against <italic toggle="yes">E. coli</italic> infections or even makes them ineffective.</p></sec><sec><title>Klebsiella pneumoniae: epidemiology and pathogenicity</title><p><italic toggle="yes">Klebsiella pneumoniae</italic> is an opportunistic pathogen that colonizes the upper respiratory tract and gastrointestinal tract. Nosocomial infections are the dominant cause of <italic toggle="yes">K. pneumoniae</italic>, accounting for 57%-70%<sup>[<xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref>]</sup>. <italic toggle="yes">K. pneumoniae</italic> usually affects middle-aged and elderly people with underlying diseases like diabetes mellitus, and its mortality is influenced by the strains, advanced age, immune deficiency, and potential comorbidities. The incidence of sepsis in survived and non-survived patients with <italic toggle="yes">K. pneumoniae</italic> ranges from 13%-26% and 54%-79% respectively<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup>. The mortality of antibiotic-susceptible <italic toggle="yes">K. pneumoniae</italic> is lowered at 26%, which increases with the increasing antibiotic resistance.</p><p>Based on their virulence and resistance to carbapenem, <italic toggle="yes">K. pneumoniae</italic> are divided into two groups: classical <italic toggle="yes">K. pneumoniae</italic> (cKp) and <italic toggle="yes">hypervirulent K. pneumoniae</italic> (hvKp). cKp is the most common subtype of <italic toggle="yes">K. pneumoniae</italic> in Western countries that carries antimicrobial plasmids. hvKp infection was first reported in Southeast Asia. It is associated with community-acquired infections, liver abscesses, endophthalmitis, and meningitis<sup>[<xref rid="R55" ref-type="bibr">55</xref>]</sup>. The invasiveness of <italic toggle="yes">K. pneumoniae</italic> is related to high mucus viscosity<sup>[<xref rid="R56" ref-type="bibr">56</xref>]</sup>. Similar to <italic toggle="yes">E. coli</italic>, pathogenic factors of <italic toggle="yes">K. pneumoniae</italic> include capsules, lipopolysaccharide (LPS), siderophores, pili and allantoin (Table <xref rid="T1" ref-type="table">1</xref>). Differently, <italic toggle="yes">K. pneumoniae</italic> lacks specific toxins like hemolysin or cytotoxic necrotizing factors. Capsules are intrinsic virulence factors of <italic toggle="yes">K. pneumoniae</italic> that allow immune evasion by protecting the bacteria from phagocytosis and serum resistance<sup>[<xref rid="R57" ref-type="bibr">57</xref>,<xref rid="R58" ref-type="bibr">58</xref>]</sup>. The capsule primarily promotes the survival of <italic toggle="yes">K. pneumoniae</italic> by evading capture by macrophages<sup>[<xref rid="R59" ref-type="bibr">59</xref>]</sup>. Endotoxin, or lipopolysaccharide, is the primary component of Gram-negative bacteria&#8217;s outer membrane that induces sepsis. LPS stimulates the release of pro-inflammatory factors (e.g., TNF-&#945;, IL-6 and IL-1&#946;) by activating immune cells (e.g., monocytes, macrophages, neutrophils and natural killer cells) via TLR4. Activated granulocytes by inflammatory cells further induce a series of events to aggravate inflammatory responses, including endothelial cell damage, platelet adhesion, and accumulation of oxygen free radicals and lipid metabolites. The complicated reciprocal causation finally causes an inflammatory cascade<sup>[<xref rid="R60" ref-type="bibr">60</xref>]</sup>. Allantoin is a nitrogen source in bacteria, and it also provides nitrogen and carbon to <italic toggle="yes">K. pneumoniae</italic>. Allantoin increases the virulence of <italic toggle="yes">K. pneumoniae</italic> in liver infections by structural operons<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup>.</p><p>Neutrophils and alveolar macrophages are essential to control the initial onset of <italic toggle="yes">K. pneumoniae</italic> lung infection and sepsis<sup>[<xref rid="R62" ref-type="bibr">62</xref>]</sup>. Host thrombospondin-1 (TSP-1) is an ECM necessary for the invasion of <italic toggle="yes">K. pneumoniae</italic> into the lungs and spleen. Inactivating neutrophil elastase, TSP-1 facilitates the survival of <italic toggle="yes">K. pneumoniae</italic> in the lungs during the early stage of infection. TSP-1<sup>&#8722;/&#8722;</sup> mice present a higher bacterial clearance rate and lower bacterial load in the spleen than those of wild-type mice<sup>[<xref rid="R63" ref-type="bibr">63</xref>]</sup>. In addition, <italic toggle="yes">K. pneumoniae</italic> escapes from pyroptosis by upregulating IL-10 and thus survives from the killing of innate immune cells<sup>[<xref rid="R64" ref-type="bibr">64</xref>]</sup>. To evade immune cell killing, <italic toggle="yes">K. pneumoniae</italic> impairs or inactivates IL-10 or TSP-1. Virulence factors of <italic toggle="yes">K. pneumoniae</italic>, like siderophores, increase angiogenesis and vascular epithelial permeability by upregulating pro-inflammatory cytokines (e.g., TNF-&#945;, IL-6 and IL-1&#946;), providing an immune escape approach from the initial infection site (the lung) to the bloodstream infection. Catheter-related sepsis offers lower mortality than secondary sepsis due to the lower incidence of <italic toggle="yes">hvKp</italic> directly infected in the bloodstream<sup>[<xref rid="R65" ref-type="bibr">65</xref>]</sup>. Secondary sepsis is usually caused by pathogens evading the immune system by penetrating the epithelial barrier. Carbapenem-resistant (CR) <italic toggle="yes">K. pneumoniae</italic> is extremely concern for its high resistance rate and virulence. ESBL-producing and CR <italic toggle="yes">K. pneumoniae</italic> are predominantly popular in Asia, with the incidence in China of 31%-37.8% (Table <xref rid="T1" ref-type="table">1</xref>). Their onset is probably linked with the subspecies of <italic toggle="yes">K. pneumoniae</italic><sup>[<xref rid="R66" ref-type="bibr">66</xref>]</sup>. ST11 CR hvKp was initially isolated in China in 2016, manifesting high virulence, multi-drug resistance and a high transmission rate. It directly induces severe infections, and more seriously, antibiotic resistance further poses a challenge in the treatment or even induces fatal events<sup>[<xref rid="R67" ref-type="bibr">67</xref>]</sup>.</p></sec><sec><title>Pseudomonas aeruginosa: epidemiology and pathogenicity</title><p><italic toggle="yes">Pseudomonas aeruginosa</italic> is the third most common Gram-negative bacterium isolated from clinical cases. In hospital environments, <italic toggle="yes">P. aeruginosa</italic> can colonize medical devices with the assistance of its binding factors like flagella, pili and biofilms<sup>[<xref rid="R68" ref-type="bibr">68</xref>]</sup>. As a result, <italic toggle="yes">P. aeruginosa</italic> infections typically occur in healthcare settings, leading to ventilator-associated pneumonia, intensive care unit (ICU) infections, central line-associated bloodstream infections, surgical site infections, urinary tract infections, burn infections, keratitis and otitis media (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref>]</sup>. Due to the high detection rate in patients with bronchiectasis and critically ill patients, the mortality of <italic toggle="yes">P. aeruginosa</italic> infection ranges from 32% to 62%<sup>[<xref rid="R71" ref-type="bibr">71</xref>-<xref rid="R73" ref-type="bibr">73</xref>]</sup>.</p><p>Classifications of <italic toggle="yes">P. aeruginosa</italic> are generally based on biology, serology and molecular biology, and the serotype classification is the established method. Serotype O11 is unique in producing glycosidases than other serotypes of <italic toggle="yes">P. aeruginosa</italic>, which is closely linked with nosocomial outbreaks and sepsis arising from drug abuse<sup>[<xref rid="R71" ref-type="bibr">71</xref>,<xref rid="R74" ref-type="bibr">74</xref>,<xref rid="R75" ref-type="bibr">75</xref>]</sup>. Serotype O11 is common in multidrug-resistant (78.4%) and ExoU-positive (89.2%) strains of <italic toggle="yes">P. aeruginosa</italic><sup>[<xref rid="R71" ref-type="bibr">71</xref>]</sup>. ExoU is a phospholipase that destroys the integrity of the host membrane. It massively spreads from the lungs to the bloodstream<sup>[<xref rid="R76" ref-type="bibr">76</xref>]</sup>. The type III secretion system (T3SS) provides a virulence mechanism enabling pathogens to spread from the lungs to the bloodstream via directly injecting bacterial effector proteins into the host cell cytoplasm, thus increasing mortality in humans and animal models<sup>[<xref rid="R73" ref-type="bibr">73</xref>]</sup>.</p><p><italic toggle="yes">P. aeruginosa</italic> produces three T3SS exotoxins: ExoU, ExoS, and ExoT. Among these, ExoU and ExoS are linked to high bacterial loads and <italic toggle="yes">P. aeruginosa</italic> infection mortality<sup>[<xref rid="R71" ref-type="bibr">71</xref>,<xref rid="R77" ref-type="bibr">77</xref>]</sup>. ExoS and ExoT directly help <italic toggle="yes">P. aeruginosa</italic> evade host immune cells by disrupting the actin cytoskeleton<sup>[<xref rid="R78" ref-type="bibr">78</xref>,<xref rid="R79" ref-type="bibr">79</xref>]</sup>. ExoS is specifically injected into neutrophils in early-stage <italic toggle="yes">P. aeruginosa</italic> pneumonia and into type I alveolar cells in the late stage<sup>[<xref rid="R80" ref-type="bibr">80</xref>]</sup>. Type I alveolar cells with ExoS form aggregates, and the abundance of dead cells increases as infection progresses<sup>[<xref rid="R78" ref-type="bibr">78</xref>]</sup>. Aggregate formation is associated with the transmission of <italic toggle="yes">P. aeruginosa</italic> from the lungs to the bloodstream. T3SS-negative P. aeruginosa secretes the toxin ExlA, which causes necrosis of the epithelium and myeloid cells. Lung invasion and hematogenous spread of <italic toggle="yes">P. aeruginosa</italic> in a murine pneumonia model are influenced by the effect of ExlA on disrupting the pulmonary vascular barrier<sup>[<xref rid="R81" ref-type="bibr">81</xref>]</sup>. In addition, the type II secretion system (T2SS) and LasB elastase are key virulent factors for <italic toggle="yes">P. aeruginosa</italic>. LasB increases vascular permeability through dissociating ECMs via interacting with vascular endothelial-cadherin<sup>[<xref rid="R82" ref-type="bibr">82</xref>]</sup>.</p><p><italic toggle="yes">P. aeruginosa</italic> strains that produce only ExoU can destroy host cells directly by rupturing the cell membrane, whereas strains that express ExoS and ExoT use exotoxins to avoid being killed by early innate immune cells. ExoS even kills type I alveolar epithelial cells and destroys the epithelial barrier. ExoT cleaves ECMs and causes vascular leakage<sup>[<xref rid="R78" ref-type="bibr">78</xref>,<xref rid="R82" ref-type="bibr">82</xref>]</sup>. T3SS is required for the virulence of <italic toggle="yes">P. aeruginosa</italic> in a burning injury model<sup>[<xref rid="R83" ref-type="bibr">83</xref>]</sup>. <italic toggle="yes">P. aeruginosa</italic> is different from <italic toggle="yes">K. pneumoniae</italic> in that it expresses strong exotoxins that are comparable to hemolysin and cytotoxic necrosis factor made by <italic toggle="yes">E. coli</italic>.</p><p><italic toggle="yes">P. aeruginosa</italic> is an opportunistic pathogen that is hardly eradicated if antimicrobial-resistant. Romania and Serbia (2015-2020) are the two countries suffering from the highest resistance rate of <italic toggle="yes">P. aeruginosa</italic>. Generally, drug resistance of <italic toggle="yes">P. aeruginosa</italic> can be intrinsic, acquired or adaptive<sup>[<xref rid="R84" ref-type="bibr">84</xref>]</sup>. Outer membrane proteins, transcriptional regulators, efflux pumps, enzymes, and biofilms play different roles in the antimicrobial resistance of <italic toggle="yes">P. aeruginosa</italic> (Table <xref rid="T1" ref-type="table">1</xref>). The production of bla is the well-recognized machinery for <italic toggle="yes">P. aeruginosa</italic> resistance. For bla, it can be divided into cephalosporinase, high-level AmpC, ESBL and carbapenemase<sup>[<xref rid="R85" ref-type="bibr">85</xref>,<xref rid="R86" ref-type="bibr">86</xref>]</sup>. Genes encoding aminoglycoside-modifying enzymes (AMEs) in <italic toggle="yes">P. aeruginosa</italic> are responsible for the high rate of drug resistance<sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup>. AMEs can be divided into acetyltransferases (AACs), nucleotidyltransferases (ANTs) and phosphotransferases (APHs) that respectively initiate <italic toggle="yes">N</italic>-acetylation, adenylation and/or O-phosphorylation of aminoglycosides to end in a treatment failure<sup>[<xref rid="R88" ref-type="bibr">88</xref>]</sup>. Efflux transporters are the key cause of the multidrug resistance of <italic toggle="yes">P. aeruginosa</italic><sup>[<xref rid="R89" ref-type="bibr">89</xref>]</sup>. Mobile genetic elements (MGEs) like integrons, plasmids, and transposons facilitate the rapid dissemination of clinically important genes<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup>. The formation of bacterial biofilms protects bacteria against various chemical and environmental stresses (e.g., phagocytosis), leading to widespread drug resistance and potential infections<sup>[<xref rid="R91" ref-type="bibr">91</xref>]</sup>.</p></sec><sec><title>Acinetobacter baumannii: epidemiology and pathogenicity</title><p>Numerous infections in the respiratory system, urinary system, wound areas, abdominal cavity, and neurological system can result from the skin, nasal cavity, and trachea being colonized by <italic toggle="yes">A. baumannii</italic> (Table <xref rid="T1" ref-type="table">1</xref>). Respiratory infections are the most common cause (60%)<sup>[<xref rid="R92" ref-type="bibr">92</xref>]</sup>. <italic toggle="yes">A. baumannii</italic> is a major cause of nosocomial infections in recent years. It is reported that hospital-acquired infections account for 75% of <italic toggle="yes">A. baumannii</italic> infections, and they are responsible for 86% of drug-resistant strains<sup>[<xref rid="R93" ref-type="bibr">93</xref>]</sup>. The attributable mortality of community-acquired pneumonia and bloodstream infections caused by <italic toggle="yes">A. baumannii</italic> is up to 60% and 43%, respectively<sup>[<xref rid="R94" ref-type="bibr">94</xref>,<xref rid="R95" ref-type="bibr">95</xref>]</sup>. Severe complications developing in ICU patients with <italic toggle="yes">A. baumannii</italic> infections are primary drivers of the extremely high mortality rates. Hospital settings provide a favorable reservoir of <italic toggle="yes">A. baumannii</italic><sup>[<xref rid="R96" ref-type="bibr">96</xref>]</sup>, and a longer length of stay predicts a higher risk of <italic toggle="yes">A. baumannii</italic><sup>[<xref rid="R97" ref-type="bibr">97</xref>]</sup>. Usually, the same strains of <italic toggle="yes">A. baumannii</italic> are detected in nasal isolates and isolates from hospital environments<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup>. The colonization rate in hospitalized patients remains higher, with the statistics of 54%-92% and 63% reported in Taiwan and the United States, respectively<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup>. People may suffer from opportunistic infections after antibiotic treatment of <italic toggle="yes">A. baumannii</italic> infections<sup>[<xref rid="R96" ref-type="bibr">96</xref>,<xref rid="R99" ref-type="bibr">99</xref>]</sup>. Prevention strategies can significantly reduce the risk of <italic toggle="yes">A. baumannii infection</italic> and the disease burden<sup>[<xref rid="R92" ref-type="bibr">92</xref>]</sup>.</p><p><italic toggle="yes">A. baumannii</italic> often results from secondary infections caused by contaminated healthcare devices and surgical site infections<sup>[<xref rid="R92" ref-type="bibr">92</xref>,<xref rid="R93" ref-type="bibr">93</xref>,<xref rid="R97" ref-type="bibr">97</xref>]</sup>. The high mortality of <italic toggle="yes">A. baumannii</italic> infection is linked with acquisitions and expressions of resistance genes, capsule production and biofilm formation (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R100" ref-type="bibr">100</xref>]</sup>. Biofilms offer a favorable environment for the survival of <italic toggle="yes">A. baumannii</italic>, serving as the basis for host infections from contaminated healthcare devices. <italic toggle="yes">A. baumannii</italic> bloodstream infection downregulates genes for biofilm formation (e.g., fimA and ompA) and adhesion molecules, but upregulates motility-associated genes (e.g., PilQ, YebC, H-NS and ExbD)<sup>[<xref rid="R101" ref-type="bibr">101</xref>,<xref rid="R102" ref-type="bibr">102</xref>]</sup>. The lytic transglycosylase gene mltB is essential for the colonization of <italic toggle="yes">A. baumannii</italic> in the respiratory tract of pneumonia mice, although the exact mechanism leading to bacterial infections is not yet clearly elucidated<sup>[<xref rid="R103" ref-type="bibr">103</xref>]</sup>. <italic toggle="yes">A. baumannii</italic> strains are resistant to killing by normal human serum<sup>[<xref rid="R104" ref-type="bibr">104</xref>]</sup>. Regulatory mechanisms on immune escape and adhesion molecules are of significance to unveil the pathogenesis of <italic toggle="yes">A. baumannii</italic> infection. Loss of mltB impairs biofilm formation and adhesion to epithelial cells by disrupting pilus assembly. Meanwhile, mltB is involved in the serum resistance of <italic toggle="yes">A. baumannii</italic><sup>[<xref rid="R103" ref-type="bibr">103</xref>]</sup>. Easily affected by physiological stresses, <italic toggle="yes">A. baumannii</italic> is more susceptible to oxidation, acidity and osmosis. The genes pntB, feoB and fepA allow the survival of <italic toggle="yes">A. baumannii</italic> by partially endowing it with antimicrobial peptide resistance<sup>[<xref rid="R104" ref-type="bibr">104</xref>]</sup>. The production of capsules is a protective mechanism, and genes required for capsule synthesis (e.g., wzc and gpi) are upregulated by serum stimulation<sup>[<xref rid="R101" ref-type="bibr">101</xref>]</sup>. Additionally, by binding plasminogen, a regulator of the complement cascade, <italic toggle="yes">A. baumannii</italic> inhibits the development of terminal complement complexes on the bacterial surface<sup>[<xref rid="R105" ref-type="bibr">105</xref>]</sup>. The above conditions contribute to the persistence of immune responses to <italic toggle="yes">A. baumannii</italic>. The intensity of immune responses varies in different strains<sup>[<xref rid="R104" ref-type="bibr">104</xref>]</sup>. Survival of <italic toggle="yes">A. baumannii</italic> in the bloodstream may be more dependent on its survival mechanisms and the ability to maintain bacterial burden in the blood rather than traditional virulence factors<sup>[<xref rid="R103" ref-type="bibr">103</xref>,<xref rid="R104" ref-type="bibr">104</xref>,<xref rid="R106" ref-type="bibr">106</xref>]</sup>. Transcriptomic analysis revealed that <italic toggle="yes">A. baumannii</italic> upregulates genes associated with capsule biosynthesis and siderophore during sepsis<sup>[<xref rid="R102" ref-type="bibr">102</xref>]</sup>. Through increasing the zinc availability in plasma via upregulating zinc transporters znuB and znuC and downregulating zur, the survival rate of <italic toggle="yes">A. baumannii</italic> is greatly elevated<sup>[<xref rid="R101" ref-type="bibr">101</xref>]</sup>.</p><p>Although <italic toggle="yes">A. baumannii</italic> is not the predominant pathogen leading to sepsis, great concerns have been raised about the multi-drug resistance issue<sup>[<xref rid="R107" ref-type="bibr">107</xref>]</sup>. In 2019, the Centers for Disease Control and Prevention (CDC) in the United States proposed that <italic toggle="yes">A. baumannii</italic> is a human threat due to the high resistance rate. In China, more than 45% of <italic toggle="yes">A. baumannii</italic> strains colonized in the lower respiratory tract are resistant to imipenem<sup>[<xref rid="R108" ref-type="bibr">108</xref>]</sup> and globally, more than 71% of strains are multidrug-resistant (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R109" ref-type="bibr">109</xref>]</sup>. In the United States, 27% of patients with mechanical ventilation are infected with multidrug-resistant <italic toggle="yes">A. baumannii</italic><sup>[<xref rid="R110" ref-type="bibr">110</xref>]</sup>. A significant increase in the drug resistance rate of <italic toggle="yes">A. baumannii</italic> was found in Ethiopia from 2017 to 2022<sup>[<xref rid="R111" ref-type="bibr">111</xref>]</sup>.
<list list-type="alpha-upper"><list-item><p><italic toggle="yes">baumannii</italic> contains three RND-type efflux pumps, which play an important role in the survival within the host and the resistance to antimicrobial drugs<sup>[<xref rid="R112" ref-type="bibr">112</xref>,<xref rid="R113" ref-type="bibr">113</xref>]</sup>. It is known that the two-component system AdeRS regulates the AdeABC efflux pumps, which promote resistance to aminoglycosides, tetracyclines, fluoroquinolones, trimethoprim, chloramphenicol, &#946;-lactams, and tigecycline (Table <xref rid="T1" ref-type="table">1</xref>)<sup>[<xref rid="R112" ref-type="bibr">112</xref>]</sup>. AdeFGH efflux pumps, regulated by a LysR-type transcriptional regulator namely adeL, induce resistance to chloramphenicol, fluoroquinolones, trimethoprim, tetracycline, tigecycline, clindamycin and sulfonamides<sup>[<xref rid="R112" ref-type="bibr">112</xref>]</sup>. AdeIJK efflux pumps, regulated by a TetR-type regulator namely AdeN, favor the resistance to bla, chloramphenicol, tetracyclines, erythromycin, fluoroquinolones, fusidic acid, novobiocin, and trimethoprim<sup>[<xref rid="R112" ref-type="bibr">112</xref>]</sup>. In multicenter studies, 1% of <italic toggle="yes">A. baumannii</italic> isolates exhibited pan-drug resistance, and colistin was the only reliable antimicrobial agent left for treatment<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R114" ref-type="bibr">114</xref>]</sup>.
</p></list-item></list></p></sec></sec><sec><title>The pathogenic mechanisms of sepsis</title><p>The innate immune system is the first line of defense against invading pathogens. After pathogens enter the body, immune cells clear the pathogens through a series of complex mechanisms, including recognizing the pathogens, initiating inflammatory responses, phagocytosing and digesting the pathogens, and activating adaptive immune responses (Fig. <xref rid="F1" ref-type="fig">1</xref>). This process involves the coordinated action of various immune cells, including macrophages, neutrophils, T cells, and B cells. Immune cells&#8217; pattern recognition receptors (PRRs) are in charge of identifying conserved motifs expressed by microbes as well as pathogen-associated molecular patterns (PAMPs). Receptors for PAMPs are positively expressed in subtypes of immune cells and parenchymal cells. Generally, the PRRs include Toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (Nod-like receptors, NLRs), retinoic acid-inducible gene (RIG)-l-like receptors (RLRs), C-type lectin receptors (CLRs) and cytosolic RNA and DNA sensors<sup>[<xref rid="R115" ref-type="bibr">115</xref>,<xref rid="R116" ref-type="bibr">116</xref>]</sup> (Fig. <xref rid="F1" ref-type="fig">1</xref>). After being recognized and interacting with PAMPs, PRRs initiate the upregulation of inflammatory genes, secretion of relevant factors, and the activation of innate immunity to eliminate pathogens and balance the immune homeostasis. Once pathogens evade the immune defense, continuous stimulation of PRRs impairs the machinery of the protective inflammatory response and eventually breaks the balance of immune homeostasis, leading to tissue damage and sepsis<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R117" ref-type="bibr">117</xref>]</sup>. PRRs interact with damage-associated molecular patterns (DAMPs), which are linked to a vicious cycle of prolonged, excessive inflammation and cell damage, in addition to recognizing exogenous PAMPs (Fig. <xref rid="F1" ref-type="fig">1</xref>).
<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Host response to infection and sepsis. The host&#8217;s innate immune system is the first line of defense against the invading pathogen, building up a protective immunity (left). Leukocytes, immunological cells, and parenchymal cells, such as epithelial and endothelial cells, are involved in the early phases of the local immune response to the invader. They are activated by cell surface receptors and PRRs, including TLRs, NLRs (activation of NLRs forms inflammasomes), RLPs and CLRs. Protective immunity typically works well enough to eradicate the invasive pathogen by inducing pro-inflammatory reactions, which include phagocyte recruitment, complement and coagulation system activation locally, and the production of cytokines and chemokines. The outcome of a compensatory mechanism to stifle the initial inflammation and avoid tissue damage is rebalanced immunological homeostasis. However, when the invading pathogen prevails over the protective immunity, the imbalanced immune homeostasis eventually results in tissue damage and sepsis (right). PRRs pattern recognition receptors, TLRs Toll-like receptors, NLRs Nod-like receptors, RLPs RIG-I-like receptors, CLRs C-type lectin receptors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6260-g001.jpg"/></fig>
</p><p>An inflammatory response in sepsis is mainly driven by inflammatory cells, cytokines, oxygen free radicals, complement and coagulation systems. A dynamic balance of the immune system is essential for immune response. Dysregulation of the immune system is a key pathogenic event in sepsis, leading to systemic inflammation, organ damage, immune suppression, or even death. Age is associated with innate immunity and cytokine signaling. Compared with those younger than 50&#160;years of age, sepsis patients older than 70&#160;years are prone to damage to the innate immunity and cytokine signaling<sup>[<xref rid="R118" ref-type="bibr">118</xref>]</sup>. Immune cells from the spleen or lungs of patients who died from sepsis have reduced ability to secrete pro-inflammatory and anti-inflammatory factors, overexpression of programmed death receptor (PD-1), and increases in regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs). It is indicated that both pro-inflammatory and anti-inflammatory responses occur in sepsis patients<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R119" ref-type="bibr">119</xref>]</sup>. Due to uncontrollable primary infection or acquired infection caused by opportunistic pathogens, dysregulation of immune cells causes immunosuppression or even death<sup>[<xref rid="R120" ref-type="bibr">120</xref>]</sup>.</p><sec><title>Excessive inflammation</title><sec><title>Neutrophils</title><p>In the early stage of sepsis, neutrophils broadly participate in the inflammatory response. Neutrophils expressing CXCR2 are recruited from the blood to the initial site of infection in response to CXCL2<sup>[<xref rid="R121" ref-type="bibr">121</xref>]</sup>. Following their migration to the infection site, neutrophils assure host defense by phagocytosis, degranulation and release of neutrophil extracellular traps (NETs)<sup>[<xref rid="R122" ref-type="bibr">122</xref>]</sup>. The migration of neutrophils to the site of infection can be impaired during the progression of severe sepsis by activating TLRs. Domer <italic toggle="yes">et al</italic><sup>[<xref rid="R123" ref-type="bibr">123</xref>]</sup> reported that TLR2 expression on neutrophils is directly activated to downregulate CXCR2 and impair chemotaxis. As a result, neutrophils build up in blood vessels and promote the infection&#8217;s spread. Under normal circumstances, neutrophils do not have CC receptor 2(CCR2), but TLR activation causes CCR2 to be expressed in circulating neutrophils (Fig. <xref rid="F2" ref-type="fig">2</xref>)<sup>[<xref rid="R124" ref-type="bibr">124</xref>]</sup>.
<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Neutrophil and sepsis. (A) Neutrophils expressing CXCR2 are drawn from blood to the infection site in response to CXCL2 during non-severe sepsis. When neutrophils arrive at the site of infection, they emit antibacterial compounds such as ROS, NO, and NETs, which destroy microorganisms. To stop infections from spreading, lymphocytes and other immune cells might move to the infection site. (B) On the other hand, neutrophils exhibit a longer lifespan and decreased functionality during severe sepsis because of the up- and down-regulation of CCR2 and CXCR2. On the one hand, infections spread as a result of impeded migration. Conversely, a large number of neutrophils are restricted to the vascular endothelium and produce NETs, which cause thrombosis, endothelial damage, and vascular inflammation. CCR2 CC receptor 2; CXCR2 CXC receptor 2; NETs neutrophil extracellular traps; ROS reactive oxygen species; TLR Toll-like receptor; RNS reactive nitrogen species; NO nitric oxide.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6260-g002.jpg"/></fig>
</p><p>NETs are extracellular fiber networks released by activated neutrophils composed of proteases, histones and DNA<sup>[<xref rid="R125" ref-type="bibr">125</xref>]</sup>. NETs are capable of neutralizing and killing bacteria, viruses and fungi, as well as inhibiting their spread<sup>[<xref rid="R126" ref-type="bibr">126</xref>,<xref rid="R127" ref-type="bibr">127</xref>]</sup>. Destruction of NETs increases bacterial burden and mortality in septic mice, suggesting the importance of NETs in host defense<sup>[<xref rid="R128" ref-type="bibr">128</xref>]</sup>. In a state of an imbalanced immune system, excessive NETs aggravate sepsis by inducing an inflammatory response and organ damage<sup>[<xref rid="R127" ref-type="bibr">127</xref>,<xref rid="R129" ref-type="bibr">129</xref>]</sup>. Abundant neutrophils are released from the bone marrow in response to infections or inflammations, during which the release of proteolytic enzymes, reactive oxygen species (ROS) and reactive nitrogen species (RNS) at the same time further amplifies the inflammatory cascade<sup>[<xref rid="R125" ref-type="bibr">125</xref>,<xref rid="R130" ref-type="bibr">130</xref>]</sup>. Neutrophils have the shortest lifespan of all types of white blood cells, and this is a favorable condition to prevent excessive inflammation. Most immune cells experience apoptosis during the process of sepsis, forming an immunosuppressive microenvironment. Sepsis, however, offers a microenvironment to delay neutrophil apoptosis, resulting in a prolonged inflammatory response<sup>[<xref rid="R131" ref-type="bibr">131</xref>]</sup>. Single-cell RNA sequencing in mice confirmed that LPS-induced overexpressed of programmed cell death ligand 1 (PD-L1) inhibits the immune system, directly triggers lymphocyte apoptosis and finally causes sepsis-associated immunosuppression<sup>[<xref rid="R132" ref-type="bibr">132</xref>]</sup>. Excessive NETosis during sepsis is responsible for intravascular thrombosis, DIC and organ failure by tissue damage and overactivation of the coagulation system<sup>[<xref rid="R133" ref-type="bibr">133</xref>]</sup>. Histones and DNA fibers form a network in NETs that draws platelets, albumin, plasma proteins, red blood cells, and other components, creating a positive feedback loop that improves thrombus formation both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> (Fig. <xref rid="F3" ref-type="fig">3</xref>)<sup>[<xref rid="R134" ref-type="bibr">134</xref>,<xref rid="R135" ref-type="bibr">135</xref>]</sup>. Neutrophils also release NETs carrying active tissue factor (TF)<sup>[<xref rid="R136" ref-type="bibr">136</xref>]</sup>. High-level TF-rich NETs in sepsis patients are linked with immune thrombosis and poor outcomes<sup>[<xref rid="R137" ref-type="bibr">137</xref>]</sup>. NET-induced thrombosis is an established factor for ischemic organ damage and DIC<sup>[<xref rid="R138" ref-type="bibr">138</xref>]</sup>. Accumulating evidence has supported the role of the correlation between damage-associated molecular patterns (DAMPs) and NET in sepsis (Fig. <xref rid="F3" ref-type="fig">3</xref>)<sup>[<xref rid="R139" ref-type="bibr">139</xref>]</sup>. Formed by histones and DNA of DAMPs, NETs activate PRRs<sup>[<xref rid="R139" ref-type="bibr">139</xref>]</sup>. DAMPs cause NETosis as well. HMBG-1 is found to promote the formation of NETs through TLR4<sup>[<xref rid="R139" ref-type="bibr">139</xref>-<xref rid="R141" ref-type="bibr">141</xref>]</sup>. Neutrophils promote macrophage pyroptosis in sepsis through NETs and aggravate sepsis-induced acute lung injury<sup>[<xref rid="R128" ref-type="bibr">128</xref>,<xref rid="R142" ref-type="bibr">142</xref>]</sup>. Moreover, NETs induce the generation of M1 macrophages to release inflammatory cytokines (such as IL-1, IL-6, IL-8, and TNF)<sup>[<xref rid="R143" ref-type="bibr">143</xref>]</sup>.<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Endothelial dysfunction and sepsis. The glycocalyx of endothelial cells is damaged and the permeability of the endothelium is increased in sepsis (A) NETs can directly degrade the glycocalyx during sepsis by using proteases and hcDNA. Furthermore, glycocalyx can be harmed by a significant variety of inflammatory cytokines, including TNF-&#945;, IL-6, and IL-8. (B) Following the breakdown of the glycocalyx, endothelial cell adhesion molecules become visible, which causes further inflammation, leukocyte and platelet attachment, and rolling. Junction cleavage is the primary cause of the increase in para-endothelial permeability. It is demonstrated that TNF-&#945; activates NF-&#954;B, which disrupts claudin. Occludin redistributes due to ROS, which reduces its ability to bind to ZO-1. VE-cadherin is prone to being broken down by enzymes. NETs use histone and MPO to promote apoptosis. GAG glycosaminoglycan; VE-cadherin vascular endothelial-cadherin; ZO zonula occluding; S1P Sphingosine-1-phosphate; TIE2 Ang-1 receptor; Ang-1 angiopoietin-1; ROS Reactive oxygen species; SYN1 Syndecan-1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6260-g003.jpg"/></fig>
</p></sec><sec><title>Endothelial cells</title><p>In sepsis, the coagulation system, vascular endothelium, and activated complement system interact and contribute to the inflammatory response. Vascular endothelial cells are mostly affected by sepsis in the early stage of inflammation and coagulation<sup>[<xref rid="R144" ref-type="bibr">144</xref>]</sup>. Endothelial injury increases vascular permeability, allowing fluid to leak from the blood vessels into the interstitial space. Consequently, hypovolemia reduces perfusion pressure and oxygen. Forming as a loss of intravascular volume, hypovolemic shock occurs within hours<sup>[<xref rid="R145" ref-type="bibr">145</xref>,<xref rid="R146" ref-type="bibr">146</xref>]</sup>.</p><p>Vascular endothelial activation and dysfunction may play a role in sepsis phenotypes and are associated with patient age. Compared with patients younger than 50&#160;years old, those aged 70 and above exhibit relatively mild endothelial activation and dysfunction due to sepsis<sup>[<xref rid="R118" ref-type="bibr">118</xref>]</sup>. In a homeostatic state, the endothelial barrier is functionally maintained by the cytoskeleton, glycocalyx, intercellular adhesion molecules, and other support proteins. Tight junctions (TJs) and adherens junctions are two predominant adhesions between endothelial cells. Occludins and claudins, which are linked to the actin cytoskeleton by zonula occludins (ZO), make up TJs (Fig. <xref rid="F4" ref-type="fig">4</xref>)<sup>[<xref rid="R147" ref-type="bibr">147</xref>,<xref rid="R148" ref-type="bibr">148</xref>]</sup>. Local infections stimulate the adherence of leukocytes and platelets to endothelial surfaces and further migration to infected sites. Increased para-endothelial permeability in sepsis is mainly attributed to junction cleavage and aggravated by excessive inflammatory responses. Finally, the loss of barrier function increases the mortality of sepsis<sup>[<xref rid="R149" ref-type="bibr">149</xref>]</sup>. Rho activity and kinases like Src and Pyk2 are stimulated when the cAMP/Rac1 signaling pathway is inhibited during the inflammatory response triggered by NETs(Fig. <xref rid="F4" ref-type="fig">4</xref>)<sup>[<xref rid="R150" ref-type="bibr">150</xref>]</sup>, both of which can lead to VE-cadherin phosphorylation, vinculin dissociation, and endocytosis<sup>[<xref rid="R151" ref-type="bibr">151</xref>]</sup>. Endocytosis of VE-cadherin expands the gap between endothelial cells and thus increases the permeability of the vascular barrier<sup>[<xref rid="R152" ref-type="bibr">152</xref>]</sup>. Endothelial barrier failure is caused by the inflammatory cytokine TNF-&#945;, which activates the NF-&#954;B pathway and degrades Claudin-5 at the intercellular junctions of endothelial cells<sup>[<xref rid="R153" ref-type="bibr">153</xref>]</sup>. ROS causes occludin to reorganize at intercellular junctions, which facilitates its dissociation from ZO-1 and raises the endothelium&#8217;s soluble permeability (Fig. <xref rid="F4" ref-type="fig">4</xref>)<sup>[<xref rid="R154" ref-type="bibr">154</xref>]</sup>. Intravascular proteins and plasma escape into the extravascular space when the barrier is compromised, which decreases tissue edema and microvascular perfusion.<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Activation of the coagulation and immune systems. Pathogens stimulate macrophages/monocytes to release cytokines and microvesicles, thereby initiating inflammation and coagulation. Activated neutrophils, by inflammatory cytokines, then expel NETs and result in endothelial cell damage. They also release DAMPs and inflammatory mediators. DAMPs activate the TLRs of immune cells, leading to the release of pro-inflammatory cytokines, which in turn activate coagulation factors VII and XII, initiating the coagulation cascade. Platelets recognize DAMPs through TLRs, RAGE, and DC-SIGN, releasing cytokines (C3) that participate in the inflammatory response. The activated complement system eventually forms the MAC and damages endothelial cells. The extrinsic and intrinsic pathways initiated by tissue factors synergistically activate the coagulation cascade to produce the key mediator thrombin. Further activating inflammation and coagulation, thrombin ultimately stimulates the formation of an inflammatory thrombus. LPS lipopolysaccharide, TLR Toll-like receptor; DAMPs damage-associated molecular patterns, RAGEs receptors for advanced glycation endproducts, DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin, NETs neutrophil extracellular traps, TF tissue factor; MAC membrane attack complex, FVIIa factor VIIa, PAI-1 plasminogen activator inhibitor-1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6260-g004.jpg"/></fig>
</p><p>One of the initial signs of endothelial dysfunction in sepsis is the destruction of the endothelial glycocalyx (eGC) structure<sup>[<xref rid="R146" ref-type="bibr">146</xref>]</sup>. The endothelial glycocalyx is a layer of carbohydrate-rich material that covers the luminal surface of endothelial cells and provides multiple protective functions to the vascular system<sup>[<xref rid="R155" ref-type="bibr">155</xref>]</sup>. Through mediating vascular permeability and endothelial cell response to shear stress, eGC inhibits leukocyte and platelet adhesion, coagulation cascade activation, as well as microthrombi formation<sup>[<xref rid="R156" ref-type="bibr">156</xref>]</sup>. Impaired eGC exacerbates endothelial dysfunction and septic complications. An <italic toggle="yes">in vivo</italic> sepsis model demonstrated that sepsis-induced reduction in the thickness of eGC leads to albumin extravasation and increased production of circulating glycocalyx products (e.g., hyaluronic acid and CD44)<sup>[<xref rid="R157" ref-type="bibr">157</xref>]</sup>. The potential mechanism can be explained through a series of cascade reactions, in which a disintegrin and metalloproteinase 15 (ADAM15) cleaves CD44 on the eGC, leading to increased concentrations of soluble CD44 and hyaluronic acid in the plasma. Subsequently, this results in a reduction of endothelial barrier integrity and the destruction of vascular endothelial cadherin and &#946;-catenin, which are important components of adherens junctions (Fig. <xref rid="F4" ref-type="fig">4</xref>)<sup>[<xref rid="R157" ref-type="bibr">157</xref>]</sup>. Endothelial TJs and gap junctions are disrupted by sepsis<sup>[<xref rid="R158" ref-type="bibr">158</xref>]</sup>. Various eGC products emerge as biomarkers to predict sepsis. Elevated plasma Syndecan-1 levels during sepsis, for example, are associated with the outcome of renal replacement, respiratory failure, and multiple organ dysfunction syndrome (MODS), serving as biomarkers to predict coagulation failure and its mortality<sup>[<xref rid="R159" ref-type="bibr">159</xref>-<xref rid="R161" ref-type="bibr">161</xref>]</sup>. Sphingosine-1-phosphate (S1P) is a component of eGC that links with vascular leakage and predicts the mortality of sepsis (Fig. <xref rid="F4" ref-type="fig">4</xref>) <sup>[<xref rid="R162" ref-type="bibr">162</xref>,<xref rid="R163" ref-type="bibr">163</xref>]</sup>.</p><p>Plasma-derived S1P can activate the S1P receptor 1 on endothelial cells to maintain vascular integrity<sup>[<xref rid="R164" ref-type="bibr">164</xref>]</sup>. Angiopoietin-1 (Ang-1) contributes to maintaining vascular integrity via activating the receptor TIE2 (also known as Ang-1 receptor) (Fig. <xref rid="F4" ref-type="fig">4</xref>). In addition, angiopoietin-2 (Ang-2) is a functional antagonist of Ang-1 that disrupts endothelial barrier function. Its plasma level is an independent predictor of organ dysfunction and death during sepsis<sup>[<xref rid="R162" ref-type="bibr">162</xref>,<xref rid="R165" ref-type="bibr">165</xref>]</sup>. The predictive performance of Ang-2 in sepsis-related acute kidney injury is superior to soluble endothelial cadherin (sVE-cadherin), endocan and syndecan-1<sup>[<xref rid="R163" ref-type="bibr">163</xref>]</sup>. An elevated plasma Ang-2/Ang-1 ratio is believed as an effective biomarker for assessing vascular barrier dysfunction in sepsis patients (Fig. <xref rid="F4" ref-type="fig">4</xref>)<sup>[<xref rid="R166" ref-type="bibr">166</xref>]</sup>.
</p></sec><sec><title>Activation of the complement system</title><p>A close interaction exists between the coagulation system and complement system (Fig. <xref rid="F3" ref-type="fig">3</xref>). Once the infection aggravates to sepsis or septic shock, the complement pathway is deeply activated and is no longer associated with dysregulated inflammatory responses or clinical outcomes. This means that the complement system has been activated to a degree that it no longer has predictive value for clinical outcomes<sup>[<xref rid="R167" ref-type="bibr">167</xref>]</sup>. It is known that the complement is activated through three independent pathways: the classical pathway involving antigen-antibody complexes, the alternative pathway involving factors B/D, and the lectin pathway. The formation of C3 convertases is the point at which the three pathways of complement activation converge. PAMPs (e.g., LPS, mannose, and antigen-antibody complexes) and DAMPs are known to activate the classical complement pathway. A cascade of complement cleavage and assembly leads to the formation of catalytic C3 convertase (C4b2b). C3 is then cleaved to obtain excess C3b that amplifies the complement response. The cleavage products of C3 covalently bind to the surface of the pathogen and promote phagocytosis by neutrophils, which is an antimicrobial process specifically referred to as opsonization. C5 forms the C5b-9 complement complex, also known as the membrane attack complex(MAC), which induces cell lysis and clears specific types of intracellular bacteria by creating pores on cells<sup>[<xref rid="R168" ref-type="bibr">168</xref>]</sup>. Anaphylatoxins C3a and C5a exert potent pro-inflammatory effects by directly binding to receptors, thus recruiting and activating leukocytes, endothelial cells and platelets<sup>[<xref rid="R169" ref-type="bibr">169</xref>]</sup>. Although the activation of the complement system guards protective immunity, an uncontrollable activation causes tissue damage and organ failure<sup>[<xref rid="R169" ref-type="bibr">169</xref>]</sup>. Continuous production of C5a paralyzes the innate immune system and weakens the killing effect on bacteria<sup>[<xref rid="R170" ref-type="bibr">170</xref>]</sup>. Treatment with C5a receptor antagonists greatly enhances the survival rate of sepsis, whereas the use of C3a receptor antagonists obtains an opposite outcome<sup>[<xref rid="R171" ref-type="bibr">171</xref>]</sup>. C5a and C3a exert different roles in the human body. Inhibiting the C5a signaling improves outcomes in mice with polymicrobial abdominal sepsis, mice with sepsis caused by <italic toggle="yes">Streptococcus pneumoniae</italic> infections, and baboons with sepsis caused by <italic toggle="yes">E. coli</italic> infections<sup>[<xref rid="R171" ref-type="bibr">171</xref>-<xref rid="R173" ref-type="bibr">173</xref>]</sup>. C3a convertase inhibitors not only inhibit the activation of the complement system in sepsis caused by <italic toggle="yes">E. coli</italic> infections, but also attenuate other inflammatory responses, coagulation activation, and multi-organ failure<sup>[<xref rid="R174" ref-type="bibr">174</xref>]</sup>.</p></sec><sec><title>Activation of the coagulation system</title><p>Sepsis often accompanies coagulation abnormalities. A multi-center clinical study in Japan found that approximately 61% of sepsis patients suffer from DIC<sup>[<xref rid="R175" ref-type="bibr">175</xref>]</sup>. There is an extensive cross-talk between coagulation and inflammation, which may be involved in the pathogenesis of organ dysfunction in sepsis patients<sup>[<xref rid="R176" ref-type="bibr">176</xref>,<xref rid="R177" ref-type="bibr">177</xref>]</sup>. Activation of the coagulation system in sepsis imbalances and leans towards thrombosis in the microvascular system<sup>[<xref rid="R178" ref-type="bibr">178</xref>]</sup>. DIC is the most threatening coagulation dysfunction in sepsis patients, leading to thrombosis and bleeding due to the consumption of coagulation factors, anticoagulant proteins, and platelets. Sepsis-related DIC is mainly caused by thrombosis in microcirculation, eventually leading to organ dysfunction<sup>[<xref rid="R178" ref-type="bibr">178</xref>]</sup>. Systemic activation during blood coagulation is one of the dominant pathogenic factors for DIC. Meanwhile, positive expressions of tissue factors on monocytes/macrophages also trigger sepsis-related DIC<sup>[<xref rid="R179" ref-type="bibr">179</xref>]</sup>. Pathologically, massive bioactive tissue factors in microvesicles derived from various cell sources contribute to amplifying the coagulation function via binding to activated platelets, neutrophils, and endothelial cells. Factor VIIa (FVIIa) exerts a vital role in sepsis, and its inhibition suppresses LPS- or bacteria-induced activation of the coagulation system in humans and non-human primates<sup>[<xref rid="R180" ref-type="bibr">180</xref>]</sup>. Under normal circumstances, the activation of coagulation is controlled by the antithrombin system, activated protein C system and tissue factor pathway inhibitor (TFPI); all three, however, are impaired in sepsis<sup>[<xref rid="R180" ref-type="bibr">180</xref>]</sup>.</p><p>Platelets are the major blood component responsible for thrombosis and hemostasis. The role of platelets in the pathogenesis of vascular inflammatory processes has been unveiled, such as autoimmune diseases, sepsis, viral infections, and tumor growth and metastasis. Therefore, platelets are considered a type of immune cell involved throughout all stages of the immune response<sup>[<xref rid="R181" ref-type="bibr">181</xref>]</sup>. Platelets directly participate in the immune and inflammatory responses via the membrane surface receptors and indirectly recognize PAMPs and DAMPs<sup>[<xref rid="R182" ref-type="bibr">182</xref>,<xref rid="R183" ref-type="bibr">183</xref>]</sup> via TLRs<sup>[<xref rid="R184" ref-type="bibr">184</xref>-<xref rid="R186" ref-type="bibr">186</xref>]</sup>, receptors for advanced glycation endproducts (RAGEs), and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN)<sup>[<xref rid="R187" ref-type="bibr">187</xref>]</sup>. DAMPs activate the TLRs of immune cells, leading to the release of pro-inflammatory cytokines (such as TNF-&#945;, IL-1, IL-6), which in turn activate coagulation factors VII and XII, initiating the coagulation cascade<sup>[<xref rid="R188" ref-type="bibr">188</xref>]</sup>. In addition, platelets are inflammation regulators by directly releasing cytokines (C3, C4a, C1 esterase inhibitor and complement factor H), chemokines and growth factors<sup>[<xref rid="R189" ref-type="bibr">189</xref>]</sup>. Cell adhesion molecules are positively expressed on the surface of platelets, thus expanding the antibacterial response of Kupffer cells, neutrophils and the complement system<sup>[<xref rid="R186" ref-type="bibr">186</xref>]</sup>. Platelets further promote coagulation and inflammatory responses directly through cell-to-cell contact (leukocytes) and indirectly through the release of proteases and platelet extracellular vesicles (PEVs)<sup>[<xref rid="R190" ref-type="bibr">190</xref>]</sup>.</p><p>LPS stimulates platelets through the TLR4 pathway, leading to the activation of c-Jun N-terminal kinase and Akt, which ultimately results in an increased secretion of IL-1&#946; in PEVs. The released IL-1&#946; further stimulates the binding of leukocytes to endothelial cells by upregulating VCAM-1<sup>[<xref rid="R191" ref-type="bibr">191</xref>]</sup>. Platelets are then responsible for endothelial cell adhesion and extravasation of leukocytes at inflammatory sites, as well as triggering the release of NETs by neutrophils<sup>[<xref rid="R192" ref-type="bibr">192</xref>]</sup>. Thromboxane A2 (TXA2) released by neutrophil-platelet aggregates activated endothelial cells through thromboxane receptors, receptor and integrin activation, platelet aggregation, and increased vascular permeability<sup>[<xref rid="R193" ref-type="bibr">193</xref>]</sup>. Blocking P-selectin is an effective approach to inhibit the formation of neutrophil-platelet aggregates and reduce plasma TXA2 level, which also greatly prolongs the survival of sepsis-induced mice with acute lung injury via improving alveolar gas exchange<sup>[<xref rid="R193" ref-type="bibr">193</xref>]</sup>. Platelets and platelet-derived microparticles expressing phospholipids (e.g., phosphatidylserine) are essential to promote coagulation by increasing the activities of tissue factors FVa and FXa<sup>[<xref rid="R190" ref-type="bibr">190</xref>]</sup>.</p><p>A bimodal interaction exists between the coagulation system and innate immunity (Fig. <xref rid="F3" ref-type="fig">3</xref>). Inflammation initiates the coagulation and triggers its activation, and coagulation in turn mediates inflammatory responses<sup>[<xref rid="R194" ref-type="bibr">194</xref>]</sup>. Neutrophil elastase, cathepsin G, and nucleosomes altogether inhibit local proteolysis by suppressing the tissue factor pathway. Consequently, the activated coagulation relying on tissue factors and FXII results in coagulation and the formation of intravascular thrombi<sup>[<xref rid="R195" ref-type="bibr">195</xref>]</sup>. The interplay between platelets and neutrophils is essential for the excessive inflammation and thrombosis in sepsis. Leukocytes are drawn to the infection site by activated platelets, and they form complexes with neutrophils that lower the neutrophils &#8216;threshold for releasing NETs and increase the neutrophils&#8217; capacity to kill pathogens (Fig. <xref rid="F3" ref-type="fig">3</xref>)<sup>[<xref rid="R196" ref-type="bibr">196</xref>]</sup>. NETs, released into the vasculature during sepsis, contribute to host defense but can also lead to tissue damage and organ dysfunction. Various components of NETs are also considered to be activators of coagulation<sup>[<xref rid="R133" ref-type="bibr">133</xref>]</sup>. NETs-induced intravascular coagulation is dependent on the interaction among histone H4, platelets, and inorganic polyphosphates<sup>[<xref rid="R133" ref-type="bibr">133</xref>]</sup>. The extent of NETs formation is a predictive factor for the development and mortality of DIC in sepsis patients, further validating the fundamental role of NETs in sepsis-related coagulopathy<sup>[<xref rid="R197" ref-type="bibr">197</xref>]</sup>.</p></sec><sec><title>Coagulation factors and tissue factors</title><p>Proinflammatory signaling is triggered by FVIIa, FXa, thrombin, and fibrin (Fig. <xref rid="F3" ref-type="fig">3</xref>), mainly by activating protease-activated receptors (PARs) such as PAR1, PAR3, and PAR4<sup>[<xref rid="R198" ref-type="bibr">198</xref>]</sup>. Tissue factors mutually activate coagulation proteases. As an illustration, thrombin, FXa, FXa, and C3 transform C3 and C5 into C3a and C5a, respectively; C5a and C5b-9, also referred to as the membrane attack complex, then promote the positive expression of tissue factors on endothelial cells (Fig. <xref rid="F3" ref-type="fig">3</xref>)<sup>[<xref rid="R199" ref-type="bibr">199</xref>]</sup>. C5a interferes with the function of eGC, thus achieving the goal of promoting coagulation. Inflammasomes and gasdermin D (GSDMD) are two mediators for the interaction between inflammation and coagulation. GSDMD causes macrophages and monocytes to undergo pyroptosis via the caspase-1 and caspase-11 enzymes. Released tissue factors in microvesicles derived from pyroptotic cells further activate the coagulation system<sup>[<xref rid="R200" ref-type="bibr">200</xref>]</sup>. The function of inflammasomes in the immune and coagulation systems is affected by TMEM173 and HMGB1. TMEM173 is an endoplasmic protein that amplifies inflammation, drives tissue factor release and participates in coagulation reactions by activating GSDMD<sup>[<xref rid="R201" ref-type="bibr">201</xref>-<xref rid="R203" ref-type="bibr">203</xref>]</sup>. Exogenous HMGB1 forms a molecular complex with LPS and is transported into lysosomes. Macrophages and endothelial cells then result in HMGB1-mediated lysosomal membrane destruction through RAGEs. The released LPS into the cytoplasm activates caspase1-dependent cellular pyrolysis, NLRP3 inflammasomes, and the lethal coagulation pathway<sup>[<xref rid="R204" ref-type="bibr">204</xref>]</sup>. Phosphatidylserine-induced GSDMD activation and pore formation are two essential events for tissue factors exposed and activated by HMGB1, rather than GSDMD-induced pyroptosis<sup>[<xref rid="R204" ref-type="bibr">204</xref>]</sup>. Caspase-induced cleavage of GSDMD initiates the release of tissue factors, serving as a central stage of DIC that bridges inflammation and coagulation by activated inflammasomes.
</p></sec></sec><sec><title>Immunosuppression</title><p>The extremely high mortality of sepsis is related to hyporesponsiveness (immune tolerance). Immune tolerance is a defense response against inflammatory responses, thus maintaining host homeostasis. Nevertheless, the immune system is unable to recover from the self-induced suppression in sepsis and becomes trapped in a paralyzed state that cannot prevent the progression of infections. Accumulating evidence has highlighted the role of immune cells, immune checkpoints, reprogramming of monocytes/macrophages and epigenetic regulation of gene expressions in sepsis-induced immune tolerance<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> (Fig. <xref rid="F5" ref-type="fig">5</xref>).
<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Mechanisms of sepsis-induced immunosuppression. Pro and anti-inflammatory mechanisms make up the host response during sepsis. An infection sets off an initial cytokine-mediated host inflammatory response, which is triggered by an interaction between pattern recognition receptors, PAMPs, and DAMPs and is linked to immune cell reprogramming, checkpoints, and epigenetic modification. Sepsis patients experience excessive inflammatory reactions, which lead to tissue damage and organ failure. At the same time, anti-inflammatory responses are induced and are most likely initiated by inflammation. These responses include cellular anergy and cell death, among other things. The anti-inflammatory milieu persists and sustains immunosuppression. DAMP, damage-associated molecular pattern; PAMP, pathogen-associated molecular pattern; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; ROS, reactive oxygen species.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6260-g005.jpg"/></fig>
</p><sec><title>Cell apoptosis and release of anti-inflammatory factors</title><p>Immunosuppression in sepsis patients is a complicated condition involving multiple types of cells with various characteristics, and linked with the release of anti-inflammatory cytokines, enhanced immune cell apoptosis, T cell exhaustion, immunosuppressive cell hyperproliferation, epigenetic reprogramming and reduced expressions of surface molecules on activated cells<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R205" ref-type="bibr">205</xref>]</sup>. Immunosuppression in sepsis patients is manifested by an increased susceptibility to secondary infections that are usually caused by opportunistic pathogens and viruses<sup>[<xref rid="R206" ref-type="bibr">206</xref>-<xref rid="R208" ref-type="bibr">208</xref>]</sup>. Apoptosis of immune cells in sepsis, including CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, B cells, NK cells and follicular dendritic cells, is activated by the mitochondria (the intrinsic pathway) or the activation of death receptors (the extrinsic pathway)<sup>[<xref rid="R209" ref-type="bibr">209</xref>,<xref rid="R210" ref-type="bibr">210</xref>]</sup>.</p><p>In sepsis patients, there is a selective depletion of memory B cells due to mitochondrial dysfunction<sup>[<xref rid="R210" ref-type="bibr">210</xref>]</sup>, a reduction in the expression of major histocompatibility complex class II, and an increase in the expression of the anti-inflammatory cytokine IL-10<sup>[<xref rid="R211" ref-type="bibr">211</xref>]</sup>. Inhibiting or preventing apoptosis improves the prognosis in clinical sepsis models, demonstrating the importance of apoptosis in the outcome of sepsis<sup>[<xref rid="R212" ref-type="bibr">212</xref>,<xref rid="R213" ref-type="bibr">213</xref>]</sup>. Autophagy is a process responsible for maintaining cellular homeostasis via recycling organelles and long-lived proteins. An impaired autophagy is another important event leading to immunosuppression. Lymphocyte-specific loss of Atg5 or Atg7 in mice with abdominal sepsis weakens autophagy, causes immune dysfunction and increases mortality, whereas a T-cell-specific deficiency of Atg5 in sepsis stimulates the secretion of IL-10<sup>[<xref rid="R214" ref-type="bibr">214</xref>]</sup>.</p><p>The ability of T cells in the blood, spleen, and lungs to produce cytokines is attenuated in sepsis patients<sup>[<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R215" ref-type="bibr">215</xref>]</sup>. Moreover, sepsis patients present worse performances in the proliferation of CD8<sup>+</sup> T cells, cytotoxic function and production of IL-2 and interferon-&#947; (IFN-&#947;)<sup>[<xref rid="R216" ref-type="bibr">216</xref>]</sup>. The anti-inflammatory response in sepsis is maintained by increased numbers of Tregs and MDSCs, both of which are a mixture of immature myeloid cells that effectively against effector immune cells, especially T cells<sup>[<xref rid="R217" ref-type="bibr">217</xref>-<xref rid="R219" ref-type="bibr">219</xref>]</sup>. Multiple mechanisms explain the immune dysfunction caused by MDSCs, including deprivation of L-arginine that is essential for T cell function, stimulation of Treg proliferation, and inhibition of macrophage and dendritic cell functions<sup>[<xref rid="R219" ref-type="bibr">219</xref>,<xref rid="R220" ref-type="bibr">220</xref>]</sup>. The proliferation of MDSCs is correlated with an increased risk of secondary infection in critically ill patients with sepsis<sup>[<xref rid="R221" ref-type="bibr">221</xref>]</sup>. Immunocompromised features are observed in neutrophils of sepsis patients, such as migration to multiple chemoattractants, reduced contents of intracellular myeloperoxidase and lactoferrin, and impaired oxidative burst<sup>[<xref rid="R132" ref-type="bibr">132</xref>,<xref rid="R222" ref-type="bibr">222</xref>]</sup>. Kinase activity in neutrophils is significantly weaker in sepsis patients than in uninfected critically ill patients<sup>[<xref rid="R223" ref-type="bibr">223</xref>]</sup>.</p></sec><sec><title>Immune checkpoints</title><p>Immune checkpoints are membrane-bound proteins involved in the immune response as a second signal<sup>[<xref rid="R224" ref-type="bibr">224</xref>]</sup>. They are important in sepsis-induced immunosuppression. Programmed cell death-1 (PD-1) is a widely analyzed immune checkpoint in sepsis. Triggering PD-1 on T cells leads to the release of immunosuppressive molecules and ultimately causes apoptosis<sup>[<xref rid="R225" ref-type="bibr">225</xref>]</sup>. Overexpression of PD-1 in peripheral blood T cells is associated with inhibited T cell proliferation and increased nosocomial infection and mortality in sepsis patients<sup>[<xref rid="R226" ref-type="bibr">226</xref>]</sup>. Blocking PD-1 can effectively improve the prognosis of sepsis in animal models<sup>[<xref rid="R227" ref-type="bibr">227</xref>,<xref rid="R228" ref-type="bibr">228</xref>]</sup>. A higher expression of PD-1 on blood monocytes, granulocytes, NK cells, T lymphocytes, and B lymphocytes in sepsis patients is associated with a higher mortality<sup>[<xref rid="R229" ref-type="bibr">229</xref>-<xref rid="R232" ref-type="bibr">232</xref>]</sup>. It is found that (programmed death-ligand 1) PD-L1 and PD-L2 are upregulated on dendritic cells and CD27&#160;+&#160;B lymphocytes<sup>[<xref rid="R119" ref-type="bibr">119</xref>]</sup>. The expression level of PD-1 on T cells and that of PD-L1 on antigen-presenting cells are associated with lymphopenia and T cell apoptosis in sepsis patients<sup>[<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R233" ref-type="bibr">233</xref>]</sup>, but higher expressions of PD-1 and PD-L1 are not correlated with mortality and high risk of nosocomial infection<sup>[<xref rid="R231" ref-type="bibr">231</xref>]</sup>. <italic toggle="yes">In vitro</italic>, treatment with anti-PD-1 antibodies suppresses the apoptosis of CD8<sup>+</sup> T cells and upregulates IFN-&#947;<sup>[<xref rid="R233" ref-type="bibr">233</xref>]</sup>. Considering the correlation of upregulated PD-L1 on neutrophils and monocytes with impaired phagocytic capacity, anti-PD-1 antibodies are found to enhance phagocytosis in leukocytes of sepsis patients<sup>[<xref rid="R234" ref-type="bibr">234</xref>]</sup>. It is found that the survival rate of sepsis mice is significantly enhanced by blocking or knocking out PD-1, highlighting the therapeutic efficacy of the PD-1 signaling pathway in sepsis<sup>[<xref rid="R228" ref-type="bibr">228</xref>,<xref rid="R231" ref-type="bibr">231</xref>]</sup>. PD-1 and PD-L1 and/or PD-L1 pathway inhibitors are expected to reverse immunosuppression, and they have been tested in phase I and II clinical trials for sepsis. Treatment of anti-PD-L1 antibodies presents an acceptable tolerance<sup>[<xref rid="R235" ref-type="bibr">235</xref>-<xref rid="R238" ref-type="bibr">238</xref>]</sup>, and it increases the absolute lymphocyte count and monocytic human leukocyte antigen-DR isotype (HLA-DR)<sup>[<xref rid="R237" ref-type="bibr">237</xref>]</sup>. Inhibition of Treg cell proliferation and PD-1/PD-L1 expression by splenectomy protects mice from sepsis-induced immune cell exhaustion<sup>[<xref rid="R239" ref-type="bibr">239</xref>]</sup>. Compared with those of wild-type (WT) mice, PD-1-deficient mice and mice treated with anti-PD-1 antibodies have increased bacterial clearance and reduced bacterial burden<sup>[<xref rid="R240" ref-type="bibr">240</xref>]</sup>.</p><p>Although a growing number of pieces of evidence have illustrated the role of other immune checkpoints in immunosuppression, their direction function involved in sepsis has been rarely reported<sup>[<xref rid="R224" ref-type="bibr">224</xref>,<xref rid="R241" ref-type="bibr">241</xref>]</sup>. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a negative checkpoint on T cells that binds to the B-lymphocyte activation antigens B7-1 (CD80) and B7-2 (CD86). CTLA-4 is overexpressed in CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells and Tregs of mice with intraabdominal sepsis, and treatment with anti-CTLA-4 antibodies greatly enhances mouse survival by reducing sepsis-induced spleen cell apoptosis<sup>[<xref rid="R242" ref-type="bibr">242</xref>]</sup>. Moreover, anti-CTLA-4 antibodies also increase the production of IFN-&#947; in mouse spleen, thereby reducing the mortality of bacterial sepsis caused by lethal cecal ligation and puncture (CLP) and fungal sepsis<sup>[<xref rid="R243" ref-type="bibr">243</xref>]</sup>.</p></sec><sec><title>Reprogramming of immune cells</title><p>Impaired reprogramming of monocytes and macrophages is a key feature in immunosuppression. Corresponding events like the reduced production of pro-inflammatory cytokines (also known as LPS tolerance) and downregulation of MHC Class II molecules are responsive to the stimulation by bacterial agonists<sup>[<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R244" ref-type="bibr">244</xref>]</sup>. An <italic toggle="yes">in vitro</italic> stimulation weakens the ability of leukocytes in sepsis patients to release pro-inflammatory cytokines (e.g., TNF, IL-1a, IL-6, and IL-12), whereas the ability to release anti-inflammatory mediators (e.g., IL-1 receptor antagonists) is unhurt or even stronger<sup>[<xref rid="R245" ref-type="bibr">245</xref>,<xref rid="R246" ref-type="bibr">246</xref>]</sup>. Flow cytometry data revealed that a reduced pro-inflammatory response in monocytes, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, B cells, and neutrophils isolated from sepsis patients is associated with the downregulation of phosphorylated NF-&#954;B<sup>[<xref rid="R247" ref-type="bibr">247</xref>]</sup>. Reprogramming of macrophages is mediated through balancing the equilibrium between p65-p50 and p50-p50 NF-&#954;B pathways in LPS tolerance<sup>[<xref rid="R248" ref-type="bibr">248</xref>]</sup>. Anti-inflammatory phenotypes of LPS-tolerant leukocytes are found in the lungs of animals with peritonitis and postmortem sepsis patients<sup>[<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R249" ref-type="bibr">249</xref>]</sup>. Cross-tolerance is a phenomenon that occurs when the ability of bacterial agonists to produce pro-inflammatory cytokines is weakened by the stimulation with another agonist. For example, an <italic toggle="yes">in vivo</italic> LPS exposure of human blood leukocytes induces cross-tolerance to reduce the production of TLR2, TLR4, TLR5, and TLR7 receptors<sup>[<xref rid="R250" ref-type="bibr">250</xref>]</sup>. DAMPs induce cross-tolerance with LPS, indicating that multiple mechanisms underlying reprogramming of monocytes in sepsis<sup>[<xref rid="R251" ref-type="bibr">251</xref>,<xref rid="R252" ref-type="bibr">252</xref>]</sup>. Notably, some types of cells in mice have initiated reprogramming without the involvement of cross-tolerance, such as alveolar macrophages, Kupffer cells, microglia, and lymphocytes in the intestinal epithelium and skin<sup>[<xref rid="R253" ref-type="bibr">253</xref>]</sup>. Downregulation of monocytic HLA-DR is a biomarker of sepsis-induced immunosuppression and is associated with a high incidence of nosocomial infections and increased mortality<sup>[<xref rid="R254" ref-type="bibr">254</xref>,<xref rid="R255" ref-type="bibr">255</xref>]</sup>.</p></sec><sec><title>Epigenetic regulation of gene expression</title><p>Epigenetic regulation of gene expression contributes to the reprogramming of immune cells in sepsis, particularly through histone modifications and DNA methylation<sup>[<xref rid="R256" ref-type="bibr">256</xref>]</sup>. Chromatin regions are responsible for gene transcription into actively transcribed genes or transcriptionally silent genes<sup>[<xref rid="R257" ref-type="bibr">257</xref>]</sup>. Histones form the structure of DNA in chromatin, and prevent DNA from becoming tangled and blocking transcription. Acetylation of lysine residues on the histone is involved in gene transcription, whereas methylation leads to the formation of silent heterochromatin<sup>[<xref rid="R257" ref-type="bibr">257</xref>]</sup>. Methylation of histone H3 lysine K4 (H3K4) and histone H3 lysine K27 (H3K27) is highly associated with transcriptional activation and repression, respectively. Downregulation of open chromatin, such as H3K4me3 (histone H3 trimethylated at lysine 4), underlies LPS-induced monocyte tolerance<sup>[<xref rid="R258" ref-type="bibr">258</xref>]</sup>. H3K9me2 is a repressive signal that increases in the promoter regions of genes encoding IL-1&#946; and TNF in LPS-resistant macrophages<sup>[<xref rid="R259" ref-type="bibr">259</xref>,<xref rid="R260" ref-type="bibr">260</xref>]</sup>. A similar finding is also yielded in LPS-resistant blood monocytes from sepsis patients<sup>[<xref rid="R260" ref-type="bibr">260</xref>]</sup>. Upregulation of histone demethylase KDM6B (also known as JMJD3) by activated NF-&#954;B<sup>[<xref rid="R261" ref-type="bibr">261</xref>]</sup>, and inhibition of transcription genes due to accumulated protein deacetylase sirtuin-1 on the promoters of TNF and IL-1&#946; explain the epigenetic mechanism of LPS in affecting gene transcription<sup>[<xref rid="R262" ref-type="bibr">262</xref>]</sup>. Single-cell RNA sequencing of peripheral blood monocytes and dendritic cells revealed a unique population of CD14<sup>+</sup> monocytes with an immunosuppressive phenotype, named MS1. Downregulation of MHC class II molecules, activation of NF-&#954;B and reduced production of TNF are found in LPS-induced MS1 cells<sup>[<xref rid="R263" ref-type="bibr">263</xref>]</sup>. Overall, single-cell sequencing provides insights into distinct cellular phenotypes of either pro-inflammatory or immunosuppressive in sepsis<sup>[<xref rid="R263" ref-type="bibr">263</xref>]</sup>.</p><p>Infections cause long-lasting epigenetic changes. IL-12 derived by dendritic cells is long-term downregulated for 6&#160;weeks and longer after the original septic event in mice, which is attributed to the transcription of IL-12 p35 and IL-12 p40 influenced by histone modifications<sup>[<xref rid="R264" ref-type="bibr">264</xref>]</sup>. A long-term epigenetic change following pneumonia results in the resistance of macrophages and impaired functions to phagocytose antigens and bacteria<sup>[<xref rid="R265" ref-type="bibr">265</xref>]</sup>. In mice, epigenetic modifications are brought about by sepsis. When inflammatory gene promoters have defective H3K4me3 (activation mark) at NF-&#954;B-binding sites, mice with recovered abdominal sepsis have downregulated Mixed-lineage leukemia 1 in their bone marrow-derived macrophages<sup>[<xref rid="R266" ref-type="bibr">266</xref>]</sup>. Long-term peripheral macrophage function degradation is caused by epigenetic alterations that begin in bone marrow progenitor stem cells after post-sepsis<sup>[<xref rid="R266" ref-type="bibr">266</xref>]</sup>. Collectively, immunosuppression is a persistent condition in newly proliferating leukocytes in sepsis and is associated with long-term recurrence and mortality.</p></sec></sec><sec><title>Gut microbiota</title><p>Gastrointestinal dysfunction, intestinal dysbiosis, bacterial translocation and destruction of intestinal homeostasis are frequently observed in sepsis patients. The intestinal mucosal barrier damage further promotes the release of inflammatory factors, and the vicious circle eventually exacerbates sepsis<sup>[<xref rid="R267" ref-type="bibr">267</xref>]</sup>. As a result, the destruction of intestinal homeostasis and intestinal mucosal barrier are both consequences and initiators of sepsis<sup>[<xref rid="R268" ref-type="bibr">268</xref>]</sup>. Commensal bacteria are present in the gut and are essential for maintaining homeostasis and protecting the host from pathogenic bacterial invasion. Physiologically, gut microbiota directly or indirectly resists colonization and invasion by harmful microorganisms. Additionally, host cells manufacture antimicrobial proteins for them. For instance, commensal (LPS and flagellin) microbe-associated molecular patterns (MAMPs) stimulate epithelial cells and dendritic cells through TLR-mediated means, resulting in the production of the islet-derived protein III&#947; by Paneth cells. The interaction between other intestinal bacteria and intestinal epithelial cells increases IgA produced by B lymphocytes, induces Th17 cell differentiation and produces pro-inflammatory factors<sup>[<xref rid="R269" ref-type="bibr">269</xref>,<xref rid="R270" ref-type="bibr">270</xref>]</sup>. Metabolites of gut microbiota influence the function of immune cells. Pathogens entering the circulation system are usually captured and killed by Kupffer cells. D-lactic acid produced by gut microbiota is transferred to the liver through the portal vein, thus influencing the response of Kupffer cells to capture and kill pathogens<sup>[<xref rid="R271" ref-type="bibr">271</xref>]</sup>. Short-chain fatty acids (SCFAs) are the main metabolites produced by microorganisms, showing pleiotropic effects on the host through driving monocyte differentiation into macrophages, inhibiting histone deacetylase-3, and regulating the barrier function of intestinal epithelium<sup>[<xref rid="R268" ref-type="bibr">268</xref>]</sup>. Butyrate produced by <italic toggle="yes">Clostridium</italic> and <italic toggle="yes">Faecalibacterium</italic> is a regulator of colonic T cell differentiation by upregulating Foxp3, and it also reduces the expression levels of inflammatory factors (TNF-&#945;, IL-6) by inhibiting histone deacetylation<sup>[<xref rid="R272" ref-type="bibr">272</xref>]</sup>. In addition, the dominant gut microbiota can directly inhibit those entering the intestine by competing for nutrients and producing virulence factors (antimicrobial peptides)<sup>[<xref rid="R269" ref-type="bibr">269</xref>,<xref rid="R270" ref-type="bibr">270</xref>]</sup>.</p><p>Disruption of the gut microbiota enhances disease susceptibility. A large-scale observational study provided indirect evidence for sepsis caused by the impaired gut microbiota<sup>[<xref rid="R273" ref-type="bibr">273</xref>-<xref rid="R275" ref-type="bibr">275</xref>]</sup>. Alterations in the gut microbiota result in the increased permeability of the intestinal barrier and pathogen spreading throughout the body<sup>[<xref rid="R276" ref-type="bibr">276</xref>]</sup>. Moreover, the host&#8217;s ability of remote organs to defend against infections, such as bone marrow and lungs, is weakened following the disruption of the gut microbiota<sup>[<xref rid="R268" ref-type="bibr">268</xref>]</sup>. Prospective cohort studies have demonstrated an association between lower diversity of gut microbiome and higher abundances of pathogenic bacteria in sepsis (e.g., aerobic Gram-negative bacteria)<sup>[<xref rid="R277" ref-type="bibr">277</xref>-<xref rid="R279" ref-type="bibr">279</xref>]</sup>. Higher abundances of <italic toggle="yes">Cronobacter</italic> and <italic toggle="yes">Cronobacter phage</italic> in patients with sepsis-associated myocardial injury than in sepsis patients without tissue injury are indicative of the prognostic value of gut microbiota<sup>[<xref rid="R280" ref-type="bibr">280</xref>]</sup>. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide have become indicators for the diagnosis and prognosis of sepsis-associated myocardial injury<sup>[<xref rid="R281" ref-type="bibr">281</xref>,<xref rid="R282" ref-type="bibr">282</xref>]</sup>. Critically ill patients with systemic inflammatory response syndrome (SIRS) have lower abundances of obligate anaerobes but higher abundances of potential pathogens like <italic toggle="yes">Staphylococcus</italic> and <italic toggle="yes">Pseudomonas</italic><sup>[<xref rid="R283" ref-type="bibr">283</xref>]</sup>. Deshmukh <italic toggle="yes">et al</italic> verified the role of gut microbiota in regulating the homeostasis and number of neutrophils in neonatal mice with sepsis of <italic toggle="yes">E. coli</italic> infection<sup>[<xref rid="R284" ref-type="bibr">284</xref>]</sup>. An increased alpha diversity in the gut microbiome via co-housing in turn increases CD4<sup>+</sup> T cell response and survival of septic mice<sup>[<xref rid="R285" ref-type="bibr">285</xref>]</sup>. Metabolites derived from gut microbiota are important mediators of liver, lung, kidney and cardiac function<sup>[<xref rid="R286" ref-type="bibr">286</xref>,<xref rid="R287" ref-type="bibr">287</xref>]</sup>. SCFAs are a typical type of metabolites produced by gut microbiota, which extensively participate in immune response, inflammatory response, and carbohydrate and lipid metabolism<sup>[<xref rid="R288" ref-type="bibr">288</xref>,<xref rid="R289" ref-type="bibr">289</xref>]</sup>. Through providing essential energy to intestinal epithelial cells in the colon, butyrate contributes to the regulation of intestinal gene expressions and suppression of LPS-induced intestinal inflammation<sup>[<xref rid="R290" ref-type="bibr">290</xref>]</sup>. Zhan <italic toggle="yes">et al</italic> summarized the capacity of SCFAs to defend against pathogen invasion as energy sources and regulators of barrier function and immune status of the host intestine<sup>[<xref rid="R291" ref-type="bibr">291</xref>]</sup>. SCFAs also reduce the expression levels of pro-inflammatory factors (e.g., NO, TNF-&#945;, IL-6, IL-1&#946;, IL-10) by mediating the production of immune cytokines<sup>[<xref rid="R292" ref-type="bibr">292</xref>,<xref rid="R293" ref-type="bibr">293</xref>]</sup>, and influence immune cell function through post-transcriptional modifications in the acute phase of infections. In mice, acetate promotes the acetylation of GAPDH to catalyze glycolysis by supplementing acetyl-CoA, thereby promoting the rapid recall response of CD8<sup>+</sup> T cells and immune responses<sup>[<xref rid="R294" ref-type="bibr">294</xref>]</sup>.</p><p>In summary, the significance of gut microbiota in the context of sepsis should not be underestimated or overlooked. Before the onset of sepsis, gut microbiota are altered to increase the susceptibility to sepsis through increasing the abundances of pathogenic bacteria, priming the immune system to produce a robust pro-inflammatory response, and reducing the production of beneficial microbial products. Once sepsis attacks the human body, the disruption of gut microbiota further worsens and causes a higher risk of Multiple Organ Dysfunction Syndrome (MODS). There is limited evidence that microbiome-based therapeutics, including the use of probiotics and selective decontamination of the digestive tract, can reduce the risk of sepsis and improve the outcomes, although safety concerns.</p></sec></sec><sec><title>Treatment of sepsis</title><p>At present, there lack of effective targeted therapies for critically ill patients with sepsis. Current management of sepsis mainly focuses on controlling the infection source (surgical removal and/or use of antibiotics), stabilizing hemodynamics (hydration, use of vasoactive drugs in patients with septic shock) and regulating the host response<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R295" ref-type="bibr">295</xref>]</sup>. Organ replacement therapies, such as renal replacement therapy and mechanical ventilation, are required to relieve organ dysfunction during sepsis. Unfortunately, effective drugs to block or disrupt pathophysiological pathways involved in the development of sepsis are not available. Despite pouring massive medical resources into rescuing sepsis, the mortality of sepsis remains as high as 25%-30%, or even 50% in septic shock patients<sup>[<xref rid="R296" ref-type="bibr">296</xref>,<xref rid="R297" ref-type="bibr">297</xref>]</sup>.</p><p>Sepsis is a clinical syndrome<sup>[<xref rid="R298" ref-type="bibr">298</xref>]</sup>. Patients with a history of previous disabilities or chronic diseases are more prone to develop sepsis. Infection is the root cause of sepsis responsible for initiating and sustaining immune dysregulation. Early identification, early antibiotic treatment, and early source control of infection are crucial for the prognosis of sepsis. Early source of infection control may require surgical or invasive procedures to manage the source of infection<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R299" ref-type="bibr">299</xref>]</sup>. Source control refers to the implementation of single or combined measures to eliminate the focus of infection or control the factors of infection, including pathogen detection, early anti-infective treatment, and removal of the causes of infection. For patients with early suspected infection, timely pathogen detection should be performed. After confirmation of the diagnosis, it is crucial to identify the site of infection and take appropriate control measures. Measures for source control of infection include the use of surgical methods to eliminate the source of infection and to control ongoing infection. These measures are based on debridement, drainage, decompression, and restoration of anatomical function<sup>[<xref rid="R300" ref-type="bibr">300</xref>,<xref rid="R301" ref-type="bibr">301</xref>]</sup>. Taking intra-abdominal infection as an example, all guidelines point out that thorough control of the source of infection at the first moment is fundamental to the treatment of intra-abdominal infection. Once intra-abdominal infection is complicated by organ dysfunction and sepsis, it is necessary to establish a multidisciplinary team for comprehensive treatment of intra-abdominal infection under the leadership of surgery<sup>[<xref rid="R301" ref-type="bibr">301</xref>,<xref rid="R302" ref-type="bibr">302</xref>]</sup>.</p><p>An early antibiotic treatment is preferred for sepsis. The <italic toggle="yes">SSC Guidelines 2021</italic> recommended an intravenous infusion of one or more broad-spectrum antibiotics within 1 hour of the diagnosis of sepsis. The mortality of patients with septic shock receiving an antibiotic treatment within 3&#160;hours significantly increases by 35% for every hour of delay in antibiotic infusions<sup>[<xref rid="R303" ref-type="bibr">303</xref>]</sup>, whereas the increased mortality is not observed in sepsis patients without confirmed shock<sup>[<xref rid="R304" ref-type="bibr">304</xref>]</sup>. However, the continuous narrowing of the antibiotic prescription window compels medical personnel to sacrifice diagnostic accuracy in pursuit of speed<sup>[<xref rid="R305" ref-type="bibr">305</xref>]</sup>, inevitably leading to the overuse of antibiotics<sup>[<xref rid="R306" ref-type="bibr">306</xref>]</sup>. Before the recognition of a certain pathogen, an early empiric antibiotic therapy provides clinical benefits to sepsis with an unknown source of infections<sup>[<xref rid="R307" ref-type="bibr">307</xref>]</sup>. A retrospective cohort study in the United States in 2014 showed that the dominant bacteria for pediatric sepsis include <italic toggle="yes">Staphylococcus aureus</italic>, methicillin-resistant <italic toggle="yes">Staphylococcus aureus, fungi, Pseudomonas</italic>, and <italic toggle="yes">Clostridium difficile</italic><sup>[<xref rid="R308" ref-type="bibr">308</xref>]</sup>. The bacterial spectrum of sepsis has changed within the past decade. An empiric antibiotic therapy for sepsis is recommended to target these suspected pathogens<sup>[<xref rid="R308" ref-type="bibr">308</xref>]</sup>.</p><p>Intravenous fluid resuscitation is a key component of the initial resuscitation of sepsis<sup>[<xref rid="R309" ref-type="bibr">309</xref>]</sup>. As early as 2001, an early goal-directed treatment was proposed to lower the mortality of severe sepsis<sup>[<xref rid="R310" ref-type="bibr">310</xref>]</sup>. The initial fluid resuscitative goal is to optimize hemodynamics to achieve a blood oxygen saturation (SO<sub>2</sub>) of &gt;70% in the superior vena cava (SVC), central venous pressure (CVP) of 8-12&#160;mmHg, mean arterial pressure (MAP) of &#8805;65&#160;mmHg, and urine output of &#8805;0.5 mL/kg/h, which is expected to reduce the incidence of MODS and in-hospital mortality of sepsis. Nevertheless, data from multi-center randomized studies reported no survival benefits of goal-directed fluid resuscitation<sup>[<xref rid="R311" ref-type="bibr">311</xref>]</sup>, and increasing the medical cost<sup>[<xref rid="R312" ref-type="bibr">312</xref>,<xref rid="R313" ref-type="bibr">313</xref>]</sup>. Consequently, the <italic toggle="yes">Third International Consensus Definitions for Sepsis and Septic Shock</italic> highlighted an expert consensus process based on the clinical practice of sepsis and septic shock<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. The time-to-treatment initiation and types and volume of infused fluid have been modified in the fluid resuscitation for sepsis. Fluid resuscitation is applied to individuals with hypotension, elevated lactic acid levels, or oliguria. At present, a new sepsis &#8220;hour-1 bundle&#8221; has been introduced to the management of sepsis, that is, fluid resuscitation is initiated within 1 hour of diagnosis of sepsis<sup>[<xref rid="R314" ref-type="bibr">314</xref>]</sup>. An optimal type of fluid infused to sepsis patients needs to have similar chemical compositions, be metabolized and completely excreted from the body without producing metabolic or adverse events but enhancing the intravascular volume. If the fluid has a high economic benefit in improving the prognosis of sepsis, then so much the better. A randomized controlled trial that compares the influence of balanced crystalloid solution versus 0.9% sodium chloride on 30-day hospitalization mortality of sepsis concludes that the better outcome of the former<sup>[<xref rid="R315" ref-type="bibr">315</xref>]</sup>. Adding an appropriate volume of colloid solution to the crystalloid fluid not only reduces the total volume of infused fluid but also lowers the risk of edema in sepsis patients<sup>[<xref rid="R316" ref-type="bibr">316</xref>]</sup>. The SSC guidelines recommended the infusion of crystalloids at a rate of 30 mL/kg (actual body weight) within the first 3&#160;hours, for 2000 mL of crystalloid fluid total<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>. The hour-1 bundle protocol for sepsis is designed to ensure early and maximal correction of hypotension. Hemodynamic monitoring on 71 sepsis patients found no significant differences in the 24-hour urine output and 28-day mortality between the treatment of crystalloid infusion at 30 mL/kg versus &lt;30 mL/kg<sup>[<xref rid="R317" ref-type="bibr">317</xref>]</sup>. The prognosis of the 3-hour bundle therapy is related to the subtype of sepsis<sup>[<xref rid="R318" ref-type="bibr">318</xref>]</sup>. Therefore, we suggested an individualized fluid resuscitation based on close monitoring of clinical data for sepsis. A series of methods are available to achieve an accurate monitoring of systemic hemodynamics, such as bedside ultrasonography, chest impedance, pulmonary artery catheterization, and use of a pulse index continuous cardiac output. Dynamic variables are used clinically to assess fluid responsiveness, mainly including parameters obtained from the passive leg raise and fluid replacement test, pulse pressure variation, stroke volume variation and respiratory variation in the diameter of the inferior vena cava<sup>[<xref rid="R319" ref-type="bibr">319</xref>,<xref rid="R320" ref-type="bibr">320</xref>]</sup>.</p><p>Sepsis resuscitation bundle, although being placed at the core of treatment, is controversial. Evidence has claimed that the hour-1 bundle does not improve the prognosis of sepsis, but causes a high risk of over-medication. Three randomized controlled trials of ARISE, ProMISe, and ProCESS all firmly demonstrated a similar outcome between the sepsis resuscitation bundle versus traditional treatment<sup>[<xref rid="R313" ref-type="bibr">313</xref>,<xref rid="R321" ref-type="bibr">321</xref>,<xref rid="R322" ref-type="bibr">322</xref>]</sup>. Antibiotics are key to treating sepsis, and the choice and timing of antibiotic use greatly influence the outcome of sepsis. Misuse of antibiotics increases the risk of drug resistance and alters the composition of gut microbiota<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>. The treatment of sepsis is complicated and challenging. An individualized precision treatment has become mainstream for sepsis.</p></sec><sec><title>Endotypes/phenotypes of sepsis and novel therapeutic approaches</title><p>For sepsis, existing drugs do not work. Sepsis is a heterogeneous disease, with varying pathogenic organisms (such as Gram-positive or Gram-negative bacteria, viruses, or fungi), origin organs (such as lungs, urinary tract, or abdomen), and host immunological characteristics (ranging from hyperinflammation to immunosuppression) among patients<sup>[<xref rid="R323" ref-type="bibr">323</xref>]</sup>. It is unrealistic to expect a single drug to modulate the distorted immune response across the entire disease spectrum.</p><p>A drug that is effective for one person may even exacerbate the condition of others, for example, when patients with immunosuppression receive immunosuppressive drugs, or when patients with hyperinflammation receive immunostimulatory drugs. Therefore, precision medicine is a disease treatment approach in which patients are stratified based on clinical and biological criteria, as well as biomarkers (including immune, laboratory, high-resolution imaging, and omics-based measurements) to identify patterns, thereby formulating more precise prevention, diagnosis, and treatment strategies that take into account individual medical and health characteristics<sup>[<xref rid="R324" ref-type="bibr">324</xref>]</sup>. To successfully implement precision medicine for sepsis, a promising approach is to classify sepsis into different subtypes and provide corresponding treatments; it is necessary to predict and enrich the prognosis for sepsis patients<sup>[<xref rid="R325" ref-type="bibr">325</xref>,<xref rid="R326" ref-type="bibr">326</xref>]</sup>. Current research on sepsis subtypes is still in its preliminary stages, and there are no unified standards regarding inclusion criteria and research methods. Based on different classification foundations, sepsis subtypes (Table <xref rid="T2" ref-type="table">2</xref>) are mainly divided into the following categories: (1) sepsis endotypes based on genomic indicators; (2) sepsis subtypes based on biomarkers and clinical indicators; (3) sepsis phenotypes based on clinical big data. Since endotypes and subtypes originate from different patient characteristics, they cannot be easily linked.
<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Phenotypes of sepsis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Phenotypes &amp; manifestations</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">Clinical data</td><td align="center" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome, including the shock with elevated creatinine, minimal MODS, shock with hypoxemia and altered mental status, and hepatic disease.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R327" ref-type="bibr">327</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Clinical phenotypes of sepsis are classified by liver function and coagulation function, including the non-hepatobiliary dysfunction/DIC group and the hepatobiliary dysfunction/DIC group.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R328" ref-type="bibr">328</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Four phenotypes of sepsis (&#945;, &#946;, &#947;, and &#948;). The &#945; phenotype is the most common phenotype of sepsis with the use of the lowest dosages of vasopressor drugs; The &#946; phenotype is usually diagnosed in older patients and those with more comorbidities or renal insufficiency; The &#947; phenotype is manifested with inflammatory responses and respiratory insufficiency; The &#948; phenotype is the most lethal, resulting in high risks of hepatic insufficiency and shock, and high lactate levels.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R329" ref-type="bibr">329</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Four subphenotypes of sepsis (profile 1-4). Profile 1 is characterized by relatively mild symptoms and the lowest mortality; Profile 2 is characterized by respiratory dysfunction; Profile 3 is characterized by MODS and shock, and the highest 90-day mortality and hospital mortality; Profile 4 is characterized by neurological dysfunction.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R330" ref-type="bibr">330</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Four subphenotypes of sepsis divided by temperature trajectories, including the hyperthermic, slow resolvers (14.9% of the cohort); hyperthermic, fast resolvers (23.2%); normothermic (32.8%); and hypothermic (29.1%).</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R331" ref-type="bibr">331</xref>]</sup></td></tr><tr><td rowspan="3" align="left" colspan="1">Biomarkers</td><td align="center" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Sepsis is divided into the MALS group and the non-MALS group, and ferritin can be used as a biomarker for an early diagnosis of MALS.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R332" ref-type="bibr">332</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Sepsis is classified into MALS, immunoparalysis and intermediate based on biomarkers of ferritin &gt;4420&#160;ng/mL and &lt;5000 HLA-DR receptors/monocytes.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R333" ref-type="bibr">333</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Glycerophospholipids are the distinct metabolic patterns in sepsis-induced ARDS, and the sphingolipid metabolism distinguishes sepsis-induced direct from indirect ARDS subphenotypes.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R334" ref-type="bibr">334</xref>]</sup></td></tr><tr><td rowspan="8" align="left" colspan="1">Genomics</td><td align="center" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">Sepsis is classified into subclasses A, B, and C based on genome-wide expression profiling. Subclass A is associated with downregulated genes related to adaptive immunity and glucocorticoid receptor signaling pathways, resulting in more severe conditions and higher mortality.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R335" ref-type="bibr">335</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">Based on the prognostic enrichment analysis of proteomics-metabolomics data, the high mortality of sepsis is associated with fatty acid transport, &#946;-oxidation, gluconeogenesis, and citric acid cycle. Profiles of proteins and metabolites change in sepsis, and cis-4-decenoylcarnitine, 2-methylbutyrylcarnitine, butyrylcarnitine, hexanoylcarnitine, lactate, age, and hematocrit are 7 biomarkers predicting the mortality of sepsis.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R336" ref-type="bibr">336</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Two distinct SRSs, SRS1 and SRS2, are determined by cluster analysis on transcriptional profiles of leukocytes in peripheral whole blood.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R337" ref-type="bibr">337</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Four molecular endotypes for sepsis designated Mars1-4, are divided based on genome-wide blood gene expression profiles. Mars1 endotype is characterized by the worst condition, slow innate immunity and adaptive immunity, highest risk of shock and highest mortality. BPGM and TAP2 genes are specific for the diagnosis of Mars1 endotype. Mars3 endotype is characterized by the lowest risk of mortality, showing an RNA expression pattern consistency with the increased adaptive immunity and T cell function.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R338" ref-type="bibr">338</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Sepsis is classified into three subtypes inflammopathic (characterized by innate immune activation and higher mortality), adaptive (characterized by adaptive immune activation and lower mortality), and coagulopathic (characterized by platelet degranulation, coagulopathy, higher mortality and older age) based on RNA expressions.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R339" ref-type="bibr">339</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">A total of 1613 sepsis patients are classified into Class 1 (characterized by immunosuppression and higher mortality) and Class 2. A 5-gene class model involving C14orf159, AKNA, PILRA, STOM and USP4 is created and validated in an external cohort, showing a better performance than the SRS endotypes and a similar performance as the APACHE II score.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R346" ref-type="bibr">346</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">RAI in rodents is an endotype of sepsis characterized by a persistent high inflammatory response. Glucocorticoids are beneficial to sepsis with RAI, but harmful to those without RAI.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R379" ref-type="bibr">379</xref>]</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Targeted metabolomics identified 14 metabolites to distinguish sepsis-induced ARDS subphenotypes, mainly including the lysophosphatidylethanolamine (lysoPE) plasmalogen, PE plasmalogen and phosphatidylcholine.</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R334" ref-type="bibr">334</xref>]</sup></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>APACHE II, acute physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; DR isotype; HLA-DR, human leukocyte antigen &#8211; SRSs, sepsis response signatures; MALS, macrophage activation-like syndrome; MODS, multi-organ dysfunction syndrome; RAI, relative adrenal insufficiency.</p></fn></table-wrap-foot></table-wrap>
</p><p>The treatment of sepsis based on precision medicine proposes specific therapies for sepsis. Zhang <italic toggle="yes">et al</italic> analyzed clinical data of 14&#160;993 sepsis patients available from the Medical Information Mart for Intensive Care III database. Through cluster analysis of medical data within 24&#160;hours of admission, sepsis patients are classified into 4 subclasses and found that sepsis patients of different subtypes had different responses to fluid therapy. Profile 3 is characterized by a lowered mortality after fluid infusion, whereas profile 4 presents the opposite result<sup>[<xref rid="R330" ref-type="bibr">330</xref>]</sup>. Based on sepsis biomarkers, precision medicine-based immunotherapy is proposed. Circulating biomarkers, such as C-reactive protein, ferritin, IL-6, and soluble urokinase plasminogen activator receptor (suPAR), are capable of identifying excessive inflammation in sepsis and dividing sepsis into the macrophage activation-like syndrome (MALS) group and non-MALS group<sup>[<xref rid="R332" ref-type="bibr">332</xref>]</sup>. Immunoparalysis is one endotype of sepsis featured as lymphopenia, impaired production of cytokines and low expression of HLA-DR on monocytes<sup>[<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R340" ref-type="bibr">340</xref>]</sup>. So far, targeted therapies for MALS (e.g., rIL-1Ra/anakinra)<sup>[<xref rid="R333" ref-type="bibr">333</xref>,<xref rid="R341" ref-type="bibr">341</xref>]</sup> and immunoparalysis (e.g., rIFNy, IL-12, GM-CDF, rIL-7, and checkpoint inhibitors) have been applied to sepsis patients with certain endotypes/phenotypes<sup>[<xref rid="R236" ref-type="bibr">236</xref>,<xref rid="R342" ref-type="bibr">342</xref>]</sup>. Small-scale phase 2 randomized trials have been performed to illustrate the efficacy and safety of sepsis treatment based on the endotype/phenotype classification<sup>[<xref rid="R333" ref-type="bibr">333</xref>]</sup>.</p><p>Genome testing of the whole blood in sepsis patients provides useful information to reflect the immune state and guide clinical treatment. Divided by the sepsis response signatures (SRSs), SRS1 is manifested as an immunosuppressive pattern consisting of endotoxin tolerance, T cell exhaustion, and downregulation of class II HLA molecules. SRS1 causes a higher mortality than SRS2<sup>[<xref rid="R337" ref-type="bibr">337</xref>,<xref rid="R343" ref-type="bibr">343</xref>]</sup>. In a cohort involving 83 SRS1 patients and 86 SRS2 patients treated with vasoactive drugs versus hydrocortisone, increased mortality in SRS2 patients with a normal immune function is linked with the use of corticosteroids<sup>[<xref rid="R344" ref-type="bibr">344</xref>]</sup>. At the same time, considering that SRS1 is similar to pediatric septic shock type A, both suggest immune suppression. Corticosteroid treatment is associated with an increased mortality rate in septic shock type A, but it is not related to SRS1<sup>[<xref rid="R335" ref-type="bibr">335</xref>,<xref rid="R344" ref-type="bibr">344</xref>]</sup>. Exposure to corticosteroids is associated with increased mortality in adults with endotype A septic shock<sup>[<xref rid="R345" ref-type="bibr">345</xref>]</sup>. Zhang <italic toggle="yes">et al</italic> analyzed clinical data of 1613 Chinese sepsis patients from the online databases of the Gene Expression Omnibus (GEO) and ArrayExpress and classified them into Class 1 (characterized by immunosuppression and higher mortality) and Class 2 (increased mortality after the use of hydrocortisone)<sup>[<xref rid="R346" ref-type="bibr">346</xref>]</sup>.</p><p>At present, precision treatment for sepsis not only involves subtype grouping treatment but also has scholars positioning precision treatment in immunotherapy. With the in-depth study of the pathogenesis of sepsis, it has been found that the disorder of inflammatory immune responses is harmful to the host and is related to organ dysfunction, making immunotherapy a new direction in the effort to treat sepsis. The current immunotherapy for sepsis mainly focuses on cellular regulatory factors, immune checkpoint inhibitors, anti-apoptosis, and the promotion of immune cell hyperactivity. With continuous exploration, a large number of in <italic toggle="yes">vivo</italic> and in <italic toggle="yes">vitro</italic> studies have used immunomodulatory drugs to treat the immunoparalysis condition in sepsis patients.</p><p>These treatment methods include popular PD-1/PD-L1 blockers, granulocyte colony-stimulating factors (G-CSF), granulocyte-macrophage colony-stimulating factors (GM-CSF), and INF-&#947;<sup>[<xref rid="R235" ref-type="bibr">235</xref>,<xref rid="R333" ref-type="bibr">333</xref>]</sup>. In recent years, with the significant achievements of mesenchymal stem cells (MSCs) in cancer and their proven ability to regulate inflammation, enhance tissue repair, and clear pathogens in sepsis animal experiments, reducing mortality, they have become a new research focus for the treatment of sepsis, currently mainly concentrating on phase 1 safety studies. A summary of these drugs can be found in Table <xref rid="T3" ref-type="table">3</xref>.
<table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Immunomodulatory drugs for immunoparalysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Immunomodulatory Drugs</th><th align="left" rowspan="1" colspan="1">Registration No.</th><th align="left" rowspan="1" colspan="1">Clinical trial phase</th><th align="left" rowspan="1" colspan="1">Period (year)</th><th align="left" rowspan="1" colspan="1">Case number</th><th align="left" rowspan="1" colspan="1">Primary endpoints</th><th align="left" rowspan="1" colspan="1">Outcomes</th><th align="left" rowspan="1" colspan="1">State</th><th align="left" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GM-CSF</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00252915">NCT00252915</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2005-2007</td><td align="left" rowspan="1" colspan="1">38 adults were assigned to an intervention group (<italic toggle="yes">n</italic> =&#160;19) and the placebo group (<italic toggle="yes">n</italic> =&#160;19)</td><td align="left" rowspan="1" colspan="1">Time of mechanical ventilation, Length of stay in hospital/ICU, reconstitution of monocytic immunity</td><td align="left" rowspan="1" colspan="1">28-day follow-up showing GM-CSF in shortening the time of mechanical ventilation and length of stay in hospital/ICU.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R347" ref-type="bibr">347</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GM-CSF</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02361528">NCT02361528</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2015-2018</td><td align="left" rowspan="1" colspan="1">98 adults were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;54) and the placebo group (<italic toggle="yes">n</italic> =&#160;44)</td><td align="left" rowspan="1" colspan="1">Number of patients presenting at least one ICU-acquired infection at D28 or ICU discharge number of patients presenting at least one ICU-acquired infection at D28 or ICU discharge</td><td align="left" rowspan="1" colspan="1">ICU-acquired infection during 28-day follow-up. GM-CSF does not affect the prevention of ICU-acquired infection in sepsis immunosuppression.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R348" ref-type="bibr">348</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">rh-GCSF</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01479114">NCT01479114</ext-link></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2009-2010</td><td align="left" rowspan="1" colspan="1">90 newborns were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;30), placebo group (<italic toggle="yes">n</italic> =&#160;30) and control group (<italic toggle="yes">n</italic> =&#160;30)</td><td align="left" rowspan="1" colspan="1">All cause mortality</td><td align="left" rowspan="1" colspan="1">12-day observation showed less use of antibiotics and a shorter length of stay in the intervention group than placebo. Rh-GCSF improves neutrophilic count and functions as an adjuvant therapy for neonatal sepsis.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R349" ref-type="bibr">349</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">GM-CSF/INF-&#947;</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01374711">NCT01374711</ext-link></td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1">2011-2011</td><td align="left" rowspan="1" colspan="1">18 healthy adults intravenously injected with LPS (1st and 6th day of two cycles) and assigned into the INF-&#947; group (<italic toggle="yes">n</italic> =&#160;6), GM-CSF group (<italic toggle="yes">n</italic> =&#160;6) and placebo group (<italic toggle="yes">n</italic> =&#160;6)</td><td align="left" rowspan="1" colspan="1">The effects of GM-CSF/IFN-&#947; on the development of in vivo immunoparalysis induced by experimental human endotoxemia</td><td align="left" rowspan="1" colspan="1">IFN-&#947; upregulates monocytic HLA-DR, but GM-CSF downregulates it (no significant difference versus placebo group). IFN-&#947; partially reverses immunoparalysis.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R350" ref-type="bibr">350</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">T&#945;1</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00711620">NCT00711620</ext-link></td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1">2008-2010</td><td align="left" rowspan="1" colspan="1">361 adults assigned in T&#945;1 group (<italic toggle="yes">n</italic> =&#160;181) and placebo group (<italic toggle="yes">n</italic> =&#160;180)</td><td align="left" rowspan="1" colspan="1">Immune response to Thymosin alpha 1</td><td align="left" rowspan="1" colspan="1">Higher monocytic HLA-DR on the 7th day in the T&#945;1 group.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R351" ref-type="bibr">351</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">T&#945;1</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02867267">NCT02867267</ext-link></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2016-2020</td><td align="left" rowspan="1" colspan="1">1089 adults assigned in T&#945;1 group (<italic toggle="yes">n</italic> =&#160;542) and placebo group (<italic toggle="yes">n</italic> =&#160;547)</td><td align="left" rowspan="1" colspan="1">Incidence of new onset infection within 28&#160;days</td><td align="left" rowspan="1" colspan="1">The trial did not find conclusive evidence that T&#945;1 can reduce the 28 &#8211; day all &#8211; cause mortality rate in adults with sepsis.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R352" ref-type="bibr">352</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">rhIL-17(CYT107)</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02640807">NCT02640807</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2016-2018</td><td align="left" rowspan="1" colspan="1">27 adults assigned into high-dose CYT107 group (<italic toggle="yes">n</italic> =&#160;9), low-dose CYT107 group (<italic toggle="yes">n</italic> =&#160;8) and placebo group (<italic toggle="yes">n</italic> =&#160;10)</td><td align="left" rowspan="1" colspan="1">CYT107 effect on absolute Lymphocyte Count</td><td align="left" rowspan="1" colspan="1">Increased lymphocytes at 28&#160;days of CYT107 treatment.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R353" ref-type="bibr">353</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Anakinra or INF-&#947;</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03332225">NCT03332225</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2017-2019</td><td align="left" rowspan="1" colspan="1">36 adults were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;15) and the placebo group (<italic toggle="yes">n</italic> =&#160;21)</td><td align="left" rowspan="1" colspan="1">Mortality, time to decrease of SOFA score by more than 50%</td><td align="left" rowspan="1" colspan="1">Mortality does not decrease at 28&#160;days in the intervention group, whereas the Sequential Organ Failure Assessment (SOFA) score decreases at 7&#160;days.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R333" ref-type="bibr">333</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Anakinra or rhINF-&#947;</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990232">NCT04990232</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2021-to date</td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="left" rowspan="1" colspan="1">Mean total Sequential Organ Failure Assessment score</td><td align="left" rowspan="1" colspan="1">The mean SOFA score at 9&#160;days is assessed.</td><td align="left" rowspan="1" colspan="1">On-going</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R354" ref-type="bibr">354</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">PD-1/PD-L1 inhibitor (BMS-936&#160;559)</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02576457">NCT02576457</ext-link></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2015-2017</td><td align="left" rowspan="1" colspan="1">24 adults were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;20) and the placebo group (<italic toggle="yes">n</italic> =&#160;4)</td><td align="left" rowspan="1" colspan="1">Immune system function based on baseline and post-dosing assessments of mHLA-DR expression on monocytes at planned sampling timepoints</td><td align="left" rowspan="1" colspan="1">High-dose BMS-936559 upregulates monocytic HLA-DR</td><td align="left" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R236" ref-type="bibr">236</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">PD-1/PD-L1 inhibitor(nivolumab)</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02960854">NCT02960854</ext-link></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2016-2018</td><td align="left" rowspan="1" colspan="1">31 adults were assigned to the high-dose group (<italic toggle="yes">n</italic> =&#160;16) and the low-dose group (<italic toggle="yes">n</italic> =&#160;15)</td><td align="left" rowspan="1" colspan="1">Monocytic HLA-DR expression</td><td align="left" rowspan="1" colspan="1">Upregulated monocytic HLA-DR in both groups</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R235" ref-type="bibr">235</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">PD-1/PD-L1 inhibitor(nivolumab)</td><td align="left" rowspan="1" colspan="1">JapicCTl-173&#160;600</td><td align="center" rowspan="1" colspan="1">1/2</td><td align="center" rowspan="1" colspan="1">2017-2018</td><td align="left" rowspan="1" colspan="1">13 adults were assigned to the high-dose group (<italic toggle="yes">n</italic> =&#160;8) and the low-dose group (<italic toggle="yes">n</italic> =&#160;5)</td><td align="left" rowspan="1" colspan="1">Lymphocyte count, monocytic HLA-DR expression</td><td align="left" rowspan="1" colspan="1">Absolute lymphocyte counts and monocytic HLA-DR increase over time in both groups.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R237" ref-type="bibr">237</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-TNF-&#945; antibody (AZD9773)</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01144624">NCT01144624</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2010-2011</td><td align="left" rowspan="1" colspan="1">20 adults were assigned to the high-dose group (<italic toggle="yes">n</italic> =&#160;7), low-dose group (<italic toggle="yes">n</italic> =&#160;7) and placebo group (<italic toggle="yes">n</italic> =&#160;6)</td><td align="left" rowspan="1" colspan="1">Pharmacodynamic Effects of AZD9773 on TNF-alpha</td><td align="left" rowspan="1" colspan="1">AZD9773 decreases TNF-&#945; level at 29&#160;days of follow-up</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R355" ref-type="bibr">355</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#946;-glucan</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01727895">NCT01727895</ext-link></td><td align="center" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1">2013-2013</td><td align="left" rowspan="1" colspan="1">15 healthy adults were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;10) and the placebo group (<italic toggle="yes">n</italic> =&#160;5)</td><td align="left" rowspan="1" colspan="1">Production of cytokines, the leukocyte capacity to phagocytose and kill the fungal pathogen <italic toggle="yes">Candida Albicans</italic> (antifungal activity).</td><td align="left" rowspan="1" colspan="1">7-day follow-up showing no significant influences of oral &#946;-glucan on cytokine production by leukocytes and bactericidal activity</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R356" ref-type="bibr">356</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02328612">NCT02328612</ext-link></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2014-2015</td><td align="left" rowspan="1" colspan="1">32 healthy adults intravenously injected with LPS and assigned into the intervention group (<italic toggle="yes">n</italic> =&#160;24) and placebo group (<italic toggle="yes">n</italic> =&#160;8)</td><td align="left" rowspan="1" colspan="1">Inflammatory response as measured by laboratory measurements and functional assays of innate immunology</td><td align="left" rowspan="1" colspan="1">Intravenous infusion of human adipose MSCs (4&#160;&#215;&#160;10<sup>6</sup> cells/kg) exerts proinflammatory, anti-inflammatory, and procoagulant effects during human endotoxemia.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R347" ref-type="bibr">347</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02421484">NCT02421484</ext-link></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2015-2018</td><td align="left" rowspan="1" colspan="1">9 septic shock patients infused with MSCs at varying doses</td><td align="left" rowspan="1" colspan="1">Number of adverse events as a measure of safety and tolerability</td><td align="left" rowspan="1" colspan="1">Infusion of freshly cultured allogeneic bone marrow-derived MSCs at a dose of 3 million cells/kg (250 million cells) into patients with septic shock is safe.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R358" ref-type="bibr">358</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05283317">NCT05283317</ext-link></td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2018-2019</td><td align="left" rowspan="1" colspan="1">30 adults were assigned to the intervention group (<italic toggle="yes">n</italic> =&#160;10) and the control group (<italic toggle="yes">n</italic> =&#160;20)</td><td align="left" rowspan="1" colspan="1">Mortality, length of stay in the hospital</td><td align="left" rowspan="1" colspan="1">Deaths occur in the control group at 1&#160;week, and intervention group at 15 and 28&#160;days during the 28-day follow-up. MSCs positively influence the survival of early-stage sepsis.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R380" ref-type="bibr">380</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04961658">NCT04961658</ext-link></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2021-2023</td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="left" rowspan="1" colspan="1">The safety of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="GEM00220">GEM00220</ext-link> will be assessed by monitoring adverse events</td><td align="left" rowspan="1" colspan="1">28-day follow-up for the safety.</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="R381" ref-type="bibr">381</xref>]</sup></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>anti-TNF-&#945;antibody, anti-tumor necrosis factor-alpha antibody; GM-CSF, granulocyte-macrophage colony-stimulating factor; INF-&#947;, interferon-gamma; MSCs, mesenchymal stem cells; LPS, lipopolysaccharide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; rhIL-17, recombinant human Interleukin-17; rhINF-&#947;, recombinant human Interferon-gamma; rh-GCSF, recombinant human granulocyte colony-stimulating factor; T&#945;1, thymosin alpha 1.</p></fn></table-wrap-foot></table-wrap>
</p><p>The treatment of sepsis is complicated and challenging. This complexity is particularly evident when considering advanced interventions like immunotherapies. For instance, while targeting the PD-1/PD-L1 pathway is a promising strategy to reverse sepsis-induced immunosuppression, the clinical application of PD-1/PD-L1 inhibitors has yielded heterogeneous outcomes. The observed heterogeneity in patient responses to PD-1/PD-L1 inhibitors in sepsis trials highlights the complexity of applying these immunotherapies<sup>[<xref rid="R225" ref-type="bibr">225</xref>,<xref rid="R235" ref-type="bibr">235</xref>]</sup>. Several factors likely contribute to this variability. A crucial determinant is the patient&#8217;s specific immune status at the time of intervention; checkpoint blockade is hypothesized to be most beneficial in individuals exhibiting clear signs of T-cell exhaustion and a dominant PD-1/PD-L1-mediated immunosuppressive phenotype<sup>[<xref rid="R212" ref-type="bibr">212</xref>,<xref rid="R359" ref-type="bibr">359</xref>]</sup>. Conversely, patients in a hyperinflammatory state, or those whose immunosuppression is driven by alternative mechanisms, may not respond favorably or could even experience adverse effects<sup>[<xref rid="R360" ref-type="bibr">360</xref>]</sup>. The timing of administration relative to the evolving immune trajectory of sepsis is therefore critical<sup>[<xref rid="R361" ref-type="bibr">361</xref>]</sup>. Furthermore, differences in the infectious pathogens &#8211; including their type (e.g., Gram-negative vs. Gram-positive bacteria, fungi, viruses), load, and virulence factor profiles &#8211; can profoundly influence the nature and extent of immune dysregulation, including the engagement of the PD-1/PD-L1 pathway<sup>[<xref rid="R362" ref-type="bibr">362</xref>]</sup>. The site of primary infection can also shape the local and systemic immune environment, potentially impacting therapeutic efficacy<sup>[<xref rid="R363" ref-type="bibr">363</xref>]</sup>. Additionally, patient-specific factors such as comorbidities, genetic predispositions, and the overall severity of sepsis and degree of organ dysfunction likely play a role. Understanding these sources of heterogeneity is paramount for developing predictive biomarkers and tailoring PD-1/PD-L1 inhibitor therapy to the septic patient subgroups most likely to derive clinical benefit, a key tenet of advancing precision immunotherapy in sepsis.</p><p>In addition to the aforementioned immune targets, some scholars are dedicated to studying the impact of hormones on the prognosis of clinical patients. Critically ill patients who have been treated in the intensive care unit for a long time may develop relative central adrenal insufficiency<sup>[<xref rid="R364" ref-type="bibr">364</xref>]</sup>. Glucocorticoid resistance and hyperlactatemia lead to the fatal septic shock<sup>[<xref rid="R365" ref-type="bibr">365</xref>]</sup>. When using small doses of hormones, cellular immunity is mainly suppressed; at high doses, humoral immune function is suppressed by inhibiting plasma cells and antibody production. Glucocorticoids can also alleviate systemic inflammatory responses and tissue damage by inhibiting the production of inflammatory factors. The use of glucocorticoids (GCs) as monotherapy for sepsis remains a controversial issue<sup>[<xref rid="R366" ref-type="bibr">366</xref>]</sup>. In 2018, two large-scale randomized controlled trials were published to assess the impact of GCs on patients with sepsis or septic shock, but no clear conclusions could be drawn. These two studies recruited a total of 5041 patients, and the ADRENAL trial (Corticosteroid Therapy for Septic Shock and Adrenal Insufficiency) showed that hydrocortisone treatment did not improve the 90-day survival rate<sup>[<xref rid="R367" ref-type="bibr">367</xref>]</sup>. In contrast, the APROCCHSS trial suggested that the treatment of human septic shock with activated protein C and corticosteroids significantly reduced the mortality rate from 49.1% to 43%<sup>[<xref rid="R368" ref-type="bibr">368</xref>]</sup>. Metabolic resuscitation with glucocorticoids, along with vitamins C and B1, did not reduce long-term mortality rates<sup>[<xref rid="R369" ref-type="bibr">369</xref>]</sup>. A meta-analysis found that corticosteroid administration was associated with reduced 28-day mortality in sepsis patients compared with placebo use or standard supportive care. Given the conflicting conclusions regarding corticosteroid treatment for sepsis, more research is needed in future studies to correlate sepsis subtypes with corticosteroid efficacy and identify subtypes that will benefit from corticosteroid therapy<sup>[<xref rid="R370" ref-type="bibr">370</xref>]</sup></p><p>Sepsis still lacks a specific cure, and Uckun <italic toggle="yes">et al</italic> have utilized existing technology to research new drugs. The two formulations of the sepsis candidate drug Rejuveinix (RJX) have been confirmed to have a protective effect in mice<sup>[<xref rid="R371" ref-type="bibr">371</xref>]</sup>. Kukoamine B mesylate has been tested in a phase IIa trial for treating sepsis<sup>[<xref rid="R372" ref-type="bibr">372</xref>]</sup>. Wang <italic toggle="yes">et al</italic> designed new drugs for treating sepsis and septic cardiomyopathy based on the nanotechnology<sup>[<xref rid="R373" ref-type="bibr">373</xref>]</sup>. Current evidence suggests that acupuncture combined with conventional therapy may be beneficial for sepsis compared to conventional therapy alone. Due to the low certainty of its impact, further research is needed<sup>[<xref rid="R374" ref-type="bibr">374</xref>]</sup>.</p></sec><sec><title>Precision therapy and future perspectives</title><p>The incidence and high mortality rate of sepsis impose a heavy burden on society. Existing drugs can provide support for controlling the source of infection and improving organ function, but there is still no specific cure. Considering the complexity of the host response during sepsis and the diversity of pathophysiological pathways involved<sup>[<xref rid="R323" ref-type="bibr">323</xref>]</sup>, the &#8220;one-size-fits-all&#8221; strategy for treating sepsis is no longer satisfactory.</p><p>To better understand sepsis and seek more effective treatment options, we have summarized the pathogenesis and etiology of sepsis, from bacterial invasion (Gram-negative bacteria), drug resistance to the body&#8217;s inflammatory response (activation of immune cells, release of inflammatory factors, and activation of the coagulation and complement systems). An uncontrolled cytokine storm can lead to multiple organ failure and even death. Dysbiosis is a factor that clinicians may easily overlook. A low diversity of the gut microbiota and an increased relative abundance of pathogenic Gram-negative bacteria and enterococci can increase the risk of sepsis.</p><p>As our understanding of the pathogenesis and pathophysiology of sepsis becomes clearer, we are also making new expectations for its treatment, pushing for precision treatment to replace the &#8220;one-size-fits-all&#8221; approach. To achieve precision treatment, many scholars have used various means, including multi-omics and analysis of clinical big data, to classify sepsis into different subtypes in an attempt to find appropriate treatment options. Among these approaches, the combination of traditional treatment and immunotherapy has shown promising results in patients with sepsis. For example, the use of immunomodulatory drugs (such as PD-1/PD-L1, G-CSF, GM-CSF) favors sepsis patients with immunoparalysis by increasing the number and function of immune cells and upregulating monocytic HLA-DR. However, it has to be acknowledged that the combination of traditional sepsis treatment strategies and immunotherapy strategies has not significantly improved the mortality rate of sepsis, and clinical trials are also in phase 2&#8211;3. For example, T &#945;1 has not improved the 28-day mortality rate of sepsis patients<sup>[<xref rid="R352" ref-type="bibr">352</xref>]</sup>. When reviewing these clinical trials, we must consider the following issues: First, the issue of reasonable experimental design. When studying such a complex syndrome as sepsis, is it necessary to consider patient subgroups? At present, in clinical drug research, all sepsis patients are directly divided into treatment and non-treatment groups, and the experimental results show that immunotherapy drugs cannot improve patient prognosis. However, in the clinical and basic research of sepsis, it has been found that immunotherapy may only be effective for patients with a higher risk of death from sepsis<sup>[<xref rid="R375" ref-type="bibr">375</xref>]</sup>, while the use of anti-inflammatory drugs for patients with a lower risk of death may increase the mortality rate<sup>[<xref rid="R376" ref-type="bibr">376</xref>]</sup>. Second, the site of infection and the pathogen are also important factors. The pathogenic mechanisms after the entry of pathogens into the human body and the host&#8217;s immune response are not the same. When we try to improve the prognosis of sepsis, we may need to classify it according to the site of infection and the pathogen, rather than widely including patients in a complex syndrome.</p><p>With the rapid development of medical techniques, precision cancer treatment affords us lessons in sepsis treatment<sup>[<xref rid="R377" ref-type="bibr">377</xref>]</sup>. The treatment of sepsis will be carried out in a pathologically specific and time-dependent manner, rather than based on clinical manifestations. To achieve precision treatment, many scholars have used various means to detect changes within the body that divide sepsis into different endotypes/phenotypes. We envision that in the future, personalized treatment plans can be formulated for septic patients. The clinic also needs to conduct a comprehensive assessment and testing of each patient&#8217;s immune function to provide precision treatment plans, such as giving targeted pro-inflammatory or anti-inflammatory treatments according to the patient&#8217;s immune status. Therefore, precision treatment strategies oriented towards clinical subtypes-immune status-drug/immunotherapy may be the next major advancement in the treatment of sepsis.</p><p>However, there are still some difficulties to overcome in achieving precision treatment for sepsis. Currently, there is no relevant research/mechanism that breaks down the barriers between various endotypes/subphenotypes, and there is no clear correlation between any subtype classification methods. Some scholars have proposed that a disease axis approach could be used to divide sepsis into different subtypes, but no specific conclusions have been drawn yet<sup>[<xref rid="R378" ref-type="bibr">378</xref>]</sup>. Therefore, there is an urgent need to establish a classification scheme for subtypes that associates the pathogenesis, pathophysiology, and target organ localization of sepsis with disease subtypes and immune status, providing clear references for clinical practice. It is hoped that in the future, we can utilize well-reproducible, timely laboratory tests or simple bedside tests to quickly and accurately determine the pathophysiological changes and disease status within the body during sepsis, guiding individualized and precision treatment for different patients.</p></sec></body><back><fn-group><fn fn-type="other"><p>Lingxia Cheng, Yu Cao, and Shihao Liu have contributed equally to this work.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 20 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>Supported by the National Natural Science Foundation of China 22477089, 22177083 (Guan Wang), Sichuan Science and Technology Program 2025ZNSFSC0690 (Guan Wang), Special Project for Scientific and Technological Research of Sichuan Provincial Administration of Traditional Chinese Medicine 2023MS494 (Ping Xu), Sichuan Medical Association Scientific Research Project S21019 (Ping Xu), Zigong Science and Technology Program (2023YLWS05 to Lingxia Cheng), Research project of Zigong City Science &amp; Technology and Intellectual Property Right Bureau 2022ZCYGY05 (Ping Xu) and 2021ZC22 (Jianjun Zhang), Zigong City Health Commission 22yb024 (Lukai lv), Zigong Fourth People&#8217;s Hospital Investigator-Initiated Trial Project 2023IIT001 (Ping Xu) and Sichuan University Science Research Foundation Grant No. 2023SCUH0053 (Guan Wang).</p></sec><sec><title>Author contributions</title><p>P.X. supervised, reviewed, and edited the project. G.W., L.C., and Y.C. summarized the literature, wrote the initial manuscript, and drew the figures. P.X., J.B., L.L., and J.Z. proofread the structures and revised the manuscript. J.B. has completed the manuscript revision and the figure preparation. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>Authors declare that they have no potential conflict of interest.</p></sec><sec><title>Guarantor</title><p>Ji Bao, Guan Wang, Ping Xu.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>This study relies on previously published data.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecconi</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>L</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name></person-group>. <article-title>Sepsis and septic shock</article-title>. <source>Lancet</source><year>2018</year>;<volume>392</volume>:<fpage>75</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">29937192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30696-2</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuurman</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sloot</surname><given-names>PMA</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>Embracing complexity in sepsis</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>102</fpage>.<pub-id pub-id-type="pmid">36906606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04374-0</pub-id><pub-id pub-id-type="pmcid">PMC10007743</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>CS</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>JAMA</source><year>2016</year>;<volume>315</volume>:<fpage>801</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudd</surname><given-names>KE</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Agesa</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study</article-title>. <source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>200</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">31954465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32989-7</pub-id><pub-id pub-id-type="pmcid">PMC6970225</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleischmann-Struzek</surname><given-names>C</given-names></name><name name-style="western"><surname>Mellhammar</surname><given-names>L</given-names></name><name name-style="western"><surname>Rose</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis</article-title>. <source>Intensive Care Med</source><year>2020</year>;<volume>46</volume>:<fpage>1552</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">32572531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-020-06151-x</pub-id><pub-id pub-id-type="pmcid">PMC7381468</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name><name name-style="western"><surname>Osterholzer</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><name name-style="western"><surname>Iwashyna</surname><given-names>TJ</given-names></name></person-group>. <article-title>Late mortality after sepsis: propensity matched cohort study</article-title>. <source>BMJ</source><year>2016</year>;<volume>353</volume>:<fpage>i2375</fpage>.<pub-id pub-id-type="pmid">27189000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i2375</pub-id><pub-id pub-id-type="pmcid">PMC4869794</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name></person-group>. <article-title>Enhancing Recovery from sepsis: a review</article-title>. <source>JAMA</source><year>2018</year>;<volume>319</volume>:<fpage>62</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">29297082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.17687</pub-id><pub-id pub-id-type="pmcid">PMC5839473</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandolfi</surname><given-names>F</given-names></name><name name-style="western"><surname>Brun-Buisson</surname><given-names>C</given-names></name><name name-style="western"><surname>Guillemot</surname><given-names>D</given-names></name><name name-style="western"><surname>Watier</surname><given-names>L</given-names></name></person-group>. <article-title>One-year hospital readmission for recurrent sepsis: associated risk factors and impact on 1-year mortality-a French nationwide study</article-title>. <source>Crit Care</source><year>2022</year>;<volume>26</volume>:<fpage>371</fpage>.<pub-id pub-id-type="pmid">36447252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-022-04212-9</pub-id><pub-id pub-id-type="pmcid">PMC9710072</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biason</surname><given-names>L</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>C</given-names></name><name name-style="western"><surname>Haas</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>CDR</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>G</given-names></name></person-group>. <article-title>Effects of sepsis on morbidity and mortality in critically ill patients 2 years after intensive care unit discharge</article-title>. <source>Am J Crit Care</source><year>2019</year>;<volume>28</volume>:<fpage>424</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">31676516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4037/ajcc2019638</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleischmann-Struzek</surname><given-names>C</given-names></name><name name-style="western"><surname>Rose</surname><given-names>N</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Epidemiology and costs of postsepsis morbidity, nursing care dependency, and mortality in Germany, 2013 to 2017</article-title>. <source>JAMA Network Open</source><year>2021</year>;<volume>4</volume>:<fpage>e2134290</fpage>.<pub-id pub-id-type="pmid">34767025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.34290</pub-id><pub-id pub-id-type="pmcid">PMC8590172</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oud</surname><given-names>L</given-names></name><name name-style="western"><surname>Garza</surname><given-names>J</given-names></name></person-group>. <article-title>Previously healthy adults among septic patients: population-level epidemiology and outcomes</article-title>. <source>J Crit Care</source><year>2024</year>;<volume>79</volume>:<fpage>154427</fpage>.<pub-id pub-id-type="pmid">37717361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2023.154427</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collaborators</surname><given-names>GBDAR</given-names></name><name name-style="western"><surname>Swetschinski</surname><given-names>LR</given-names></name><name name-style="western"><surname>Robles Aguilar</surname><given-names>G</given-names></name></person-group>. <article-title>Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019</article-title>. <source>Lancet</source><year>2022</year>;<volume>400</volume>:<fpage>2221</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">36423648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)02185-7</pub-id><pub-id pub-id-type="pmcid">PMC9763654</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antimicrobial Resistance</surname><given-names>C</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>KS</given-names></name><name name-style="western"><surname>Sharara</surname><given-names>F</given-names></name></person-group>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source><year>2022</year>;<volume>399</volume>:<fpage>629</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>NR</given-names></name><name name-style="western"><surname>Balraj</surname><given-names>TA</given-names></name><name name-style="western"><surname>Kempegowda</surname><given-names>SN</given-names></name><name name-style="western"><surname>Prashant</surname><given-names>A</given-names></name></person-group>. <article-title>Multidrug-resistant sepsis: a critical healthcare challenge</article-title>. <source>Antibiotics</source><year>2024</year>;<volume>13</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">38247605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics13010046</pub-id><pub-id pub-id-type="pmcid">PMC10812490</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Sakr</surname><given-names>Y</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prevalence and outcomes of infection among patients in intensive care units in 2017</article-title>. <source>JAMA J Am Med Assoc</source><year>2020</year>;<volume>323</volume>:<fpage>1478</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.2717</pub-id><pub-id pub-id-type="pmcid">PMC7093816</pub-id><pub-id pub-id-type="pmid">32207816</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>LK</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>Sepsis-induced immunosuppression</article-title>. <source>Annu Rev Physiol</source><year>2022</year>;<volume>84</volume>:<fpage>157</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">34705481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-061121-040214</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name></person-group>. <article-title>The immunology of sepsis</article-title>. <source>Immunity</source><year>2021</year>;<volume>54</volume>:<fpage>2450</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">34758337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.10.012</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>L</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021</article-title>. <source>Intensive Care Med</source><year>2021</year>;<volume>47</volume>:<fpage>1181</fpage>&#8211;<lpage>247</lpage>.<pub-id pub-id-type="pmid">34599691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-021-06506-y</pub-id><pub-id pub-id-type="pmcid">PMC8486643</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>A</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Prognostic differences in sepsis caused by gram-negative bacteria and gram-positive bacteria: a systematic review and meta-analysis</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>467</fpage>.<pub-id pub-id-type="pmid">38037118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04750-w</pub-id><pub-id pub-id-type="pmcid">PMC10691150</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><name name-style="western"><surname>Cristofaro</surname><given-names>P</given-names></name><name name-style="western"><surname>Carlet</surname><given-names>J</given-names></name><name name-style="western"><surname>Opal</surname><given-names>S</given-names></name></person-group>. <article-title>New method of classifying infections in critically ill patients</article-title>. <source>Crit Care Med</source><year>2004</year>;<volume>32</volume>:<fpage>1510</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">15241096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ccm.0000129973.13104.2d</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sligl</surname><given-names>W</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G</given-names></name><name name-style="western"><surname>Brindley</surname><given-names>PG</given-names></name></person-group>. <article-title>Five years of nosocomial gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes</article-title>. <source>Int J Infect Dis</source><year>2006</year>;<volume>10</volume>:<fpage>320</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">16460982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2005.07.003</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial INtelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>2025</volume>:<fpage>100082</fpage>.</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zielinski</surname><given-names>C</given-names></name><name name-style="western"><surname>Winker</surname><given-names>MA</given-names></name></person-group>. <article-title>research RAEFHFLAPICAVHbotWBJCm, opinion. Chatbots, generative AI, and scholarly manuscripts: WAME recommendations on chatbots and generative artificial intelligence in relation to scholarly publications</article-title>. <source>Colomb M&#233;d</source><year>2024</year>;<volume>40</volume>:<fpage>11</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03007995.2023.2286102</pub-id><pub-id pub-id-type="pmid">38112256</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klos</surname><given-names>M</given-names></name><name name-style="western"><surname>Jachowicz</surname><given-names>E</given-names></name><name name-style="western"><surname>Pomorska-Wesolowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Romaniszyn</surname><given-names>D</given-names></name><name name-style="western"><surname>Kandzierski</surname><given-names>G</given-names></name><name name-style="western"><surname>Wojkowska-Mach</surname><given-names>J</given-names></name></person-group>. <article-title>Antimicrobial resistance of enterobacteriaceae in bloodstream infections in hospitalized patients in Southern Poland</article-title>. <source>J Clin Med</source><year>2022</year>;<volume>11</volume>:<fpage>3927</fpage>.<pub-id pub-id-type="pmid">35887691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11143927</pub-id><pub-id pub-id-type="pmcid">PMC9321740</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diekema</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>PR</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>RE</given-names></name><etal/></person-group>. <article-title>The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program</article-title>. <source>Antimicrob Chemother</source><year>2019</year>;<volume>63</volume>: <fpage>10</fpage>-<lpage>1128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00355-19</pub-id><pub-id pub-id-type="pmcid">PMC6591610</pub-id><pub-id pub-id-type="pmid">31010862</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ababneh</surname><given-names>MA</given-names></name><name name-style="western"><surname>Al Domi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rababa&#8217;h</surname><given-names>AM</given-names></name></person-group>. <article-title>Surveillance study of bloodstream infections, antimicrobial use, and resistance patterns among intensive care unit patients: a retrospective cross-sectional study</article-title>. <source>Int J Crit Illness Inj Sci</source><year>2022</year>;<volume>12</volume>:<fpage>82</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijciis.ijciis_70_21</pub-id><pub-id pub-id-type="pmcid">PMC9285123</pub-id><pub-id pub-id-type="pmid">35845122</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laupland</surname><given-names>KB</given-names></name><name name-style="western"><surname>Gregson</surname><given-names>DB</given-names></name><name name-style="western"><surname>Church</surname><given-names>DL</given-names></name><name name-style="western"><surname>Ross</surname><given-names>T</given-names></name><name name-style="western"><surname>Pitout</surname><given-names>JD</given-names></name></person-group>. <article-title>Incidence, risk factors and outcomes of <italic toggle="yes">Escherichia coli</italic> bloodstream infections in a large Canadian region</article-title>. <source>Clin Microbiol Infect</source><year>2008</year>;<volume>14</volume>:<fpage>1041</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19040476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1469-0691.2008.02089.x</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mora-Rillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Fernandez-Romero</surname><given-names>N</given-names></name><name name-style="western"><surname>Navarro-San Francisco</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Impact of virulence genes on sepsis severity and survival in <italic toggle="yes">Escherichia coli</italic> bacteremia</article-title>. <source>Virulence</source><year>2015</year>;<volume>6</volume>:<fpage>93</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="pmid">25654604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/21505594.2014.991234</pub-id><pub-id pub-id-type="pmcid">PMC4603433</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samet</surname><given-names>A</given-names></name><name name-style="western"><surname>Sledzinska</surname><given-names>A</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Leukemia and risk of recurrent <italic toggle="yes">Escherichia coli</italic> bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream</article-title>. <source>Eur J Clin Microbiol Infect Dis</source><year>2013</year>;<volume>32</volume>:<fpage>1393</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">23649557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10096-013-1886-9</pub-id><pub-id pub-id-type="pmcid">PMC3824565</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tourret</surname><given-names>J</given-names></name><name name-style="western"><surname>Denamur</surname><given-names>E</given-names></name></person-group>. <article-title>Population phylogenomics of extraintestinal pathogenic <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Microbiol Spectr</source><year>2016</year>;<volume>4</volume>; <fpage>207</fpage>-<lpage>233</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/microbiolspec.UTI-0010-2012</pub-id><pub-id pub-id-type="pmid">26999389</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Bano</surname><given-names>J</given-names></name><name name-style="western"><surname>Mingorance</surname><given-names>J</given-names></name><name name-style="western"><surname>Fernandez-Romero</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Virulence profiles of bacteremic extended-spectrum beta-lactamase-producing <italic toggle="yes">Escherichia coli</italic>: association with epidemiological and clinical features</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e44238</fpage>.<pub-id pub-id-type="pmid">22970186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0044238</pub-id><pub-id pub-id-type="pmcid">PMC3436869</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curova</surname><given-names>K</given-names></name><name name-style="western"><surname>Slebodnikova</surname><given-names>R</given-names></name><name name-style="western"><surname>Kmetova</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Virulence, phylogenetic background and antimicrobial resistance in <italic toggle="yes">Escherichia coli</italic> associated with extraintestinal infections</article-title>. <source>J Infect Public Health</source><year>2020</year>;<volume>13</volume>:<fpage>1537</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">32690453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiph.2020.06.032</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marschall</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Foxman</surname><given-names>B</given-names></name><name name-style="western"><surname>Warren</surname><given-names>DK</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>JP</given-names></name><name name-style="western"><surname>Program</surname><given-names>CDCPE</given-names></name></person-group>. <article-title>Both host and pathogen factors predispose to <italic toggle="yes">Escherichia coli</italic> urinary-source bacteremia in hospitalized patients</article-title>. <source>Clinl Infect Dis</source><year>2012</year>;<volume>54</volume>:<fpage>1692</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cis252</pub-id><pub-id pub-id-type="pmcid">PMC3357479</pub-id><pub-id pub-id-type="pmid">22431806</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>O-acetylation of capsular polysialic acid enables <italic toggle="yes">Escherichia coli</italic> K1 escaping from siglec-mediated innate immunity and lysosomal degradation of e. coli-containing vacuoles in macrophage-like cells</article-title>. <source>Microbiol Spectr</source><year>2021</year>;<volume>9</volume>:<fpage>e0039921</fpage>.<pub-id pub-id-type="pmid">34878295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/spectrum.00399-21</pub-id><pub-id pub-id-type="pmcid">PMC8653822</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutra</surname><given-names>IL</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>LG</given-names></name><name name-style="western"><surname>Assuncao</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>Pic-producing <italic toggle="yes">Escherichia coli</italic> induces high production of proinflammatory mediators by the host leading to death by sepsis</article-title>. <source>Int J Mol Sci</source><year>2020</year>;<volume>21</volume>:<fpage>2068</fpage>.<pub-id pub-id-type="pmid">32197297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21062068</pub-id><pub-id pub-id-type="pmcid">PMC7139334</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abreu</surname><given-names>AG</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>TR</given-names></name><name name-style="western"><surname>Granados Mart&#237;nez</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>The serine protease pic from enteroaggregative <italic toggle="yes">Escherichia coli</italic> mediates immune evasion by the direct cleavage of complement proteins</article-title>. <source>J Infect Dis</source><year>2015</year>;<volume>212</volume>:<fpage>106</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">25583166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiv013</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>SN</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>EC</given-names></name><name name-style="western"><surname>Lane</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>HL</given-names></name></person-group>. <article-title>Dissemination and systemic colonization of uropathogenic <italic toggle="yes">Escherichia coli</italic> in a murine model of bacteremia</article-title>. <source>mBio</source><year>2010</year>;<volume>1</volume>: <fpage>10</fpage>-<lpage>1128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00262-10</pub-id><pub-id pub-id-type="pmcid">PMC2993011</pub-id><pub-id pub-id-type="pmid">21116344</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watts</surname><given-names>RE</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CK</given-names></name><name name-style="western"><surname>Ulett</surname><given-names>GC</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Escherichia coli</italic> 83972 expressing a P fimbriae oligosaccharide receptor mimic impairs adhesion of uropathogenic E. coli</article-title>. <source>J Infect Dis</source><year>2012</year>;<volume>206</volume>:<fpage>1242</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">22872729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jis493</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnsen</surname><given-names>N</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>ADM</given-names></name><name name-style="western"><surname>Greve</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Alpha-haemolysin production, as a single factor, causes fulminant sepsis in a model of <italic toggle="yes">Escherichia coli</italic>-induced bacteraemia</article-title>. <source>Cell Microbiol</source><year>2019</year>;<volume>21</volume>:<fpage>e13017</fpage>.<pub-id pub-id-type="pmid">30761726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cmi.13017</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subashchandrabose</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SN</given-names></name><name name-style="western"><surname>Spurbeck</surname><given-names>RR</given-names></name><name name-style="western"><surname>Kole</surname><given-names>MM</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>HL</given-names></name></person-group>. <article-title>Genome-wide detection of fitness genes in uropathogenic <italic toggle="yes">Escherichia coli</italic> during systemic infection</article-title>. <source>PLoS Pathog</source><year>2013</year>;<volume>9</volume>:<fpage>e1003788</fpage>.<pub-id pub-id-type="pmid">24339777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003788</pub-id><pub-id pub-id-type="pmcid">PMC3855560</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerner</surname><given-names>RR</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S</given-names></name><name name-style="western"><surname>Sargun</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Siderophore immunization restricted colonization of adherent-invasive <italic toggle="yes">Escherichia coli</italic> and ameliorated experimental colitis</article-title>. <source>mBio</source><year>2022</year>;<volume>13</volume>:<fpage>e0218422</fpage>.<pub-id pub-id-type="pmid">36094114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mbio.02184-22</pub-id><pub-id pub-id-type="pmcid">PMC9600343</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckles</surname><given-names>EL</given-names></name><name name-style="western"><surname>Luterbach</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Signature-tagged mutagenesis and co-infection studies demonstrate the importance of P fimbriae in a murine model of urinary tract infection</article-title>. <source>Pathog Dis</source><year>2015</year>;<volume>73</volume>: <fpage>p.ftv014</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femspd/ftv014</pub-id><pub-id pub-id-type="pmcid">PMC4542639</pub-id><pub-id pub-id-type="pmid">25673667</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davey</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ukai</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Bacterial fimbriae stimulate proinflammatory activation in the endothelium through distinct TLRs</article-title>. <source>J Immunol</source><year>2008</year>;<volume>180</volume>:<fpage>2187</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">18250425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.180.4.2187</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wullt</surname><given-names>B</given-names></name><name name-style="western"><surname>Bergsten</surname><given-names>G</given-names></name><name name-style="western"><surname>Connell</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>P-fimbriae trigger mucosal responses to <italic toggle="yes">Escherichia coli</italic> in the human urinary tract</article-title>. <source>Cell Microbiol</source><year>2001</year>;<volume>3</volume>:<fpage>255</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">11298649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1462-5822.2001.00111.x</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungquist</surname><given-names>O</given-names></name><name name-style="western"><surname>Blomstergren</surname><given-names>A</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>A</given-names></name><name name-style="western"><surname>Sunnerhagen</surname><given-names>T</given-names></name><name name-style="western"><surname>Holm</surname><given-names>K</given-names></name><name name-style="western"><surname>Torisson</surname><given-names>G</given-names></name></person-group>. <article-title>Incidence, aetiology and temporal trend of bloodstream infections in Southern Sweden from 2006 to 2019: a population-based study</article-title>. <source>Eurosurveillance</source><year>2023</year>;<volume>28</volume>: <fpage>p 2200519</fpage>.<pub-id pub-id-type="pmid">36892472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2023.28.10.2200519</pub-id><pub-id pub-id-type="pmcid">PMC9999458</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilmavirta</surname><given-names>H</given-names></name><name name-style="western"><surname>Ollgren</surname><given-names>J</given-names></name><name name-style="western"><surname>Raisanen</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Increasing proportions of extended-spectrum beta-lactamase-producing isolates among <italic toggle="yes">Escherichia coli</italic> from urine and bloodstream infections: results from a nationwide surveillance network, Finland, 2008 to 2019</article-title>. <source>Euro Surveill</source><year>2023</year>;<volume>28</volume>: <fpage>p.2200934</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2023.28.43.2200934</pub-id><pub-id pub-id-type="pmcid">PMC10604539</pub-id><pub-id pub-id-type="pmid">37883040</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Genetic diversity and characteristics of bla (NDM)-positive plasmids in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Front Microbiol</source><year>2021</year>;<volume>12</volume>:<fpage>729952</fpage>.<pub-id pub-id-type="pmid">34867846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2021.729952</pub-id><pub-id pub-id-type="pmcid">PMC8636099</pub-id></mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Stothard</surname><given-names>P</given-names></name><name name-style="western"><surname>Banting</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Characterization of water treatment-resistant and multidrug-resistant urinary pathogenic <italic toggle="yes">Escherichia coli</italic> in treated wastewater</article-title>. <source>Water Res</source><year>2020</year>;<volume>182</volume>: <fpage>p.115827</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.watres.2020.115827</pub-id><pub-id pub-id-type="pmid">32580076</pub-id></mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decano</surname><given-names>AG</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N</given-names></name><name name-style="western"><surname>Al-Foori</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Plasmids shape the diverse accessory resistomes of <italic toggle="yes">Escherichia coli</italic> ST131</article-title>. <source>Access Microbiol.</source><year>2021</year>;<volume>3</volume>:<fpage>acmi000179</fpage>.<pub-id pub-id-type="pmid">33997610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/acmi.0.000179</pub-id><pub-id pub-id-type="pmcid">PMC8115979</pub-id></mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Udval</surname><given-names>U</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y-T</given-names></name><etal/></person-group>. <article-title>Molecular characterization of extended-spectrum &#946;-lactamase-producing <italic toggle="yes">Escherichia coli</italic> and klebsiella spp. Isolates in Mongolia</article-title>. <source>J Microbiol Immunol Infect</source><year>2016</year>;<volume>49</volume>:<fpage>692</fpage>&#8211;<lpage>700</lpage>.<pub-id pub-id-type="pmid">26194952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2015.05.009</pub-id></mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name></person-group>. <article-title>The characteristics of extended-spectrum beta-lactamases (ESBLs)-producing <italic toggle="yes">Escherichia coli</italic> in bloodstream infection</article-title>. <source>Infect Drug Resist</source><year>2023</year>;<volume>16</volume>:<fpage>2043</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">37056484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S400170</pub-id><pub-id pub-id-type="pmcid">PMC10086224</pub-id></mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meatherall</surname><given-names>BL</given-names></name><name name-style="western"><surname>Gregson</surname><given-names>D</given-names></name><name name-style="western"><surname>Ross</surname><given-names>T</given-names></name><name name-style="western"><surname>Pitout</surname><given-names>JD</given-names></name><name name-style="western"><surname>Laupland</surname><given-names>KB</given-names></name></person-group>. <article-title>Incidence, risk factors, and outcomes of <italic toggle="yes">Klebsiella pneumoniae</italic> bacteremia</article-title>. <source>Am J Med</source><year>2009</year>;<volume>122</volume>:<fpage>866</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">19699383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2009.03.034</pub-id></mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sin</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>Differences in characteristics between healthcare-associated and community-acquired infection in community-onset <italic toggle="yes">Klebsiella pneumoniae</italic> bloodstream infection in Korea</article-title>. <source>BMC Infect Dis</source><year>2012</year>;<volume>12</volume>:<fpage>239</fpage>.<pub-id pub-id-type="pmid">23034099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-12-239</pub-id><pub-id pub-id-type="pmcid">PMC3519694</pub-id></mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Niki</surname><given-names>M</given-names></name><name name-style="western"><surname>Niki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Siderophore production as a biomarker for <italic toggle="yes">Klebsiella pneumoniae</italic> strains that cause sepsis: a pilot study</article-title>. <source>J Formos Med Assoc</source><year>2022</year>;<volume>121</volume>:<fpage>848</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">34272150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jfma.2021.06.027</pub-id></mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>TA</given-names></name><name name-style="western"><surname>Marr</surname><given-names>CM</given-names></name></person-group>. <article-title>Hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Clin Microbiol Rev</source><year>2019</year>;<volume>32</volume>: <fpage>10</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00001-19</pub-id><pub-id pub-id-type="pmcid">PMC6589860</pub-id><pub-id pub-id-type="pmid">31092506</pub-id></mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palacios</surname><given-names>M</given-names></name><name name-style="western"><surname>Miner</surname><given-names>TA</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Identification of two regulators of virulence that are conserved in <italic toggle="yes">Klebsiella pneumoniae</italic> classical and hypervirulent strains</article-title>. <source>mBio</source><year>2018</year>:<volume>9</volume>: <fpage>10</fpage>-<lpage>1128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01443-18</pub-id><pub-id pub-id-type="pmcid">PMC6083908</pub-id><pub-id pub-id-type="pmid">30087173</pub-id></mixed-citation></ref><ref id="R57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domenico</surname><given-names>P</given-names></name><name name-style="western"><surname>Salo</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>BA</given-names></name></person-group>. <article-title>Polysaccharide capsule-mediated resistance to opsonophagocytosis in <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source>Infect Immun</source><year>1994</year>;<volume>62</volume>:<fpage>4495</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">7927714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.62.10.4495-4499.1994</pub-id><pub-id pub-id-type="pmcid">PMC303135</pub-id></mixed-citation></ref><ref id="R58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merino</surname><given-names>S</given-names></name><name name-style="western"><surname>Camprub&#237;</surname><given-names>S</given-names></name><name name-style="western"><surname>Albert&#237;</surname><given-names>S</given-names></name><name name-style="western"><surname>Bened&#237;</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Tom&#225;s</surname><given-names>JM</given-names></name></person-group>. <article-title>Mechanisms of <italic toggle="yes">Klebsiella pneumoniae</italic> resistance to complement-mediated killing</article-title>. <source>Infect Immun</source><year>1992</year>;<volume>60</volume>:<fpage>2529</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">1587619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.60.6.2529-2535.1992</pub-id><pub-id pub-id-type="pmcid">PMC257192</pub-id></mixed-citation></ref><ref id="R59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>An</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Capsule type defines the capability of <italic toggle="yes">Klebsiella pneumoniae</italic> in evading kupffer cell capture in the liver</article-title>. <source>Plos Pathog</source><year>2022</year>;<volume>18</volume>:<fpage>e1010693</fpage>.<pub-id pub-id-type="pmid">35914009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1010693</pub-id><pub-id pub-id-type="pmcid">PMC9342791</pub-id></mixed-citation></ref><ref id="R60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roger</surname><given-names>T</given-names></name><name name-style="western"><surname>Froidevaux</surname><given-names>C</given-names></name><name name-style="western"><surname>Le Roy</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4</article-title>. <source>Proc Natl Acad Sci USA</source><year>2009</year>;<volume>106</volume>:<fpage>2348</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">19181857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0808146106</pub-id><pub-id pub-id-type="pmcid">PMC2650125</pub-id></mixed-citation></ref><ref id="R61"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CZ</given-names></name><name name-style="western"><surname>Ma</surname><given-names>LC</given-names></name><name name-style="western"><surname>Fang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JT</given-names></name></person-group>. <article-title>Isolation of a chromosomal region of <italic toggle="yes">Klebsiella pneumoniae</italic> associated with allantoin metabolism and liver infection</article-title>. <source>Infect Immun</source><year>2004</year>;<volume>72</volume>:<fpage>3783</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">15213119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.72.7.3783-3792.2004</pub-id><pub-id pub-id-type="pmcid">PMC427404</pub-id></mixed-citation></ref><ref id="R62"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broug-Holub</surname><given-names>E</given-names></name><name name-style="western"><surname>Toews</surname><given-names>GB</given-names></name><name name-style="western"><surname>van Iwaarden</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>Alveolar macrophages are required for protective pulmonary defenses in murine klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival</article-title>. <source>Infect Immun</source><year>1997</year>;<volume>65</volume>:<fpage>1139</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">9119443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.65.4.1139-1146.1997</pub-id><pub-id pub-id-type="pmcid">PMC175109</pub-id></mixed-citation></ref><ref id="R63"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Olonisakin</surname><given-names>TF</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during <italic toggle="yes">Klebsiella pneumoniae</italic> infection</article-title>. <source>Mucosal Immunol</source><year>2015</year>;<volume>8</volume>:<fpage>896</fpage>&#8211;<lpage>905</lpage>.<pub-id pub-id-type="pmid">25492474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2014.120</pub-id><pub-id pub-id-type="pmcid">PMC4465063</pub-id></mixed-citation></ref><ref id="R64"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Codo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>AC</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>Inhibition of inflammasome activation by a clinical strain of <italic toggle="yes">Klebsiella pneumoniae</italic> impairs efferocytosis and leads to bacterial dissemination</article-title>. <source>Cell Death Dis</source><year>2018</year>;<volume>9</volume>:<fpage>1182</fpage>.<pub-id pub-id-type="pmid">30518854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-1214-5</pub-id><pub-id pub-id-type="pmcid">PMC6281591</pub-id></mixed-citation></ref><ref id="R65"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarkotou</surname><given-names>O</given-names></name><name name-style="western"><surname>Pournaras</surname><given-names>S</given-names></name><name name-style="western"><surname>Tselioti</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Predictors of mortality in patients with bloodstream infections caused by KPC-producing <italic toggle="yes">Klebsiella pneumoniae</italic> and impact of appropriate antimicrobial treatment</article-title>. <source>Clin Microbiol Infect</source><year>2011</year>;<volume>17</volume>:<fpage>1798</fpage>&#8211;<lpage>803</lpage>.<pub-id pub-id-type="pmid">21595793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1469-0691.2011.03514.x</pub-id></mixed-citation></ref><ref id="R66"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shon</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>RP</given-names></name><name name-style="western"><surname>Russo</surname><given-names>TA</given-names></name></person-group>. <article-title>Hypervirulent (hypermucoviscous) <italic toggle="yes">Klebsiella pneumoniae</italic>: a new and dangerous breed</article-title>. <source>Virulence</source><year>2013</year>;<volume>4</volume>:<fpage>107</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">23302790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/viru.22718</pub-id><pub-id pub-id-type="pmcid">PMC3654609</pub-id></mixed-citation></ref><ref id="R67"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>D</given-names></name><name name-style="western"><surname>Dong</surname><given-names>N</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A fatal outbreak of ST11 carbapenem-resistant hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic> in a Chinese hospital: a molecular epidemiological study</article-title>. <source>Lancet Infect Dis</source><year>2018</year>;<volume>18</volume>:<fpage>37</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">28864030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(17)30489-9</pub-id></mixed-citation></ref><ref id="R68"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remold</surname><given-names>SK</given-names></name><name name-style="western"><surname>Brown</surname><given-names>CK</given-names></name><name name-style="western"><surname>Farris</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hundley</surname><given-names>TC</given-names></name><name name-style="western"><surname>Perpich</surname><given-names>JA</given-names></name><name name-style="western"><surname>Purdy</surname><given-names>ME</given-names></name></person-group>. <article-title>Differential habitat use and niche partitioning by pseudomonas species in human homes</article-title>. <source>Microb Ecol</source><year>2011</year>;<volume>62</volume>:<fpage>505</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">21503776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00248-011-9844-5</pub-id></mixed-citation></ref><ref id="R69"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>CAS</given-names></name><name name-style="western"><surname>Bail</surname><given-names>L</given-names></name><name name-style="western"><surname>Arend</surname><given-names>L</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>KDS</given-names></name><name name-style="western"><surname>Tuon</surname><given-names>FF</given-names></name></person-group>. <article-title>The activity of ceftazidime/avibactam against carbapenem-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Infect Dis (Lond)</source><year>2021</year>;<volume>53</volume>:<fpage>386</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">33423568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23744235.2020.1867763</pub-id></mixed-citation></ref><ref id="R70"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheatley</surname><given-names>RM</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>JD</given-names></name><name name-style="western"><surname>van der Schalk</surname><given-names>TE</given-names></name><etal/></person-group>. <article-title>Gut to lung translocation and antibiotic mediated selection shape the dynamics of <italic toggle="yes">Pseudomonas aeruginosa</italic> in an ICU patient</article-title>. <source>Nat Commun</source><year>2022</year>;<volume>13</volume>:<fpage>6523</fpage>.<pub-id pub-id-type="pmid">36414617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-34101-2</pub-id><pub-id pub-id-type="pmcid">PMC9681761</pub-id></mixed-citation></ref><ref id="R71"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Recio</surname><given-names>R</given-names></name><name name-style="western"><surname>Manche&#241;o</surname><given-names>M</given-names></name><name name-style="western"><surname>Viedma</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Predictors of mortality in bloodstream infections caused by <italic toggle="yes">Pseudomonas aeruginosa</italic> and impact of antimicrobial resistance and bacterial virulence</article-title>. <source>Antimicrob Agents Chemother</source><year>2020</year>:<volume>64</volume>: <fpage>10</fpage>-<lpage>1128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01759-19</pub-id><pub-id pub-id-type="pmcid">PMC6985728</pub-id><pub-id pub-id-type="pmid">31767719</pub-id></mixed-citation></ref><ref id="R72"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Recio</surname><given-names>R</given-names></name><name name-style="western"><surname>Villa</surname><given-names>J</given-names></name><name name-style="western"><surname>Viedma</surname><given-names>E</given-names></name><name name-style="western"><surname>Orellana</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lora-Tamayo</surname><given-names>J</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>F</given-names></name></person-group>. <article-title>Bacteraemia due to extensively drug-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic> sequence type 235 high-risk clone: facing the perfect storm</article-title>. <source>Int J Antimicrob Agents</source><year>2018</year>;<volume>52</volume>:<fpage>172</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">29621591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2018.03.018</pub-id></mixed-citation></ref><ref id="R73"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Solh</surname><given-names>AA</given-names></name><name name-style="western"><surname>Hattemer</surname><given-names>A</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>AR</given-names></name><name name-style="western"><surname>Alhajhusain</surname><given-names>A</given-names></name><name name-style="western"><surname>Vora</surname><given-names>H</given-names></name></person-group>. <article-title>Clinical outcomes of type III <italic toggle="yes">Pseudomonas aeruginosa</italic> bacteremia</article-title>. <source>Crit Care Med</source><year>2012</year>;<volume>40</volume>:<fpage>1157</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">22080633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3182377906</pub-id><pub-id pub-id-type="pmcid">PMC3288436</pub-id></mixed-citation></ref><ref id="R74"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitt</surname><given-names>TL</given-names></name></person-group>. <article-title>Epidemiological typing of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>1988</year>;<volume>7</volume>:<fpage>238</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">2455640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01963095</pub-id></mixed-citation></ref><ref id="R75"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrio-Tofi&#241;o E</surname><given-names>D</given-names></name><name name-style="western"><surname>S&#225;nchez-Diener</surname><given-names>I</given-names></name><name name-style="western"><surname>Zamorano</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Association between <italic toggle="yes">Pseudomonas aeruginosa</italic> O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey</article-title>. <source>J Antimicrob Chemother</source><year>2019</year>;<volume>74</volume>:<fpage>3217</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">31430372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkz346</pub-id></mixed-citation></ref><ref id="R76"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaver</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>AR</given-names></name></person-group>. <article-title>Relative contributions of <italic toggle="yes">Pseudomonas aeruginosa</italic> ExoU, ExoS, and ExoT to virulence in the lung</article-title>. <source>Infect Immun</source><year>2004</year>;<volume>72</volume>:<fpage>6969</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">15557619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.72.12.6969-6977.2004</pub-id><pub-id pub-id-type="pmcid">PMC529154</pub-id></mixed-citation></ref><ref id="R77"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawa</surname><given-names>T</given-names></name></person-group>. <article-title>The molecular mechanism of acute lung injury caused by <italic toggle="yes">Pseudomonas aeruginosa</italic>: from bacterial pathogenesis to host response</article-title>. <source>J Intensive Care</source><year>2014</year>;<volume>2</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">25520826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2052-0492-2-10</pub-id><pub-id pub-id-type="pmcid">PMC4267601</pub-id></mixed-citation></ref><ref id="R78"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berube</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>AR</given-names></name></person-group>. <article-title><italic toggle="yes">Pseudomonas aeruginosa</italic>: breaking down barriers</article-title>. <source>Curr Genet</source><year>2016</year>;<volume>62</volume>:<fpage>109</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">26407972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00294-015-0522-x</pub-id><pub-id pub-id-type="pmcid">PMC4724561</pub-id></mixed-citation></ref><ref id="R79"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrity-Ryan</surname><given-names>L</given-names></name><name name-style="western"><surname>Kazmierczak</surname><given-names>B</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>R</given-names></name><name name-style="western"><surname>Comolli</surname><given-names>J</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>A</given-names></name><name name-style="western"><surname>Engel</surname><given-names>JN</given-names></name></person-group>. <article-title>The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of <italic toggle="yes">Pseudomonas aeruginosa</italic> by epithelial cells and macrophages</article-title>. <source>Infect Immun</source><year>2000</year>;<volume>68</volume>:<fpage>7100</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">11083836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.68.12.7100-7113.2000</pub-id><pub-id pub-id-type="pmcid">PMC97821</pub-id></mixed-citation></ref><ref id="R80"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangel</surname><given-names>SM</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Knoten</surname><given-names>CA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>AR</given-names></name></person-group>. <article-title>The role of ExoS in dissemination of <italic toggle="yes">Pseudomonas aeruginosa</italic> during pneumonia</article-title>. <source>PLoS Pathog</source><year>2015</year>;<volume>11</volume>:<fpage>e1004945</fpage>.<pub-id pub-id-type="pmid">26090668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1004945</pub-id><pub-id pub-id-type="pmcid">PMC4474835</pub-id></mixed-citation></ref><ref id="R81"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouillot</surname><given-names>S</given-names></name><name name-style="western"><surname>Munro</surname><given-names>P</given-names></name><name name-style="western"><surname>Gallet</surname><given-names>B</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> exolysin promotes bacterial growth in lungs, alveolar damage and bacterial dissemination</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>2120</fpage>.<pub-id pub-id-type="pmid">28522850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-02349-0</pub-id><pub-id pub-id-type="pmcid">PMC5437091</pub-id></mixed-citation></ref><ref id="R82"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golovkine</surname><given-names>G</given-names></name><name name-style="western"><surname>Faudry</surname><given-names>E</given-names></name><name name-style="western"><surname>Bouillot</surname><given-names>S</given-names></name><name name-style="western"><surname>Voulhoux</surname><given-names>R</given-names></name><name name-style="western"><surname>Attree</surname><given-names>I</given-names></name><name name-style="western"><surname>Huber</surname><given-names>P</given-names></name></person-group>. <article-title>VE-cadherin cleavage by LasB protease from <italic toggle="yes">Pseudomonas aeruginosa</italic> facilitates type III secretion system toxicity in endothelial cells</article-title>. <source>PLoS Pathog</source><year>2014</year>;<volume>10</volume>:<fpage>e1003939</fpage>.<pub-id pub-id-type="pmid">24626230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003939</pub-id><pub-id pub-id-type="pmcid">PMC3953407</pub-id></mixed-citation></ref><ref id="R83"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holder</surname><given-names>IA</given-names></name><name name-style="western"><surname>Neely</surname><given-names>AN</given-names></name><name name-style="western"><surname>Frank</surname><given-names>DW</given-names></name></person-group>. <article-title>Type III secretion/intoxication system important in virulence of <italic toggle="yes">Pseudomonas aeruginosa</italic> infections in burns</article-title>. <source>Burns</source><year>2001</year>;<volume>27</volume>:<fpage>129</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">11226648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0305-4179(00)00142-x</pub-id></mixed-citation></ref><ref id="R84"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomic</surname><given-names>T</given-names></name><name name-style="western"><surname>Henman</surname><given-names>M</given-names></name><name name-style="western"><surname>Tadic</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Antimicrobial utilization and resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic> using segmented regression analysis: a comparative study between serbia and eight European Countries</article-title>. <source>Int J Clin Pharm</source><year>2023</year>;<volume>45</volume>:<fpage>989</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">37284904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-023-01603-y</pub-id><pub-id pub-id-type="pmcid">PMC10246517</pub-id></mixed-citation></ref><ref id="R85"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Raudonis</surname><given-names>R</given-names></name><name name-style="western"><surname>Glick</surname><given-names>BR</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name></person-group>. <article-title>Antibiotic resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic>: mechanisms and alternative therapeutic strategies</article-title>. <source>Biotechnol Adv</source><year>2019</year>;<volume>37</volume>:<fpage>177</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">30500353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biotechadv.2018.11.013</pub-id></mixed-citation></ref><ref id="R86"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciofu</surname><given-names>O</given-names></name><name name-style="western"><surname>Tolker-Nielsen</surname><given-names>T</given-names></name></person-group>. <article-title>Tolerance and resistance of <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics</article-title>. <source>Front Microbiol</source><year>2019</year>;<volume>10</volume>:<fpage>913</fpage>.<pub-id pub-id-type="pmid">31130925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.00913</pub-id><pub-id pub-id-type="pmcid">PMC6509751</pub-id></mixed-citation></ref><ref id="R87"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belaynehe</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SW</given-names></name><name name-style="western"><surname>Hong-Tae</surname><given-names>P</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>HS</given-names></name></person-group>. <article-title>Occurrence of aminoglycoside-modifying enzymes among isolates of <italic toggle="yes">Escherichia coli</italic> exhibiting high levels of aminoglycoside resistance isolated from Korean cattle farms</article-title>. <source>FEMS Microbiol Lett</source><year>2017</year>;<volume>364</volume>:<fpage>fnx129</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsle/fnx129</pub-id><pub-id pub-id-type="pmid">28637330</pub-id></mixed-citation></ref><ref id="R88"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>K</given-names></name></person-group>. <article-title>Aminoglycoside resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title>. <source>Antimicrob Agents Chemother</source><year>2005</year>;<volume>49</volume>:<fpage>479</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">15673721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.49.2.479-487.2005</pub-id><pub-id pub-id-type="pmcid">PMC547279</pub-id></mixed-citation></ref><ref id="R89"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Plesiat</surname><given-names>P</given-names></name><name name-style="western"><surname>Nikaido</surname><given-names>H</given-names></name></person-group>. <article-title>The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria</article-title>. <source>Clin Microbiol Rev</source><year>2015</year>;<volume>28</volume>:<fpage>337</fpage>&#8211;<lpage>418</lpage>.<pub-id pub-id-type="pmid">25788514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00117-14</pub-id><pub-id pub-id-type="pmcid">PMC4402952</pub-id></mixed-citation></ref><ref id="R90"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>J</given-names></name><name name-style="western"><surname>Grosso</surname><given-names>F</given-names></name><name name-style="western"><surname>Peixe</surname><given-names>L</given-names></name></person-group>. <article-title>Antibiotic resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic> &#8211; mechanisms, epidemiology and evolution</article-title>. <source>Drug Resist Updat</source><year>2019</year>;<volume>44</volume>:<fpage>100640</fpage>.<pub-id pub-id-type="pmid">31492517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drup.2019.07.002</pub-id></mixed-citation></ref><ref id="R91"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuon</surname><given-names>FF</given-names></name><name name-style="western"><surname>Dantas</surname><given-names>LR</given-names></name><name name-style="western"><surname>Suss</surname><given-names>PH</given-names></name><name name-style="western"><surname>Tasca Ribeiro</surname><given-names>VS</given-names></name></person-group>. <article-title>Pathogenesis of the <italic toggle="yes">Pseudomonas aeruginosa</italic> biofilm: a review</article-title>. <source>Pathogens</source><year>2022</year>;<volume>11</volume>:<fpage>300</fpage>.<pub-id pub-id-type="pmid">35335624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens11030300</pub-id><pub-id pub-id-type="pmcid">PMC8950561</pub-id></mixed-citation></ref><ref id="R92"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>DL</given-names></name><name name-style="western"><surname>Uslan</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Grogan</surname><given-names>TR</given-names></name><name name-style="western"><surname>Martin</surname><given-names>EM</given-names></name></person-group>. <article-title>Multidrug resistant acinetobacter baumanii: a 15-year trend analysis</article-title>. <source>Infect Control Hosp Epidemiol</source><year>2018</year>;<volume>39</volume>:<fpage>608</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29582720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/ice.2018.52</pub-id><pub-id pub-id-type="pmcid">PMC7315822</pub-id></mixed-citation></ref><ref id="R93"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Community-acquired bloodstream infections caused by <italic toggle="yes">Acinetobacter baumannii</italic>: a matched case-control study</article-title>. <source>J Microbiol Immunol Infect</source><year>2018</year>;<volume>51</volume>:<fpage>629</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">28701266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2017.02.004</pub-id></mixed-citation></ref><ref id="R94"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peleg</surname><given-names>AY</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name></person-group>. <article-title><italic toggle="yes">Acinetobacter baumannii</italic>: emergence of a successful pathogen</article-title>. <source>Clin Microbiol Rev</source><year>2008</year>;<volume>21</volume>:<fpage>538</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">18625687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00058-07</pub-id><pub-id pub-id-type="pmcid">PMC2493088</pub-id></mixed-citation></ref><ref id="R95"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roca</surname><given-names>I</given-names></name><name name-style="western"><surname>Espinal</surname><given-names>P</given-names></name><name name-style="western"><surname>Vila-Farr&#233;s</surname><given-names>X</given-names></name><name name-style="western"><surname>Vila</surname><given-names>J</given-names></name></person-group>. <article-title>The <italic toggle="yes">Acinetobacter baumannii</italic> oxymoron: commensal hospital dweller turned pan-drug-resistant menace</article-title>. <source>Front Microbiol</source><year>2012</year>;<volume>3</volume>:<fpage>148</fpage>.<pub-id pub-id-type="pmid">22536199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2012.00148</pub-id><pub-id pub-id-type="pmcid">PMC3333477</pub-id></mixed-citation></ref><ref id="R96"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shenoy</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>VM</given-names></name><name name-style="western"><surname>Sater</surname><given-names>MRA</given-names></name><etal/></person-group>. <article-title>Community-acquired in name only: a cluster of carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> in a burn intensive care unit and beyond</article-title>. <source>Infect Control Hosp Epidemiol</source><year>2020</year>;<volume>41</volume>:<fpage>531</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">32106898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/ice.2020.15</pub-id></mixed-citation></ref><ref id="R97"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>NY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>TC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial <italic toggle="yes">Acinetobacter baumannii</italic> complex bacteremia</article-title>. <source>J Infect</source><year>2010</year>;<volume>61</volume>:<fpage>219</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">20624424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2010.07.002</pub-id></mixed-citation></ref><ref id="R98"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liou</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>HL</given-names></name><name name-style="western"><surname>Lai</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name></person-group>. <article-title>Persistent nasal carriers of <italic toggle="yes">Acinetobacter baumannii</italic> in long-term-care facilities</article-title>. <source>Am J Infect Control</source><year>2017</year>;<volume>45</volume>:<fpage>723</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">28284750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajic.2017.02.005</pub-id></mixed-citation></ref><ref id="R99"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>AR</given-names></name><name name-style="western"><surname>Vowles</surname><given-names>M</given-names></name><name name-style="western"><surname>Horth</surname><given-names>RZ</given-names></name><etal/></person-group>. <article-title>Infection control response to an outbreak of OXA-23 carbapenemase-producing carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> in a skilled nursing facility in Utah</article-title>. <source>Am J Infect Control</source><year>2021</year>;<volume>49</volume>:<fpage>792</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">33217512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajic.2020.11.012</pub-id><pub-id pub-id-type="pmcid">PMC8803644</pub-id></mixed-citation></ref><ref id="R100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConnell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Actis</surname><given-names>L</given-names></name><name name-style="western"><surname>Pach&#243;n</surname><given-names>J</given-names></name></person-group>. <article-title><italic toggle="yes">Acinetobacter baumannii</italic>: human infections, factors contributing to pathogenesis and animal models</article-title>. <source>FEMS Microbiol Rev</source><year>2013</year>;<volume>37</volume>:<fpage>130</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22568581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6976.2012.00344.x</pub-id></mixed-citation></ref><ref id="R101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>B</given-names></name><name name-style="western"><surname>Rodman</surname><given-names>N</given-names></name><name name-style="western"><surname>Jara</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Human serum albumin alters specific genes that can play a role in survival and persistence in <italic toggle="yes">Acinetobacter baumannii</italic></article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>14741</fpage>.<pub-id pub-id-type="pmid">30282985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-33072-z</pub-id><pub-id pub-id-type="pmcid">PMC6170387</pub-id></mixed-citation></ref><ref id="R102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>GL</given-names></name><name name-style="western"><surname>Tsyganov</surname><given-names>K</given-names></name><name name-style="western"><surname>Kostoulias</surname><given-names>XP</given-names></name><etal/></person-group>. <article-title>Global gene expression profile of <italic toggle="yes">Acinetobacter baumannii</italic> during bacteremia</article-title>. <source>J Infect Dis</source><year>2017</year>;<volume>215</volume>:<fpage>S52</fpage>&#8211;<lpage>S7</lpage>.<pub-id pub-id-type="pmid">28375520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiw529</pub-id></mixed-citation></ref><ref id="R103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crepin</surname><given-names>S</given-names></name><name name-style="western"><surname>Ottosen</surname><given-names>EN</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The lytic transglycosylase MltB connects membrane homeostasis and in vivo fitness of <italic toggle="yes">Acinetobacter baumannii</italic></article-title>. <source>Mol Microbiol</source><year>2018</year>;<volume>109</volume>:<fpage>745</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29884996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/mmi.14000</pub-id><pub-id pub-id-type="pmcid">PMC6185781</pub-id></mixed-citation></ref><ref id="R104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subashchandrabose</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name><name name-style="western"><surname>DeOrnellas</surname><given-names>V</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Acinetobacter baumannii</italic> genes required for bacterial survival during bloodstream infection</article-title>. <source>mSphere</source><year>2016</year>:<volume>1</volume>:<fpage>10</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mSphere.00013-15</pub-id><pub-id pub-id-type="pmcid">PMC4863628</pub-id><pub-id pub-id-type="pmid">27303682</pub-id></mixed-citation></ref><ref id="R105"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brissette</surname><given-names>CA</given-names></name><name name-style="western"><surname>Koenigs</surname><given-names>A</given-names></name><name name-style="western"><surname>Zipfel</surname><given-names>PF</given-names></name><name name-style="western"><surname>Kraiczy</surname><given-names>P</given-names></name></person-group>. <article-title>Translation elongation factor tuf of <italic toggle="yes">Acinetobacter baumannii</italic> is a plasminogen-binding protein</article-title>. <source>Plos One</source><year>2015</year>;<volume>10</volume>:<fpage>e0134418</fpage>.<pub-id pub-id-type="pmid">26230848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0134418</pub-id><pub-id pub-id-type="pmcid">PMC4521846</pub-id></mixed-citation></ref><ref id="R106"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruhn</surname><given-names>KW</given-names></name><name name-style="western"><surname>Pantapalangkoor</surname><given-names>P</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Host fate is rapidly determined by innate effector-microbial interactions during <italic toggle="yes">Acinetobacter baumannii</italic> bacteremia</article-title>. <source>J Infect Dis</source><year>2015</year>;<volume>211</volume>:<fpage>1296</fpage>&#8211;<lpage>305</lpage>.<pub-id pub-id-type="pmid">25378635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiu593</pub-id><pub-id pub-id-type="pmcid">PMC4447835</pub-id></mixed-citation></ref><ref id="R107"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Oliveira</surname><given-names>DMP</given-names></name><name name-style="western"><surname>Forde</surname><given-names>BM</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Antimicrobial resistance in ESKAPE pathogens</article-title>. <source>Clin Microbiol Rev</source><year>2020</year>:<volume>33</volume>:<fpage>10</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00181-19</pub-id><pub-id pub-id-type="pmcid">PMC7227449</pub-id><pub-id pub-id-type="pmid">32404435</pub-id></mixed-citation></ref><ref id="R108"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Drug-resistant genes carried by acinetobacter baumanii isolated from patients with lower respiratory tract infection</article-title>. <source>Chinese Med J</source><year>2010</year>;<volume>123</volume>:<fpage>2571</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">21034630</pub-id></mixed-citation></ref><ref id="R109"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herc</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Marini</surname><given-names>BL</given-names></name><name name-style="western"><surname>Perissinotti</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Miceli</surname><given-names>MH</given-names></name></person-group>. <article-title>Daptomycin nonsusceptible vancomycin resistant enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes</article-title>. <source>Leuk Lymphoma</source><year>2017</year>;<volume>58</volume>:<fpage>2852</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">28402152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10428194.2017.1312665</pub-id></mixed-citation></ref><ref id="R110"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schembri</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zakour</surname><given-names>NL</given-names></name><name name-style="western"><surname>Phan</surname><given-names>MD</given-names></name><name name-style="western"><surname>Forde</surname><given-names>BM</given-names></name><name name-style="western"><surname>Stanton-Cook</surname><given-names>M</given-names></name><name name-style="western"><surname>Beatson</surname><given-names>SA</given-names></name></person-group>. <article-title>Molecular characterization of the multidrug resistant <italic toggle="yes">Escherichia coli</italic> ST131 clone</article-title>. <source>Pathogens</source><year>2015</year>;<volume>4</volume>:<fpage>422</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">26131613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens4030422</pub-id><pub-id pub-id-type="pmcid">PMC4584265</pub-id></mixed-citation></ref><ref id="R111"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araya</surname><given-names>S</given-names></name><name name-style="western"><surname>Gebreyohannes</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tadlo</surname><given-names>G</given-names></name><name name-style="western"><surname>Gessew</surname><given-names>GT</given-names></name><name name-style="western"><surname>Negesso</surname><given-names>AE</given-names></name></person-group>. <article-title>Epidemiology and multidrug resistance of <italic toggle="yes">Pseudomonas aeruginosa</italic> and acinetobacter baumanni isolated from clinical samples in Ethiopia</article-title>. <source>Infect Drug Resist</source><year>2023</year>;<volume>16</volume>:<fpage>2765</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">37187480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S402894</pub-id><pub-id pub-id-type="pmcid">PMC10178297</pub-id></mixed-citation></ref><ref id="R112"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Courvalin</surname><given-names>P</given-names></name><name name-style="western"><surname>Grillot-Courvalin</surname><given-names>C</given-names></name></person-group>. <article-title>RND-type efflux pumps in multidrug-resistant clinical isolates of <italic toggle="yes">Acinetobacter baumannii</italic>: major role for AdeABC overexpression and AdeRS mutations</article-title>. <source>Antimicrob Agents Chemother</source><year>2013</year>;<volume>57</volume>:<fpage>2989</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">23587960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02556-12</pub-id><pub-id pub-id-type="pmcid">PMC3697384</pub-id></mixed-citation></ref><ref id="R113"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Balloy</surname><given-names>V</given-names></name><name name-style="western"><surname>Fiette</surname><given-names>L</given-names></name><name name-style="western"><surname>Chignard</surname><given-names>M</given-names></name><name name-style="western"><surname>Courvalin</surname><given-names>P</given-names></name><name name-style="western"><surname>Grillot-Courvalin</surname><given-names>C</given-names></name></person-group>. <article-title>Contribution of the ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of <italic toggle="yes">Acinetobacter baumannii</italic></article-title>. <source>mBio</source><year>2016</year>;<volume>7</volume>:<fpage>10</fpage>&#8211;<lpage>128</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00697-16</pub-id><pub-id pub-id-type="pmcid">PMC4895114</pub-id><pub-id pub-id-type="pmid">27247231</pub-id></mixed-citation></ref><ref id="R114"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamieh</surname><given-names>A</given-names></name><name name-style="western"><surname>Nawfal</surname><given-names>TD</given-names></name><name name-style="western"><surname>Ballouz</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Control and elimination of extensively drug-resistant acinetobacter baumanii in an intensive care unit</article-title>. <source>Emerging Infectious Diseases</source><year>2019</year>;<volume>25</volume>:<fpage>1928</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">31538925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2510.181626</pub-id><pub-id pub-id-type="pmcid">PMC6759246</pub-id></mixed-citation></ref><ref id="R115"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>SL</given-names></name><name name-style="western"><surname>Holden</surname><given-names>DC</given-names></name><name name-style="western"><surname>Mira</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Microbial recognition and danger signals in sepsis and trauma</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source><year>2017</year>;<volume>1863</volume>:<fpage>2564</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">28115287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.01.013</pub-id><pub-id pub-id-type="pmcid">PMC5519458</pub-id></mixed-citation></ref><ref id="R116"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>H</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>DV</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H</given-names></name></person-group>. <article-title>Recognition of bacterial infection by innate immune sensors</article-title>. <source>Crit Rev Microbiol</source><year>2013</year>;<volume>39</volume>:<fpage>229</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22866947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/1040841X.2012.706249</pub-id></mixed-citation></ref><ref id="R117"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SM</given-names></name></person-group>. <article-title>DAMPs activating innate immune responses in sepsis</article-title>. <source>Ageing Res Rev</source><year>2015</year>;<volume>24</volume>:<fpage>54</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25816752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2015.03.003</pub-id></mixed-citation></ref><ref id="R118"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michels</surname><given-names>EHA</given-names></name><name name-style="western"><surname>Butler</surname><given-names>JM</given-names></name><name name-style="western"><surname>Reijnders</surname><given-names>TDY</given-names></name><etal/></person-group>. <article-title>Association between age and the host response in critically ill patients with sepsis</article-title>. <source>Crit Care</source><year>2022</year>;<volume>26</volume>:<fpage>385</fpage>.<pub-id pub-id-type="pmid">36514130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-022-04266-9</pub-id><pub-id pub-id-type="pmcid">PMC9747080</pub-id></mixed-citation></ref><ref id="R119"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boomer</surname><given-names>JS</given-names></name><name name-style="western"><surname>To</surname><given-names>K</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name><etal/></person-group>. <article-title>Immunosuppression in patients who die of sepsis and multiple organ failure</article-title>. <source>Jama</source><year>2011</year>;<volume>306</volume>:<fpage>2594</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">22187279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.1829</pub-id><pub-id pub-id-type="pmcid">PMC3361243</pub-id></mixed-citation></ref><ref id="R120"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>GP</given-names></name><name name-style="western"><surname>Sossdorf</surname><given-names>M</given-names></name><name name-style="western"><surname>Claus</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>The late phase of sepsis is characterized by an increased microbiological burden and death rate</article-title>. <source>Crit Care</source><year>2011</year>;<volume>15</volume>:<fpage>R183</fpage>.<pub-id pub-id-type="pmid">21798063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc10332</pub-id><pub-id pub-id-type="pmcid">PMC3387626</pub-id></mixed-citation></ref><ref id="R121"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonecchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Locati</surname><given-names>M</given-names></name></person-group>. <article-title>Tuning inflammation and immunity by chemokine sequestration: decoys and more</article-title>. <source>Nat Rev Immunol</source><year>2006</year>;<volume>6</volume>:<fpage>907</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">17124512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri1964</pub-id></mixed-citation></ref><ref id="R122"><label>[122]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosales</surname><given-names>C</given-names></name></person-group>. <article-title>Neutrophils at the crossroads of innate and adaptive immunity</article-title>. <source>J Leukoc Biol</source><year>2020</year>;<volume>108</volume>:<fpage>377</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">32202340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.4MIR0220-574RR</pub-id></mixed-citation></ref><ref id="R123"><label>[123]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves-Filho</surname><given-names>JC</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>A</given-names></name><name name-style="western"><surname>Souto</surname><given-names>FO</given-names></name><etal/></person-group>. <article-title>Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis</article-title>. <source>Proc Natl Acad Sci USA</source><year>2009</year>;<volume>106</volume>:<fpage>4018</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19234125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0900196106</pub-id><pub-id pub-id-type="pmcid">PMC2656197</pub-id></mixed-citation></ref><ref id="R124"><label>[124]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souto</surname><given-names>FO</given-names></name><name name-style="western"><surname>Alves-Filho</surname><given-names>JC</given-names></name><name name-style="western"><surname>Turato</surname><given-names>WM</given-names></name><name name-style="western"><surname>Auxiliadora-Martins</surname><given-names>M</given-names></name><name name-style="western"><surname>Basile-Filho</surname><given-names>A</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>FQ</given-names></name></person-group>. <article-title>Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis</article-title>. <source>Am J Respir Crit Care Med</source><year>2011</year>;<volume>183</volume>:<fpage>234</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">20732989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201003-0416OC</pub-id></mixed-citation></ref><ref id="R125"><label>[125]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>V</given-names></name></person-group>. <article-title>Neutrophil Extracellular Traps in the Second Decade</article-title>. <source>J Innate Immun</source><year>2018</year>;<volume>10</volume>:<fpage>414</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">29909412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000489829</pub-id><pub-id pub-id-type="pmcid">PMC6784051</pub-id></mixed-citation></ref><ref id="R126"><label>[126]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domer</surname><given-names>D</given-names></name><name name-style="western"><surname>Walther</surname><given-names>T</given-names></name><name name-style="western"><surname>Moller</surname><given-names>S</given-names></name><name name-style="western"><surname>Behnen</surname><given-names>M</given-names></name><name name-style="western"><surname>Laskay</surname><given-names>T</given-names></name></person-group>. <article-title>Neutrophil extracellular traps activate proinflammatory functions of human neutrophils</article-title>. <source>Front Immunol</source><year>2021</year>;<volume>12</volume>:<fpage>636954</fpage>.<pub-id pub-id-type="pmid">34168641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.636954</pub-id><pub-id pub-id-type="pmcid">PMC8217666</pub-id></mixed-citation></ref><ref id="R127"><label>[127]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps impair intestinal barrier functions in sepsis by regulating TLR9-mediated endoplasmic reticulum stress pathway</article-title>. <source>Cell Death Dis</source><year>2021</year>;<volume>12</volume>:<fpage>606</fpage>.<pub-id pub-id-type="pmid">34117211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-021-03896-1</pub-id><pub-id pub-id-type="pmcid">PMC8195983</pub-id></mixed-citation></ref><ref id="R128"><label>[128]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czaikoski</surname><given-names>PG</given-names></name><name name-style="western"><surname>Mota</surname><given-names>JM</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>DC</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<fpage>e0148142</fpage>.<pub-id pub-id-type="pmid">26849138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0148142</pub-id><pub-id pub-id-type="pmcid">PMC4743982</pub-id></mixed-citation></ref><ref id="R129"><label>[129]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsabani</surname><given-names>M</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>ST</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis</article-title>. <source>Br J Anaesth</source><year>2022</year>;<volume>128</volume>:<fpage>283</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">34893315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2021.10.039</pub-id><pub-id pub-id-type="pmcid">PMC8792833</pub-id></mixed-citation></ref><ref id="R130"><label>[130]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neutrophil, neutrophil extracellular traps and endothelial cell dysfunction in sepsis</article-title>. <source>Clin Transl Med</source><year>2023</year>;<volume>13</volume>:<fpage>e1170</fpage>.<pub-id pub-id-type="pmid">36629024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1170</pub-id><pub-id pub-id-type="pmcid">PMC9832433</pub-id></mixed-citation></ref><ref id="R131"><label>[131]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonego</surname><given-names>F</given-names></name><name name-style="western"><surname>Castanheira</surname><given-names>FV</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>Paradoxical roles of the neutrophil in sepsis: protective and deleterious</article-title>. <source>Front Immunol</source><year>2016</year>;<volume>7</volume>:<fpage>155</fpage>.<pub-id pub-id-type="pmid">27199981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00155</pub-id><pub-id pub-id-type="pmcid">PMC4844928</pub-id></mixed-citation></ref><ref id="R132"><label>[132]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Identification and characterization of neutrophil heterogeneity in sepsis</article-title>. <source>Crit Care</source><year>2021</year>;<volume>25</volume>:<fpage>50</fpage>.<pub-id pub-id-type="pmid">33549126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03481-0</pub-id><pub-id pub-id-type="pmcid">PMC7865119</pub-id></mixed-citation></ref><ref id="R133"><label>[133]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>B</given-names></name><name name-style="western"><surname>Davis</surname><given-names>RP</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S-J</given-names></name><etal/></person-group>. <article-title>Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice</article-title>. <source>Blood</source><year>2017</year>;<volume>129</volume>:<fpage>1357</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">28073784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2016-09-741298</pub-id><pub-id pub-id-type="pmcid">PMC5345735</pub-id></mixed-citation></ref><ref id="R134"><label>[134]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Lysophosphatidic acid promotes thrombus stability by inducing rapid formation of neutrophil extracellular traps: a new mechanism of thrombosis</article-title>. <source>J Thromb Haemost</source><year>2020</year>;<volume>18</volume>:<fpage>1952</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">32291893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.14839</pub-id></mixed-citation></ref><ref id="R135"><label>[135]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Totoki</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Serum histone H3 levels and platelet counts are potential markers for coagulopathy with high risk of death in septic patients: a single-center observational study</article-title>. <source>J Intensive Care</source><year>2019</year>;<volume>7</volume>:<fpage>63</fpage>.<pub-id pub-id-type="pmid">31890225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40560-019-0420-2</pub-id><pub-id pub-id-type="pmcid">PMC6933899</pub-id></mixed-citation></ref><ref id="R136"><label>[136]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skendros</surname><given-names>P</given-names></name><name name-style="western"><surname>Mitsios</surname><given-names>A</given-names></name><name name-style="western"><surname>Chrysanthopoulou</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis</article-title>. <source>J Clin Invest</source><year>2020</year>;<volume>130</volume>:<fpage>6151</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">32759504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI141374</pub-id><pub-id pub-id-type="pmcid">PMC7598040</pub-id></mixed-citation></ref><ref id="R137"><label>[137]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Tissue factor-enriched neutrophil extracellular traps promote immunothrombosis and disease progression in sepsis-induced lung injury</article-title>. <source>Front Cell Infect Microbiol</source><year>2021</year>;<volume>11</volume>:<fpage>677902</fpage>.<pub-id pub-id-type="pmid">34336711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2021.677902</pub-id><pub-id pub-id-type="pmcid">PMC8317465</pub-id></mixed-citation></ref><ref id="R138"><label>[138]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Review: the emerging role of neutrophil extracellular traps in sepsis and sepsis-associated thrombosis</article-title>. <source>Front Cell Infect Microbiol</source><year>2021</year>;<volume>11</volume>:<fpage>653228</fpage>.<pub-id pub-id-type="pmid">33816356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2021.653228</pub-id><pub-id pub-id-type="pmcid">PMC8010653</pub-id></mixed-citation></ref><ref id="R139"><label>[139]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>NL</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M</given-names></name><name name-style="western"><surname>Gurien</surname><given-names>SD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name></person-group>. <article-title>DAMPs and NETs in sepsis</article-title>. <source>Front Immunol</source><year>2019</year>;<volume>10</volume>:<fpage>2536</fpage>.<pub-id pub-id-type="pmid">31736963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02536</pub-id><pub-id pub-id-type="pmcid">PMC6831555</pub-id></mixed-citation></ref><ref id="R140"><label>[140]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadie</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bae</surname><given-names>HB</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>HMGB1 promotes neutrophil extracellular trap formation through interactions with toll-like receptor 4</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source><year>2013</year>;<volume>304</volume>:<fpage>L342</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23316068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajplung.00151.2012</pub-id><pub-id pub-id-type="pmcid">PMC3602738</pub-id></mixed-citation></ref><ref id="R141"><label>[141]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>H</given-names></name><name name-style="western"><surname>Rossaint</surname><given-names>J</given-names></name><name name-style="western"><surname>Zarbock</surname><given-names>A</given-names></name></person-group>. <article-title>The fatal circle of NETs and NET-associated DAMPs contributing to organ dysfunction</article-title>. <source>Cells</source><year>2022</year>;<volume>11</volume>:<fpage>1919</fpage>.<pub-id pub-id-type="pmid">35741047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11121919</pub-id><pub-id pub-id-type="pmcid">PMC9222025</pub-id></mixed-citation></ref><ref id="R142"><label>[142]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Neutrophil extracellular traps promote macrophage pyroptosis in sepsis</article-title>. <source>Cell Death Dis</source><year>2018</year>;<volume>9</volume>:<fpage>597</fpage>.<pub-id pub-id-type="pmid">29789550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-0538-5</pub-id><pub-id pub-id-type="pmcid">PMC5964241</pub-id></mixed-citation></ref><ref id="R143"><label>[143]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization</article-title>. <source>Exp. Cell. Res.</source><year>2019</year>;<volume>382</volume>:<fpage>111486</fpage>.<pub-id pub-id-type="pmid">31255598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2019.06.031</pub-id></mixed-citation></ref><ref id="R144"><label>[144]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montero-Jodra</surname><given-names>A</given-names></name><name name-style="western"><surname>de la Fuente</surname><given-names>M</given-names></name><name name-style="western"><surname>Gobelli</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The mitochondrial signature of cultured endothelial cells in sepsis: identifying potential targets for treatment</article-title>. <source>Biochim Et Biophys Acta-Mol Basis Dis</source><year>2024</year>;<volume>1870</volume>:<fpage>166946</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2023.166946</pub-id><pub-id pub-id-type="pmid">37939908</pub-id></mixed-citation></ref><ref id="R145"><label>[145]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Saadi</surname><given-names>W</given-names></name><name name-style="western"><surname>Beltran-Garcia</surname><given-names>J</given-names></name><name name-style="western"><surname>Garcia-Gimenez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Pallardo</surname><given-names>FV</given-names></name></person-group>. <article-title>The endothelial glycocalyx and neonatal sepsis</article-title>. <source>Int J Mol Sci</source><year>2022</year>;<volume>24</volume>:<fpage>364</fpage>.<pub-id pub-id-type="pmid">36613805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24010364</pub-id><pub-id pub-id-type="pmcid">PMC9820255</pub-id></mixed-citation></ref><ref id="R146"><label>[146]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lupu</surname><given-names>F</given-names></name><name name-style="western"><surname>Kinasewitz</surname><given-names>G</given-names></name><name name-style="western"><surname>Dormer</surname><given-names>K</given-names></name></person-group>. <article-title>The role of endothelial shear stress on haemodynamics, inflammation, coagulation and glycocalyx during sepsis</article-title>. <source>J Cell Mol Med</source><year>2020</year>;<volume>24</volume>:<fpage>12258</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">32951280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.15895</pub-id><pub-id pub-id-type="pmcid">PMC7687012</pub-id></mixed-citation></ref><ref id="R147"><label>[147]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>V</given-names></name><name name-style="western"><surname>Meegan</surname><given-names>JE</given-names></name><name name-style="western"><surname>Beard</surname><given-names>RSJRS</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>SY</given-names></name></person-group>. <article-title>Role of neutrophil extracellular traps and vesicles in regulating vascular endothelial permeability</article-title>. <source>Front Immunol</source><year>2019</year>;<volume>10</volume>:<fpage>1037</fpage>.<pub-id pub-id-type="pmid">31143182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01037</pub-id><pub-id pub-id-type="pmcid">PMC6520655</pub-id></mixed-citation></ref><ref id="R148"><label>[148]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darwish</surname><given-names>I</given-names></name><name name-style="western"><surname>Liles</surname><given-names>WC</given-names></name></person-group>. <article-title>Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction</article-title>. <source>Virulence</source><year>2013</year>;<volume>4</volume>:<fpage>572</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">23863603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/viru.25740</pub-id><pub-id pub-id-type="pmcid">PMC5359747</pub-id></mixed-citation></ref><ref id="R149"><label>[149]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ran</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Tissue kallikrein exacerbating sepsis-induced endothelial hyperpermeability is highly predictive of severity and mortality in sepsis</article-title>. <source>J Inflamm Res</source><year>2021</year>;<volume>14</volume>:<fpage>3321</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">34290517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S317874</pub-id><pub-id pub-id-type="pmcid">PMC8289368</pub-id></mixed-citation></ref><ref id="R150"><label>[150]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allingham</surname><given-names>MJ</given-names></name><name name-style="western"><surname>van Buul</surname><given-names>JD</given-names></name><name name-style="western"><surname>Burridge</surname><given-names>K</given-names></name></person-group>. <article-title>ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration</article-title>. <source>J Immunol</source><year>2007</year>;<volume>179</volume>:<fpage>4053</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">17785844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.179.6.4053</pub-id></mixed-citation></ref><ref id="R151"><label>[151]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radeva</surname><given-names>MY</given-names></name><name name-style="western"><surname>Waschke</surname><given-names>J</given-names></name></person-group>. <article-title>Mind the gap: mechanisms regulating the endothelial barrier</article-title>. <source>Acta Physiol</source><year>2018</year>;<volume>222</volume>:<fpage>e12860</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apha.12860</pub-id><pub-id pub-id-type="pmid">28231640</pub-id></mixed-citation></ref><ref id="R152"><label>[152]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>WL</given-names></name><name name-style="western"><surname>Slutsky</surname><given-names>AS</given-names></name></person-group>. <article-title>Sepsis and endothelial permeability</article-title>. <source>N Engl J Med</source><year>2010</year>;<volume>363</volume>:<fpage>689</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">20818861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMcibr1007320</pub-id></mixed-citation></ref><ref id="R153"><label>[153]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>PR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RK</given-names></name><name name-style="western"><surname>Pober</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kluger</surname><given-names>MS</given-names></name></person-group>. <article-title>Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-kappaB-dependent phases</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0120075</fpage>.<pub-id pub-id-type="pmid">25816133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0120075</pub-id><pub-id pub-id-type="pmcid">PMC4376850</pub-id></mixed-citation></ref><ref id="R154"><label>[154]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kevil</surname><given-names>CG</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>B</given-names></name><name name-style="western"><surname>Coe</surname><given-names>LL</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JS</given-names></name></person-group>. <article-title>H(2)O(2)-mediated permeability: role of MAPK and occludin</article-title>. <source>Am J Physiol Cell Physiol</source><year>2000</year>;<volume>279</volume>:<fpage>C21</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">10898713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpcell.2000.279.1.C21</pub-id></mixed-citation></ref><ref id="R155"><label>[155]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukasz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hillgruber</surname><given-names>C</given-names></name><name name-style="western"><surname>Oberleithner</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Endothelial glycocalyx breakdown is mediated by angiopoietin-2</article-title>. <source>Cardiovasc Res</source><year>2017</year>;<volume>113</volume>:<fpage>671</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">28453727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvx023</pub-id></mixed-citation></ref><ref id="R156"><label>[156]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iba</surname><given-names>T</given-names></name><name name-style="western"><surname>Levy</surname><given-names>JH</given-names></name></person-group>. <article-title>Derangement of the endothelial glycocalyx in sepsis</article-title>. <source>J Thromb Haemost</source><year>2019</year>;<volume>17</volume>:<fpage>283</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">30582882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.14371</pub-id></mixed-citation></ref><ref id="R157"><label>[157]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Meegan</surname><given-names>JE</given-names></name><name name-style="western"><surname>Jannaway</surname><given-names>M</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>DC</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>SY</given-names></name></person-group>. <article-title>A disintegrin and metalloproteinase 15-mediated glycocalyx shedding contributes to vascular leakage during inflammation</article-title>. <source>Cardiovasc Res</source><year>2018</year>;<volume>114</volume>:<fpage>1752</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">29939250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvy167</pub-id><pub-id pub-id-type="pmcid">PMC6198742</pub-id></mixed-citation></ref><ref id="R158"><label>[158]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolmatova</surname><given-names>EV</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Mandavilli</surname><given-names>R</given-names></name><name name-style="western"><surname>Griendling</surname><given-names>KK</given-names></name></person-group>. <article-title>The effects of sepsis on endothelium and clinical implications</article-title>. <source>Cardiovasc Res</source><year>2021</year>;<volume>117</volume>:<fpage>60</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32215570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvaa070</pub-id><pub-id pub-id-type="pmcid">PMC7810126</pub-id></mixed-citation></ref><ref id="R159"><label>[159]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Sarmiento</surname><given-names>J</given-names></name><name name-style="western"><surname>Molina</surname><given-names>CF</given-names></name><name name-style="western"><surname>Salazar-Pelaez</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Biomarkers of glycocalyx injury and endothelial activation are associated with clinical outcomes in patients with sepsis: a systematic review and meta-analysis</article-title>. <source>J Int Care Med</source><year>2023</year>;<volume>38</volume>:<fpage>95</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08850666221109186</pub-id><pub-id pub-id-type="pmid">35722738</pub-id></mixed-citation></ref><ref id="R160"><label>[160]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Meessen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS</article-title>. <source>Crit Care</source><year>2021</year>;<volume>25</volume>:<fpage>113</fpage>.<pub-id pub-id-type="pmid">33741039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03545-1</pub-id><pub-id pub-id-type="pmcid">PMC7980645</pub-id></mixed-citation></ref><ref id="R161"><label>[161]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saoraya</surname><given-names>J</given-names></name><name name-style="western"><surname>Wongsamita</surname><given-names>L</given-names></name><name name-style="western"><surname>Srisawat</surname><given-names>N</given-names></name><name name-style="western"><surname>Musikatavorn</surname><given-names>K</given-names></name></person-group>. <article-title>Plasma syndecan-1 is associated with fluid requirements and clinical outcomes in emergency department patients with sepsis</article-title>. <source>Am J Emerg Med</source><year>2021</year>;<volume>42</volume>:<fpage>83</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">33493833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2021.01.019</pub-id></mixed-citation></ref><ref id="R162"><label>[162]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikacenic</surname><given-names>C</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>WO</given-names></name><name name-style="western"><surname>Price</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>Biomarkers of endothelial activation are associated with poor outcome in critical illness</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0141251</fpage>.<pub-id pub-id-type="pmid">26492036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0141251</pub-id><pub-id pub-id-type="pmcid">PMC4619633</pub-id></mixed-citation></ref><ref id="R163"><label>[163]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>WK</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wickersham</surname><given-names>NE</given-names></name><name name-style="western"><surname>Shaver</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bastarache</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ware</surname><given-names>LB</given-names></name></person-group>. <article-title>Angiopoietin-2 outperforms other endothelial biomarkers associated with severe acute kidney injury in patients with severe sepsis and respiratory failure</article-title>. <source>Crit Care</source><year>2021</year>;<volume>25</volume>:<fpage>48</fpage>.<pub-id pub-id-type="pmid">33541396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03474-z</pub-id><pub-id pub-id-type="pmcid">PMC7859898</pub-id></mixed-citation></ref><ref id="R164"><label>[164]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>T</given-names></name></person-group>. <article-title>Sphingosine-1-phosphate signaling in endothelial disorders</article-title>. <source>Curr Atheroscler Rep</source><year>2016</year>;<volume>18</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">27115142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11883-016-0586-1</pub-id></mixed-citation></ref><ref id="R165"><label>[165]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>XW</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Sustained increase in angiopoietin-2, heparin-binding protein, and procalcitonin is associated with severe sepsis</article-title>. <source>J Crit Care</source><year>2018</year>;<volume>45</volume>:<fpage>14</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">29413717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2018.01.010</pub-id></mixed-citation></ref><ref id="R166"><label>[166]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Shao</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group>. <article-title>The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: a prospective observational study</article-title>. <source>Thromb Res</source><year>2018</year>;<volume>171</volume>:<fpage>149</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">30312800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thromres.2018.09.059</pub-id></mixed-citation></ref><ref id="R167"><label>[167]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Nooijer</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kotsaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Kranidioti</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>63</fpage>.<pub-id pub-id-type="pmid">36797757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04344-6</pub-id><pub-id pub-id-type="pmcid">PMC9933299</pub-id></mixed-citation></ref><ref id="R168"><label>[168]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattahi</surname><given-names>F</given-names></name><name name-style="western"><surname>Zetoune</surname><given-names>FS</given-names></name><name name-style="western"><surname>Ward</surname><given-names>PA</given-names></name></person-group>. <article-title>Complement as a major inducer of harmful events in infectious sepsis</article-title>. <source>Shock</source><year>2020</year>;<volume>54</volume>:<fpage>595</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">32187106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000001531</pub-id><pub-id pub-id-type="pmcid">PMC9704109</pub-id></mixed-citation></ref><ref id="R169"><label>[169]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merle</surname><given-names>NS</given-names></name><name name-style="western"><surname>Noe</surname><given-names>R</given-names></name><name name-style="western"><surname>Halbwachs-Mecarelli</surname><given-names>L</given-names></name><name name-style="western"><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><name name-style="western"><surname>Roumenina</surname><given-names>LT</given-names></name></person-group>. <article-title>Complement system part II: role in immunity</article-title>. <source>Front Immunol</source><year>2015</year>;<volume>6</volume>:<fpage>257</fpage>.<pub-id pub-id-type="pmid">26074922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2015.00257</pub-id><pub-id pub-id-type="pmcid">PMC4443744</pub-id></mixed-citation></ref><ref id="R170"><label>[170]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber-Lang</surname><given-names>MS</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>EM</given-names></name><name name-style="western"><surname>Sarma</surname><given-names>JV</given-names></name><etal/></person-group>. <article-title>Complement-induced impairment of innate immunity during sepsis</article-title>. <source>J Immunol</source><year>2002</year>;<volume>169</volume>:<fpage>3223</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">12218141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.169.6.3223</pub-id></mixed-citation></ref><ref id="R171"><label>[171]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Leung</surname><given-names>LL</given-names></name><name name-style="western"><surname>Morser</surname><given-names>J</given-names></name></person-group>. <article-title>Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model</article-title>. <source>J Thromb Haemost</source><year>2015</year>;<volume>13</volume>:<fpage>1090</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="pmid">25851247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.12956</pub-id><pub-id pub-id-type="pmcid">PMC4452409</pub-id></mixed-citation></ref><ref id="R172"><label>[172]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller-Redetzky</surname><given-names>H</given-names></name><name name-style="western"><surname>Kellermann</surname><given-names>U</given-names></name><name name-style="western"><surname>Wienhold</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Neutralizing complement C5a protects mice with pneumococcal pulmonary sepsis</article-title>. <source>Anesthesiology</source><year>2020</year>;<volume>132</volume>:<fpage>795</fpage>&#8211;<lpage>807</lpage>.<pub-id pub-id-type="pmid">32101978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000003149</pub-id></mixed-citation></ref><ref id="R173"><label>[173]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keshari</surname><given-names>RS</given-names></name><name name-style="western"><surname>Silasi</surname><given-names>R</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>NI</given-names></name><etal/></person-group>. <article-title>Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of <italic toggle="yes">Escherichia coli</italic> sepsis</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2017</year>;<volume>114</volume>:<fpage>E6390</fpage>&#8211;<lpage>E9</lpage>.<pub-id pub-id-type="pmid">28720697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1706818114</pub-id><pub-id pub-id-type="pmcid">PMC5547645</pub-id></mixed-citation></ref><ref id="R174"><label>[174]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silasi-Mansat</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>NI</given-names></name><etal/></person-group>. <article-title>Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of <italic toggle="yes">Escherichia coli</italic> sepsis</article-title>. <source>Blood</source><year>2010</year>;<volume>116</volume>:<fpage>1002</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">20466856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-02-269746</pub-id><pub-id pub-id-type="pmcid">PMC2924221</pub-id></mixed-citation></ref><ref id="R175"><label>[175]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>S</given-names></name><name name-style="western"><surname>Uchino</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems</article-title>. <source>J Crit Care</source><year>2019</year>;<volume>50</volume>:<fpage>23</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">30471557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2018.11.009</pub-id></mixed-citation></ref><ref id="R176"><label>[176]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Disseminated intravascular coagulation associated organ failure in obstetric patients admitted to intensive care units: a multicenter study in China</article-title>. <source>Sci Rep</source><year>2021</year>;<volume>11</volume>:<fpage>16379</fpage>.<pub-id pub-id-type="pmid">34385545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-95841-7</pub-id><pub-id pub-id-type="pmcid">PMC8360968</pub-id></mixed-citation></ref><ref id="R177"><label>[177]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juffermans</surname><given-names>NP</given-names></name><name name-style="western"><surname>van den Brom</surname><given-names>CE</given-names></name><name name-style="western"><surname>Kleinveld</surname><given-names>DJB</given-names></name></person-group>. <article-title>Targeting endothelial dysfunction in acute critical illness to reduce organ failure</article-title>. <source>Anesth Analg</source><year>2020</year>;<volume>131</volume>:<fpage>1708</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">33186159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000005023</pub-id></mixed-citation></ref><ref id="R178"><label>[178]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iba</surname><given-names>T</given-names></name><name name-style="western"><surname>Umemura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wada</surname><given-names>H</given-names></name><name name-style="western"><surname>Levy</surname><given-names>JH</given-names></name></person-group>. <article-title>Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment</article-title>. <source>Arch Med Res</source><year>2021</year>;<volume>52</volume>:<fpage>788</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">34344558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arcmed.2021.07.003</pub-id></mixed-citation></ref><ref id="R179"><label>[179]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#216;sterud</surname><given-names>B</given-names></name><name name-style="western"><surname>Bj&#248;rklid</surname><given-names>E</given-names></name></person-group>. <article-title>The tissue factor pathway in disseminated intravascular coagulation</article-title>. <source>Semin Thromb Hemost</source><year>2001</year>;<volume>27</volume>:<fpage>605</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">11740684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2001-18866</pub-id></mixed-citation></ref><ref id="R180"><label>[180]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levi</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>Coagulation and sepsis</article-title>. <source>Thromb Res</source><year>2017</year>;<volume>149</volume>:<fpage>38</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">27886531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thromres.2016.11.007</pub-id></mixed-citation></ref><ref id="R181"><label>[181]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolai</surname><given-names>L</given-names></name><name name-style="western"><surname>Gaertner</surname><given-names>F</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S</given-names></name></person-group>. <article-title>Platelets in host defense: experimental and clinical insights</article-title>. <source>Trends Immunol</source><year>2019</year>;<volume>40</volume>:<fpage>922</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">31601520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2019.08.004</pub-id></mixed-citation></ref><ref id="R182"><label>[182]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semple</surname><given-names>JW</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>JE</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>J</given-names></name></person-group>. <article-title>Platelets and the immune continuum</article-title>. <source>Nat Rev Immunol</source><year>2011</year>;<volume>11</volume>:<fpage>264</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">21436837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2956</pub-id></mixed-citation></ref><ref id="R183"><label>[183]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerrigan</surname><given-names>SW</given-names></name></person-group>. <article-title>The expanding field of platelet-bacterial interconnections</article-title>. <source>Platelets</source><year>2015</year>;<volume>26</volume>:<fpage>293</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">25734214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09537104.2014.997690</pub-id></mixed-citation></ref><ref id="R184"><label>[184]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Strains of group B streptococci from septic patients induce platelet activation via toll-like receptor 2</article-title>. <source>Clin Exp Pharmacol Physiol</source><year>2017</year>;<volume>44</volume>:<fpage>335</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27885699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.12707</pub-id></mixed-citation></ref><ref id="R185"><label>[185]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anhe</surname><given-names>FF</given-names></name><name name-style="western"><surname>Barra</surname><given-names>NG</given-names></name><name name-style="western"><surname>Cavallari</surname><given-names>JF</given-names></name><name name-style="western"><surname>Henriksbo</surname><given-names>BD</given-names></name><name name-style="western"><surname>Schertzer</surname><given-names>JD</given-names></name></person-group>. <article-title>Metabolic endotoxemia is dictated by the type of lipopolysaccharide</article-title>. <source>Cell Rep</source><year>2021</year>;<volume>36</volume>:<fpage>109691</fpage>.<pub-id pub-id-type="pmid">34525353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2021.109691</pub-id></mixed-citation></ref><ref id="R186"><label>[186]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carestia</surname><given-names>A</given-names></name><name name-style="western"><surname>Godin</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jenne</surname><given-names>CN</given-names></name></person-group>. <article-title>Step up to the platelet: role of platelets in inflammation and infection</article-title>. <source>Thromb Res</source><year>2022</year>;<volume>231</volume>:<fpage>182</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">36307228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.thromres.2022.10.001</pub-id></mixed-citation></ref><ref id="R187"><label>[187]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hottz</surname><given-names>ED</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>MF</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>PC</given-names></name><etal/></person-group>. <article-title>Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases</article-title>. <source>J Thromb Haemost</source><year>2013</year>;<volume>11</volume>:<fpage>951</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23433144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jth.12178</pub-id><pub-id pub-id-type="pmcid">PMC3971842</pub-id></mixed-citation></ref><ref id="R188"><label>[188]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group>. <article-title>The mechanisms of sepsis induced coagulation dysfunction and its treatment</article-title>. <source>J Inflamm Res</source><year>2025</year>;<volume>18</volume>:<fpage>1479</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">39925935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S504184</pub-id><pub-id pub-id-type="pmcid">PMC11804232</pub-id></mixed-citation></ref><ref id="R189"><label>[189]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolai</surname><given-names>L</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S</given-names></name></person-group>. <article-title>Platelets as key players in inflammation and infection</article-title>. <source>Curr Opin Hematol</source><year>2020</year>;<volume>27</volume>:<fpage>34</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">31688457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOH.0000000000000551</pub-id></mixed-citation></ref><ref id="R190"><label>[190]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerris</surname><given-names>EWJ</given-names></name><name name-style="western"><surname>Hoptay</surname><given-names>C</given-names></name><name name-style="western"><surname>Calderon</surname><given-names>T</given-names></name><name name-style="western"><surname>Freishtat</surname><given-names>RJ</given-names></name></person-group>. <article-title>Platelets and platelet extracellular vesicles in hemostasis and sepsis</article-title>. <source>J Investig Med</source><year>2020</year>;<volume>68</volume>:<fpage>813</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jim-2019-001195</pub-id><pub-id pub-id-type="pmid">31843956</pub-id></mixed-citation></ref><ref id="R191"><label>[191]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>GT</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>TM</given-names></name></person-group>. <article-title>Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1&#946;-rich microparticles</article-title>. <source>J Immunol</source><year>2011</year>;<volume>186</volume>:<fpage>5489</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">21430222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1001623</pub-id><pub-id pub-id-type="pmcid">PMC3100655</pub-id></mixed-citation></ref><ref id="R192"><label>[192]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>B</given-names></name><name name-style="western"><surname>Urrutia</surname><given-names>R</given-names></name><name name-style="western"><surname>Yipp</surname><given-names>BG</given-names></name><name name-style="western"><surname>Jenne</surname><given-names>CN</given-names></name><name name-style="western"><surname>Kubes</surname><given-names>P</given-names></name></person-group>. <article-title>Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis</article-title>. <source>Cell Host Microbe</source><year>2012</year>;<volume>12</volume>:<fpage>324</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22980329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2012.06.011</pub-id></mixed-citation></ref><ref id="R193"><label>[193]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarbock</surname><given-names>A</given-names></name><name name-style="western"><surname>Singbartl</surname><given-names>K</given-names></name><name name-style="western"><surname>Ley</surname><given-names>K</given-names></name></person-group>. <article-title>Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation</article-title>. <source>J Clin Invest</source><year>2006</year>;<volume>116</volume>:<fpage>3211</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">17143330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI29499</pub-id><pub-id pub-id-type="pmcid">PMC1679711</pub-id></mixed-citation></ref><ref id="R194"><label>[194]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levi</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>Two-way interactions between inflammation and coagulation</article-title>. <source>Trends Cardiovasc Med</source><year>2005</year>;<volume>15</volume>:<fpage>254</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">16226680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcm.2005.07.004</pub-id></mixed-citation></ref><ref id="R195"><label>[195]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Grahl</surname><given-names>L</given-names></name><name name-style="western"><surname>von Bruehl</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases</article-title>. <source>Nat Med</source><year>2010</year>;<volume>16</volume>:<fpage>887</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">20676107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2184</pub-id></mixed-citation></ref><ref id="R196"><label>[196]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuchs</surname><given-names>TA</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>AA</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>DD</given-names></name></person-group>. <article-title>Histones induce rapid and profound thrombocytopenia in mice</article-title>. <source>Blood</source><year>2011</year>;<volume>118</volume>:<fpage>3708</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">21700775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-01-332676</pub-id><pub-id pub-id-type="pmcid">PMC3186342</pub-id></mixed-citation></ref><ref id="R197"><label>[197]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrams</surname><given-names>ST</given-names></name><name name-style="western"><surname>Morton</surname><given-names>B</given-names></name><name name-style="western"><surname>Alhamdi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A novel assay for neutrophil extracellular trap formation independently predicts disseminated intravascular coagulation and mortality in critically ill patients</article-title>. <source>Am J Respir Crit Care Med</source><year>2019</year>;<volume>200</volume>:<fpage>869</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">31162936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201811-2111OC</pub-id><pub-id pub-id-type="pmcid">PMC6812439</pub-id></mixed-citation></ref><ref id="R198"><label>[198]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberelli</surname><given-names>MA</given-names></name><name name-style="western"><surname>De Candia</surname><given-names>E</given-names></name></person-group>. <article-title>Functional role of protease activated receptors in vascular biology</article-title>. <source>Vascul Pharmacol</source><year>2014</year>;<volume>62</volume>:<fpage>72</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">24924409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vph.2014.06.001</pub-id></mixed-citation></ref><ref id="R199"><label>[199]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keragala</surname><given-names>CB</given-names></name><name name-style="western"><surname>Draxler</surname><given-names>DF</given-names></name><name name-style="western"><surname>McQuilten</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Medcalf</surname><given-names>RL</given-names></name></person-group>. <article-title>Haemostasis and innate immunity &#8211; a complementary relationship: a review of the intricate relationship between coagulation and complement pathways</article-title>. <source>Br J Haematol</source><year>2018</year>;<volume>180</volume>:<fpage>782</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">29265338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.15062</pub-id></mixed-citation></ref><ref id="R200"><label>[200]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Inflammasome activation triggers blood clotting and host death through pyroptosis</article-title>. <source>Immunity</source><year>2019</year>;<volume>50</volume>:<fpage>1401</fpage>&#8211;<lpage>11e4</lpage>.<pub-id pub-id-type="pmid">31076358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.04.003</pub-id><pub-id pub-id-type="pmcid">PMC6791531</pub-id></mixed-citation></ref><ref id="R201"><label>[201]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Barber</surname><given-names>GN</given-names></name></person-group>. <article-title>STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</article-title>. <source>Nature</source><year>2008</year>;<volume>455</volume>:<fpage>674</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">18724357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature07317</pub-id><pub-id pub-id-type="pmcid">PMC2804933</pub-id></mixed-citation></ref><ref id="R202"><label>[202]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pandol</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Habtezion</surname><given-names>A</given-names></name></person-group>. <article-title>STING signaling promotes inflammation in experimental acute pancreatitis</article-title>. <source>Gastroenterology</source><year>2018</year>;<volume>154</volume>:<fpage>1822</fpage>&#8211;<lpage>35e2</lpage>.<pub-id pub-id-type="pmid">29425920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.01.065</pub-id><pub-id pub-id-type="pmcid">PMC6112120</pub-id></mixed-citation></ref><ref id="R203"><label>[203]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>TMEM173 drives lethal coagulation in sepsis</article-title>. <source>Cell Host Microbe</source><year>2020</year>;<volume>27</volume>:<fpage>556</fpage>&#8211;<lpage>70e6</lpage>.<pub-id pub-id-type="pmid">32142632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2020.02.004</pub-id><pub-id pub-id-type="pmcid">PMC7316085</pub-id></mixed-citation></ref><ref id="R204"><label>[204]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The endotoxin delivery protein HMGB1 mediates caspase-11-Dependent lethality in sepsis</article-title>. <source>Immunity</source><year>2018</year>;<volume>49</volume>:<fpage>740</fpage>&#8211;<lpage>53e7</lpage>.<pub-id pub-id-type="pmid">30314759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.08.016</pub-id><pub-id pub-id-type="pmcid">PMC6300139</pub-id></mixed-citation></ref><ref id="R205"><label>[205]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options</article-title>. <source>Mil Med Res</source><year>2022</year>;<volume>9</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">36209190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-022-00422-y</pub-id><pub-id pub-id-type="pmcid">PMC9547753</pub-id></mixed-citation></ref><ref id="R206"><label>[206]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>DSY</given-names></name><name name-style="western"><surname>Bonten</surname><given-names>MJM</given-names></name><name name-style="western"><surname>Spitoni</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock</article-title>. <source>Clinl Infect Dis</source><year>2017</year>;<volume>64</volume>:<fpage>1204</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cix120</pub-id><pub-id pub-id-type="pmid">28158551</pub-id></mixed-citation></ref><ref id="R207"><label>[207]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>S</given-names></name><name name-style="western"><surname>Kametani</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Reduced immunocompetent B cells and increased secondary infection in elderly patients with severe sepsis</article-title>. <source>Shock</source><year>2016</year>;<volume>46</volume>:<fpage>270</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">27172158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000000619</pub-id></mixed-citation></ref><ref id="R208"><label>[208]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ctb</surname><given-names>V</given-names></name><name name-style="western"><surname>Thammahong</surname><given-names>A</given-names></name><name name-style="western"><surname>Leelahavanichkul</surname><given-names>A</given-names></name><name name-style="western"><surname>Ritprajak</surname><given-names>P</given-names></name></person-group>. <article-title>Alteration of macrophage immune phenotype in a murine sepsis model is associated with susceptibility to secondary fungal infection</article-title>. <source>Asian Pac J Allergy Immunol</source><year>2022</year>;<volume>40</volume>:<fpage>162</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">31586490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12932/AP-170519-0565</pub-id></mixed-citation></ref><ref id="R209"><label>[209]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y</given-names></name></person-group>. <article-title>Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis</article-title>. <source>Cell Death Dis</source><year>2019</year>;<volume>10</volume>:<fpage>782</fpage>.<pub-id pub-id-type="pmid">31611560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-019-2015-1</pub-id><pub-id pub-id-type="pmcid">PMC6791888</pub-id></mixed-citation></ref><ref id="R210"><label>[210]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name><name name-style="western"><surname>Fear</surname><given-names>D</given-names></name><name name-style="western"><surname>Lavender</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Activation-associated accelerated apoptosis of memory B cells in critically ill patients with sepsis</article-title>. <source>Crit Care Med</source><year>2017</year>;<volume>45</volume>:<fpage>875</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">28296810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000002380</pub-id></mixed-citation></ref><ref id="R211"><label>[211]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gustave</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gossez</surname><given-names>M</given-names></name><name name-style="western"><surname>Demaret</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Septic shock shapes B cell response toward an exhausted-like/immunoregulatory profile in patients</article-title>. <source>J Immunol</source><year>2018</year>;<volume>200</volume>:<fpage>2418</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">29459404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1700929</pub-id></mixed-citation></ref><ref id="R212"><label>[212]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Monneret</surname><given-names>G</given-names></name><name name-style="western"><surname>Payen</surname><given-names>D</given-names></name></person-group>. <article-title>Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy</article-title>. <source>Nat Rev Immunol</source><year>2013</year>;<volume>13</volume>:<fpage>862</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">24232462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3552</pub-id><pub-id pub-id-type="pmcid">PMC4077177</pub-id></mixed-citation></ref><ref id="R213"><label>[213]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Xun</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name></person-group>. <article-title>Honokiol alleviates sepsis-associated cardiac dysfunction via attenuating inflammation, apoptosis and oxidative stress</article-title>. <source>J Pharm Pharmacol</source><year>2023</year>;<volume>75</volume>:<fpage>397</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">36718013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpp/rgac102</pub-id></mixed-citation></ref><ref id="R214"><label>[214]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oami</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>E</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Suppression of T cell autophagy results in decreased viability and function of T cells through accelerated apoptosis in a murine sepsis model</article-title>. <source>Crit Care Med</source><year>2017</year>;<volume>45</volume>:<fpage>e77</fpage>&#8211;<lpage>e85</lpage>.<pub-id pub-id-type="pmid">27618275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000002016</pub-id><pub-id pub-id-type="pmcid">PMC5364514</pub-id></mixed-citation></ref><ref id="R215"><label>[215]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boomer</surname><given-names>JS</given-names></name><name name-style="western"><surname>Shuherk-Shaffer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Green</surname><given-names>JM</given-names></name></person-group>. <article-title>A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis</article-title>. <source>Crit Care</source><year>2012</year>;<volume>16</volume>:<fpage>R112</fpage>.<pub-id pub-id-type="pmid">22742734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc11404</pub-id><pub-id pub-id-type="pmcid">PMC3580670</pub-id></mixed-citation></ref><ref id="R216"><label>[216]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danahy</surname><given-names>DB</given-names></name><name name-style="western"><surname>Strother</surname><given-names>RK</given-names></name><name name-style="western"><surname>Badovinac</surname><given-names>VP</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>TS</given-names></name></person-group>. <article-title>Clinical and experimental sepsis impairs CD8 T-cell-mediated immunity</article-title>. <source>Critl Rev Immunol</source><year>2016</year>;<volume>36</volume>:<fpage>57</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1615/CritRevImmunol.2016017098</pub-id><pub-id pub-id-type="pmcid">PMC5314458</pub-id><pub-id pub-id-type="pmid">27480902</pub-id></mixed-citation></ref><ref id="R217"><label>[217]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>LF</given-names></name><name name-style="western"><surname>Yao</surname><given-names>YM</given-names></name><name name-style="western"><surname>Dong</surname><given-names>N</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>LX</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>ZY</given-names></name></person-group>. <article-title>Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study</article-title>. <source>Crit Care</source><year>2010</year>;<volume>14</volume>:<fpage>R3</fpage>.<pub-id pub-id-type="pmid">20064232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc8232</pub-id><pub-id pub-id-type="pmcid">PMC2875505</pub-id></mixed-citation></ref><ref id="R218"><label>[218]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>DC</given-names></name><name name-style="western"><surname>Melo</surname><given-names>PH</given-names></name><name name-style="western"><surname>Pi&#241;eros</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>14919</fpage>.<pub-id pub-id-type="pmid">28374774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14919</pub-id><pub-id pub-id-type="pmcid">PMC5382289</pub-id></mixed-citation></ref><ref id="R219"><label>[219]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ost</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Peschel</surname><given-names>A</given-names></name><name name-style="western"><surname>Mehling</surname><given-names>R</given-names></name><name name-style="western"><surname>Rieber</surname><given-names>N</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>D</given-names></name></person-group>. <article-title>Myeloid-derived suppressor cells in bacterial infections</article-title>. <source>Front Cell Infect Microbiol</source><year>2016</year>;<volume>6</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">27066459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2016.00037</pub-id><pub-id pub-id-type="pmcid">PMC4814452</pub-id></mixed-citation></ref><ref id="R220"><label>[220]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets</article-title>. <source>Cytokine Growth Factor Rev.</source><year>2023</year>;<volume>69</volume>:<fpage>90</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">35927154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2022.07.007</pub-id></mixed-citation></ref><ref id="R221"><label>[221]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathias</surname><given-names>B</given-names></name><name name-style="western"><surname>Delmas</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ozrazgat-Baslanti</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock</article-title>. <source>Ann Surg</source><year>2017</year>;<volume>265</volume>:<fpage>827</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">27163951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000001783</pub-id><pub-id pub-id-type="pmcid">PMC5102824</pub-id></mixed-citation></ref><ref id="R222"><label>[222]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruserud</surname><given-names>&#216;</given-names></name><name name-style="western"><surname>Mosevoll</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bruserud</surname><given-names>&#216;</given-names></name><name name-style="western"><surname>Reikvam</surname><given-names>H</given-names></name><name name-style="western"><surname>Wendelbo</surname><given-names>&#216;</given-names></name></person-group>. <article-title>The regulation of neutrophil migration in patients with sepsis: the complexity of the molecular mechanisms and their modulation in sepsis and the heterogeneity of sepsis patients</article-title>. <source>Cells</source><year>2023</year>;<volume>12</volume>:<fpage>1003</fpage>.<pub-id pub-id-type="pmid">37048076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12071003</pub-id><pub-id pub-id-type="pmcid">PMC10093057</pub-id></mixed-citation></ref><ref id="R223"><label>[223]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoogendijk</surname><given-names>AJ</given-names></name><name name-style="western"><surname>van Vught</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wiewel</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Kinase activity is impaired in neutrophils of sepsis patients</article-title>. <source>Haematologica</source><year>2019</year>;<volume>104</volume>:<fpage>e233</fpage>&#8211;<lpage>e5</lpage>.<pub-id pub-id-type="pmid">30514797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2018.201913</pub-id><pub-id pub-id-type="pmcid">PMC6545843</pub-id></mixed-citation></ref><ref id="R224"><label>[224]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakeley</surname><given-names>ME</given-names></name><name name-style="western"><surname>Gray</surname><given-names>CC</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>SF</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>DS</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>A</given-names></name></person-group>. <article-title>Check point inhibitors and their role in immunosuppression in sepsis</article-title>. <source>Crit Care Clin</source><year>2020</year>;<volume>36</volume>:<fpage>69</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">31733683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccc.2019.08.006</pub-id><pub-id pub-id-type="pmcid">PMC6863093</pub-id></mixed-citation></ref><ref id="R225"><label>[225]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu-Jing</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name></person-group>. <article-title>Role of regulation of PD-1 and PD-L1 expression in sepsis</article-title>. <source>Front Immunol</source><year>2023</year>;<volume>14</volume>:<fpage>1029438</fpage>.<pub-id pub-id-type="pmid">36969168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1029438</pub-id><pub-id pub-id-type="pmcid">PMC10035551</pub-id></mixed-citation></ref><ref id="R226"><label>[226]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guignant</surname><given-names>C</given-names></name><name name-style="western"><surname>Lepape</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients</article-title>. <source>Crit Care</source><year>2011</year>;<volume>15</volume>:<fpage>R99</fpage>.<pub-id pub-id-type="pmid">21418617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc10112</pub-id><pub-id pub-id-type="pmcid">PMC3219369</pub-id></mixed-citation></ref><ref id="R227"><label>[227]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bo</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>C-S</given-names></name></person-group>. <article-title>Programmed cell death-1/programmed death-ligand 1 blockade improves survival of animals with sepsis: a systematic review and meta-analysis</article-title>. <source>Biomed Res. Int.</source><year>2018</year>;<volume>2018</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/1969474</pub-id><pub-id pub-id-type="pmcid">PMC6109543</pub-id><pub-id pub-id-type="pmid">30159323</pub-id></mixed-citation></ref><ref id="R228"><label>[228]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shindo</surname><given-names>Y</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Ramachandra</surname><given-names>M</given-names></name><name name-style="western"><surname>Sasikumar</surname><given-names>PG</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name></person-group>. <article-title>Anti-PD-L1 peptide improves survival in sepsis</article-title>. <source>J Surg Res</source><year>2017</year>;<volume>208</volume>:<fpage>33</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">27993215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2016.08.099</pub-id><pub-id pub-id-type="pmcid">PMC5535083</pub-id></mixed-citation></ref><ref id="R229"><label>[229]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name></person-group>. <article-title>Expression of PD-1 on memory t lymphocytes predicts 28-day mortality of patients with sepsis: a prospective observational study</article-title>. <source>J Inflamm Res</source><year>2022</year>;<volume>15</volume>:<fpage>5043</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">36072779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S376897</pub-id><pub-id pub-id-type="pmcid">PMC9444038</pub-id></mixed-citation></ref><ref id="R230"><label>[230]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monaghan</surname><given-names>SF</given-names></name><name name-style="western"><surname>Thakkar</surname><given-names>RK</given-names></name><name name-style="western"><surname>Tran</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Programmed death 1 expression as a marker for immune and physiological dysfunction in the critically ill surgical patient</article-title>. <source>Shock</source><year>2012</year>;<volume>38</volume>:<fpage>117</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22683728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0b013e31825de6a3</pub-id></mixed-citation></ref><ref id="R231"><label>[231]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J</given-names></name><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name></person-group>. <article-title>Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis &#8211; pilot study</article-title>. <source>Crit Care</source><year>2018</year>;<volume>22</volume>:<fpage>95</fpage>.<pub-id pub-id-type="pmid">29661225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-018-2020-2</pub-id><pub-id pub-id-type="pmcid">PMC5902875</pub-id></mixed-citation></ref><ref id="R232"><label>[232]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Increased percentage of PD-L1(+) natural killer cells predicts poor prognosis in sepsis patients: a prospective observational cohort study</article-title>. <source>Crit Care</source><year>2020</year>;<volume>24</volume>:<fpage>617</fpage>.<pub-id pub-id-type="pmid">33076951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-03329-z</pub-id><pub-id pub-id-type="pmcid">PMC7574346</pub-id></mixed-citation></ref><ref id="R233"><label>[233]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>K</given-names></name><name name-style="western"><surname>Svabek</surname><given-names>C</given-names></name><name name-style="western"><surname>Vazquez-Guillamet</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis</article-title>. <source>Crit Care</source><year>2014</year>;<volume>18</volume>:<fpage>R3</fpage>.<pub-id pub-id-type="pmid">24387680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc13176</pub-id><pub-id pub-id-type="pmcid">PMC4056005</pub-id></mixed-citation></ref><ref id="R234"><label>[234]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patera</surname><given-names>AC</given-names></name><name name-style="western"><surname>Drewry</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K</given-names></name><name name-style="western"><surname>Beiter</surname><given-names>ER</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>D</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name></person-group>. <article-title>Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1</article-title>. <source>J Leukoc Biol</source><year>2016</year>;<volume>100</volume>:<fpage>1239</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">27671246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.4HI0616-255R</pub-id><pub-id pub-id-type="pmcid">PMC5110001</pub-id></mixed-citation></ref><ref id="R235"><label>[235]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Colston</surname><given-names>E</given-names></name><name name-style="western"><surname>Yende</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab</article-title>. <source>Intensive Care Med</source><year>2019</year>;<volume>45</volume>:<fpage>1360</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">31576433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-019-05704-z</pub-id><pub-id pub-id-type="pmcid">PMC9006384</pub-id></mixed-citation></ref><ref id="R236"><label>[236]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Colston</surname><given-names>E</given-names></name><name name-style="western"><surname>Yende</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)</article-title>. <source>Crit Care Med</source><year>2019</year>;<volume>47</volume>:<fpage>632</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">30747773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000003685</pub-id><pub-id pub-id-type="pmcid">PMC7254685</pub-id></mixed-citation></ref><ref id="R237"><label>[237]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>E</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>O</given-names></name><name name-style="western"><surname>Kakihana</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1/2 study</article-title>. <source>Shock</source><year>2020</year>;<volume>53</volume>:<fpage>686</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">31513050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000001443</pub-id><pub-id pub-id-type="pmcid">PMC7448837</pub-id></mixed-citation></ref><ref id="R238"><label>[238]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Haak</surname><given-names>DAC</given-names></name><name name-style="western"><surname>Otten</surname><given-names>LS</given-names></name><name name-style="western"><surname>Koenen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression</article-title>. <source>Clin Transl Sci</source><year>2023</year>;<volume>16</volume>:<fpage>978</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">37002646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13503</pub-id><pub-id pub-id-type="pmcid">PMC10264964</pub-id></mixed-citation></ref><ref id="R239"><label>[239]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Splenectomy provides protective effects against CLP-induced sepsis by reducing TRegs and PD-1/PD-L1 expression</article-title>. <source>Int J Biochem Cell Biol</source><year>2021</year>;<volume>136</volume>:<fpage>105970</fpage>.<pub-id pub-id-type="pmid">33774183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2021.105970</pub-id></mixed-citation></ref><ref id="R240"><label>[240]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triantafyllou</surname><given-names>E</given-names></name><name name-style="western"><surname>Gudd</surname><given-names>CL</given-names></name><name name-style="western"><surname>Mawhin</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>PD-1 blockade improves kupffer cell bacterial clearance in acute liver injury</article-title>. <source>J Clin Invest</source><year>2021</year>:<volume>131</volume>:<fpage>e140196</fpage>.<pub-id pub-id-type="pmid">33320839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI140196</pub-id><pub-id pub-id-type="pmcid">PMC7880414</pub-id></mixed-citation></ref><ref id="R241"><label>[241]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>MA</given-names></name><name name-style="western"><surname>Patil</surname><given-names>TK</given-names></name><name name-style="western"><surname>Bohannon</surname><given-names>JK</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>ER</given-names></name><name name-style="western"><surname>Patil</surname><given-names>NK</given-names></name></person-group>. <article-title>Immune checkpoints: novel therapeutic targets to attenuate sepsis-induced immunosuppression</article-title>. <source>Front Immunol</source><year>2020</year>;<volume>11</volume>:<fpage>624272</fpage>.<pub-id pub-id-type="pmid">33613563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.624272</pub-id><pub-id pub-id-type="pmcid">PMC7886986</pub-id></mixed-citation></ref><ref id="R242"><label>[242]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>S</given-names></name><name name-style="western"><surname>Bo</surname><given-names>L</given-names></name><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Unsinger</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K</given-names></name><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name></person-group>. <article-title>Dose-dependent effect of anti-CTLA-4 on survival in sepsis</article-title>. <source>Shock</source><year>2011</year>;<volume>36</volume>:<fpage>38</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">21368717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0b013e3182168cce</pub-id><pub-id pub-id-type="pmcid">PMC3412306</pub-id></mixed-citation></ref><ref id="R243"><label>[243]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name><name name-style="western"><surname>Compton</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis</article-title>. <source>Crit Care</source><year>2013</year>;<volume>17</volume>:<fpage>R85</fpage>.<pub-id pub-id-type="pmid">23663657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc12711</pub-id><pub-id pub-id-type="pmcid">PMC3706819</pub-id></mixed-citation></ref><ref id="R244"><label>[244]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lopez-Collazo</surname><given-names>E</given-names></name></person-group>. <article-title>Endotoxin tolerance: new mechanisms, molecules and clinical significance</article-title>. <source>Trends Immunol</source><year>2009</year>;<volume>30</volume>:<fpage>475</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">19781994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2009.07.009</pub-id></mixed-citation></ref><ref id="R245"><label>[245]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adib-Conquy</surname><given-names>M</given-names></name><name name-style="western"><surname>Adrie</surname><given-names>C</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>C</given-names></name><name name-style="western"><surname>Gattolliat</surname><given-names>O</given-names></name><name name-style="western"><surname>Beyaert</surname><given-names>R</given-names></name><name name-style="western"><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group>. <article-title>Up-regulation of MyD88s and SIGIRR, molecules inhibiting toll-like receptor signaling, in monocytes from septic patients</article-title>. <source>Crit Care Med</source><year>2006</year>;<volume>34</volume>:<fpage>2377</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">16850005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.CCM.0000233875.93866.88</pub-id></mixed-citation></ref><ref id="R246"><label>[246]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz</surname><given-names>C</given-names></name><name name-style="western"><surname>Carlet</surname><given-names>J</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>C</given-names></name><name name-style="western"><surname>Misset</surname><given-names>B</given-names></name><name name-style="western"><surname>Bl&#233;riot</surname><given-names>JP</given-names></name><name name-style="western"><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group>. <article-title>Dysregulation of in vitro cytokine production by monocytes during sepsis</article-title>. <source>J Clin Invest</source><year>1991</year>;<volume>88</volume>:<fpage>1747</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">1939659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI115493</pub-id><pub-id pub-id-type="pmcid">PMC295719</pub-id></mixed-citation></ref><ref id="R247"><label>[247]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoogendijk</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Garcia-Laorden</surname><given-names>MI</given-names></name><name name-style="western"><surname>van Vught</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Sepsis patients display a reduced capacity to activate nuclear factor-kappaB in multiple cell types</article-title>. <source>Crit Care Med</source><year>2017</year>;<volume>45</volume>:<fpage>e524</fpage>&#8211;<lpage>e31</lpage>.<pub-id pub-id-type="pmid">28240686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000002294</pub-id></mixed-citation></ref><ref id="R248"><label>[248]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rackov</surname><given-names>G</given-names></name><name name-style="western"><surname>Hernandez-Jimenez</surname><given-names>E</given-names></name><name name-style="western"><surname>Shokri</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>p21 mediates macrophage reprogramming through regulation of p50-p50 NF-kappaB and IFN-beta</article-title>. <source>J Clin Invest</source><year>2016</year>;<volume>126</volume>:<fpage>3089</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">27427981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI83404</pub-id><pub-id pub-id-type="pmcid">PMC4966310</pub-id></mixed-citation></ref><ref id="R249"><label>[249]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippart</surname><given-names>F</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>C</given-names></name><name name-style="western"><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group>. <article-title>Lung microenvironment contributes to the resistance of alveolar macrophages to develop tolerance to endotoxin*</article-title>. <source>Crit Care Med</source><year>2012</year>;<volume>40</volume>:<fpage>2987</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">22878679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e31825b8d57</pub-id></mixed-citation></ref><ref id="R250"><label>[250]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vos</surname><given-names>AF</given-names></name><name name-style="western"><surname>Pater</surname><given-names>JM</given-names></name><name name-style="western"><surname>van den Pangaart</surname><given-names>PS</given-names></name><name name-style="western"><surname>de Kruif</surname><given-names>MD</given-names></name><name name-style="western"><surname>van &#8216;t Veer</surname><given-names>C</given-names></name><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name></person-group>. <article-title>In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands</article-title>. <source>J Immunol</source><year>2009</year>;<volume>183</volume>:<fpage>533</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">19542464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0802189</pub-id></mixed-citation></ref><ref id="R251"><label>[251]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austermann</surname><given-names>J</given-names></name><name name-style="western"><surname>Friesenhagen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fassl</surname><given-names>SK</given-names></name><etal/></person-group>. <article-title>Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions</article-title>. <source>Cell Rep</source><year>2014</year>;<volume>9</volume>:<fpage>2112</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">25497086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2014.11.020</pub-id></mixed-citation></ref><ref id="R252"><label>[252]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aneja</surname><given-names>RK</given-names></name><name name-style="western"><surname>Tsung</surname><given-names>A</given-names></name><name name-style="western"><surname>Sjodin</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance</article-title>. <source>J Leukoc Biol</source><year>2008</year>;<volume>84</volume>:<fpage>1326</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">18687905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.0108030</pub-id><pub-id pub-id-type="pmcid">PMC2567896</pub-id></mixed-citation></ref><ref id="R253"><label>[253]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio</surname><given-names>I</given-names></name><name name-style="western"><surname>Osuchowski</surname><given-names>MF</given-names></name><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Current gaps in sepsis immunology: new opportunities for translational research</article-title>. <source>Lancet Infect Dis</source><year>2019</year>;<volume>19</volume>:<fpage>e422</fpage>&#8211;<lpage>e36</lpage>.<pub-id pub-id-type="pmid">31630991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(19)30567-5</pub-id></mixed-citation></ref><ref id="R254"><label>[254]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leijte</surname><given-names>GP</given-names></name><name name-style="western"><surname>Rimmele</surname><given-names>T</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes</article-title>. <source>Crit Care</source><year>2020</year>;<volume>24</volume>:<fpage>110</fpage>.<pub-id pub-id-type="pmid">32192532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-2830-x</pub-id><pub-id pub-id-type="pmcid">PMC7082984</pub-id></mixed-citation></ref><ref id="R255"><label>[255]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schefold</surname><given-names>JC</given-names></name></person-group>. <article-title>Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure</article-title>. <source>Intensive Care Med</source><year>2010</year>;<volume>36</volume>:<fpage>1810</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">20652681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-010-1965-7</pub-id></mixed-citation></ref><ref id="R256"><label>[256]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Poll</surname><given-names>T</given-names></name><name name-style="western"><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name name-style="western"><surname>Scicluna</surname><given-names>BP</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>. <article-title>The immunopathology of sepsis and potential therapeutic targets</article-title>. <source>Nat Rev Immunol</source><year>2017</year>;<volume>17</volume>:<fpage>407</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">28436424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2017.36</pub-id></mixed-citation></ref><ref id="R257"><label>[257]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vachharajani</surname><given-names>V</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>McCall</surname><given-names>CE</given-names></name></person-group>. <article-title>Epigenetic coordination of acute systemic inflammation: potential therapeutic targets</article-title>. <source>Expert Rev Clin Immunol</source><year>2014</year>;<volume>10</volume>:<fpage>1141</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">25088223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/1744666X.2014.943192</pub-id><pub-id pub-id-type="pmcid">PMC4634938</pub-id></mixed-citation></ref><ref id="R258"><label>[258]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>DC</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Gene-specific control of inflammation by TLR-induced chromatin modifications</article-title>. <source>Nature</source><year>2007</year>;<volume>447</volume>:<fpage>972</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">17538624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature05836</pub-id></mixed-citation></ref><ref id="R259"><label>[259]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>McCall</surname><given-names>CE</given-names></name><name name-style="western"><surname>Yoza</surname><given-names>BK</given-names></name></person-group>. <article-title>Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter</article-title>. <source>J Immunol</source><year>2005</year>;<volume>175</volume>:<fpage>461</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">15972680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.175.1.461</pub-id></mixed-citation></ref><ref id="R260"><label>[260]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Gazzar</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoza</surname><given-names>BK</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>BA</given-names></name><name name-style="western"><surname>Young</surname><given-names>NL</given-names></name><name name-style="western"><surname>McCall</surname><given-names>CE</given-names></name></person-group>. <article-title>Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance</article-title>. <source>Mol Cell Biol</source><year>2009</year>;<volume>29</volume>:<fpage>1959</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">19158276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.01862-08</pub-id><pub-id pub-id-type="pmcid">PMC2655606</pub-id></mixed-citation></ref><ref id="R261"><label>[261]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Santa</surname><given-names>F</given-names></name><name name-style="western"><surname>Totaro</surname><given-names>MG</given-names></name><name name-style="western"><surname>Prosperini</surname><given-names>E</given-names></name><name name-style="western"><surname>Notarbartolo</surname><given-names>S</given-names></name><name name-style="western"><surname>Testa</surname><given-names>G</given-names></name><name name-style="western"><surname>Natoli</surname><given-names>G</given-names></name></person-group>. <article-title>The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing</article-title>. <source>Cell</source><year>2007</year>;<volume>130</volume>:<fpage>1083</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">17825402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2007.08.019</pub-id></mixed-citation></ref><ref id="R262"><label>[262]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>TF</given-names></name><name name-style="western"><surname>Yoza</surname><given-names>BK</given-names></name><name name-style="western"><surname>El Gazzar</surname><given-names>M</given-names></name><name name-style="western"><surname>Vachharajani</surname><given-names>VT</given-names></name><name name-style="western"><surname>McCall</surname><given-names>CE</given-names></name></person-group>. <article-title>NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance</article-title>. <source>J Biol Chem</source><year>2011</year>;<volume>286</volume>:<fpage>9856</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">21245135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.196790</pub-id><pub-id pub-id-type="pmcid">PMC3058977</pub-id></mixed-citation></ref><ref id="R263"><label>[263]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>M</given-names></name><name name-style="western"><surname>Filbin</surname><given-names>MR</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>An immune-cell signature of bacterial sepsis</article-title>. <source>Nat Med</source><year>2020</year>;<volume>26</volume>:<fpage>333</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">32066974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0752-4</pub-id><pub-id pub-id-type="pmcid">PMC7235950</pub-id></mixed-citation></ref><ref id="R264"><label>[264]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>H</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hogaboam</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>SL</given-names></name></person-group>. <article-title>Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response</article-title>. <source>Blood</source><year>2008</year>;<volume>111</volume>:<fpage>1797</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">18055863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2007-08-106443</pub-id><pub-id pub-id-type="pmcid">PMC2234040</pub-id></mixed-citation></ref><ref id="R265"><label>[265]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roquilly</surname><given-names>A</given-names></name><name name-style="western"><surname>Jacqueline</surname><given-names>C</given-names></name><name name-style="western"><surname>Davieau</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis</article-title>. <source>Nat Immunol</source><year>2020</year>;<volume>21</volume>:<fpage>636</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">32424365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-0673-x</pub-id></mixed-citation></ref><ref id="R266"><label>[266]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>FM</given-names></name><name name-style="western"><surname>Schaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dendekker</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Sepsis induces prolonged epigenetic modifications in bone marrow and peripheral macrophages impairing inflammation and wound healing</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2019</year>;<volume>39</volume>:<fpage>2353</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="pmid">31644352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.119.312754</pub-id><pub-id pub-id-type="pmcid">PMC6818743</pub-id></mixed-citation></ref><ref id="R267"><label>[267]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haak</surname><given-names>BW</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name></person-group>. <article-title>The role of the gut microbiota in sepsis</article-title>. <source>Lancet Gastroenterol Hepatol</source><year>2017</year>;<volume>2</volume>:<fpage>135</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">28403983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(16)30119-4</pub-id></mixed-citation></ref><ref id="R268"><label>[268]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adelman</surname><given-names>MW</given-names></name><name name-style="western"><surname>Woodworth</surname><given-names>MH</given-names></name><name name-style="western"><surname>Langelier</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The gut microbiome&#8217;s role in the development, maintenance, and outcomes of sepsis</article-title>. <source>Crit Care</source><year>2020</year>;<volume>24</volume>:<fpage>278</fpage>.<pub-id pub-id-type="pmid">32487252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-02989-1</pub-id><pub-id pub-id-type="pmcid">PMC7266132</pub-id></mixed-citation></ref><ref id="R269"><label>[269]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamada</surname><given-names>N</given-names></name><name name-style="western"><surname>Seo</surname><given-names>SU</given-names></name><name name-style="western"><surname>Chen</surname><given-names>GY</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>G</given-names></name></person-group>. <article-title>Role of the gut microbiota in immunity and inflammatory disease</article-title>. <source>Nat Rev Immunol</source><year>2013</year>;<volume>13</volume>:<fpage>321</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">23618829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3430</pub-id></mixed-citation></ref><ref id="R270"><label>[270]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name></person-group>. <article-title>Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens</article-title>. <source>Science</source><year>2016</year>;<volume>352</volume>:<fpage>535</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">27126035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad9382</pub-id><pub-id pub-id-type="pmcid">PMC4984266</pub-id></mixed-citation></ref><ref id="R271"><label>[271]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>B</given-names></name><name name-style="western"><surname>Zucoloto</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>IL</given-names></name><etal/></person-group>. <article-title>Programing of an intravascular immune firewall by the gut microbiota protects against pathogen dissemination during infection</article-title>. <source>Cell Host Microbe</source><year>2020</year>;<volume>28</volume>:<fpage>660</fpage>&#8211;<lpage>8.e4</lpage>.<pub-id pub-id-type="pmid">32810440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2020.07.014</pub-id></mixed-citation></ref><ref id="R272"><label>[272]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parada Venegas</surname><given-names>D</given-names></name><name name-style="western"><surname>la Fuente Mk</surname><given-names>D</given-names></name><name name-style="western"><surname>Landskron</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases</article-title>. <source>Front Immunol</source><year>2019</year>;<volume>10</volume>:<fpage>277</fpage>.<pub-id pub-id-type="pmid">30915065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00277</pub-id><pub-id pub-id-type="pmcid">PMC6421268</pub-id></mixed-citation></ref><ref id="R273"><label>[273]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayres</surname><given-names>JS</given-names></name><name name-style="western"><surname>Trinidad</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Vance</surname><given-names>RE</given-names></name></person-group>. <article-title>Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota</article-title>. <source>Nat Med</source><year>2012</year>;<volume>18</volume>:<fpage>799</fpage>&#8211;<lpage>806</lpage>.<pub-id pub-id-type="pmid">22522562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2729</pub-id><pub-id pub-id-type="pmcid">PMC3472005</pub-id></mixed-citation></ref><ref id="R274"><label>[274]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ubeda</surname><given-names>C</given-names></name><name name-style="western"><surname>Taur</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jenq</surname><given-names>RR</given-names></name><etal/></person-group>. <article-title>Vancomycin-resistant enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans</article-title>. <source>J Clin Invest</source><year>2010</year>;<volume>120</volume>:<fpage>4332</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">21099116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI43918</pub-id><pub-id pub-id-type="pmcid">PMC2993598</pub-id></mixed-citation></ref><ref id="R275"><label>[275]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>RP</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>MA</given-names></name><name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name><name name-style="western"><surname>Iwashyna</surname><given-names>TJ</given-names></name></person-group>. <article-title>Hospitalization type and subsequent severe sepsis</article-title>. <source>Am J Respir Crit Care Med</source><year>2015</year>;<volume>192</volume>:<fpage>581</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">26016947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201503-0483OC</pub-id><pub-id pub-id-type="pmcid">PMC4595694</pub-id></mixed-citation></ref><ref id="R276"><label>[276]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bragazzi</surname><given-names>MC</given-names></name><name name-style="western"><surname>Venere</surname><given-names>R</given-names></name><name name-style="western"><surname>Vignone</surname><given-names>A</given-names></name><name name-style="western"><surname>Alvaro</surname><given-names>D</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>V</given-names></name></person-group>. <article-title>Role of the gut-liver axis in the pathobiology of cholangiopathies: basic and clinical evidence</article-title>. <source>Int J Mol Sci</source><year>2023</year>;<volume>24</volume>:<fpage>6660</fpage>.<pub-id pub-id-type="pmid">37047635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24076660</pub-id><pub-id pub-id-type="pmcid">PMC10095354</pub-id></mixed-citation></ref><ref id="R277"><label>[277]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Enteric dysbiosis is associated with sepsis in patients</article-title>. <source>FASEB J</source><year>2019</year>;<volume>33</volume>:<fpage>12299</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">31465241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201900398RR</pub-id><pub-id pub-id-type="pmcid">PMC6902702</pub-id></mixed-citation></ref><ref id="R278"><label>[278]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaborin</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D</given-names></name><name name-style="western"><surname>Garfield</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness</article-title>. <source>mBio</source><year>2014</year>;<volume>5</volume>:<fpage>e01361</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">25249279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01361-14</pub-id><pub-id pub-id-type="pmcid">PMC4173762</pub-id></mixed-citation></ref><ref id="R279"><label>[279]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>YD</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>RX</given-names></name><name name-style="western"><surname>Wu</surname><given-names>ZQ</given-names></name><etal/></person-group>. <article-title>Gut microbiota disruption in septic shock patients: a pilot study</article-title>. <source>Med Sci Monit</source><year>2018</year>;<volume>24</volume>:<fpage>8639</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">30488879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.911768</pub-id><pub-id pub-id-type="pmcid">PMC6282651</pub-id></mixed-citation></ref><ref id="R280"><label>[280]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>QS</given-names></name><etal/></person-group>. <article-title>Gut microbiota dysbiosis is associated with sepsis-induced cardiomyopathy in patients: a case-control study</article-title>. <source>J Med Virol</source><year>2023</year>;<volume>95</volume>:<fpage>e28267</fpage>.<pub-id pub-id-type="pmid">36319439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.28267</pub-id></mixed-citation></ref><ref id="R281"><label>[281]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duchnowski</surname><given-names>P</given-names></name><name name-style="western"><surname>&#346;migielski</surname><given-names>W</given-names></name></person-group>. <article-title>Usefulness of myocardial damage biomarkers in predicting cardiogenic shock in patients undergoing heart valve surgery</article-title>. <source>Kardiologia Polska</source><year>2024</year>;<volume>82</volume>:<fpage>423</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">38493460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.33963/v.phj.99553</pub-id></mixed-citation></ref><ref id="R282"><label>[282]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>JL</given-names></name><name name-style="western"><surname>Fan</surname><given-names>B</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>LQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>GY</given-names></name></person-group>. <article-title>Brain natriuretic peptide as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis</article-title>. <source>BMC Anesthesiol</source><year>2024</year>;<volume>24</volume>:<fpage>276</fpage>.<pub-id pub-id-type="pmid">39112946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12871-024-02661-z</pub-id><pub-id pub-id-type="pmcid">PMC11304783</pub-id></mixed-citation></ref><ref id="R283"><label>[283]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>K</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>H</given-names></name><name name-style="western"><surname>Goto</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Altered gut flora and environment in patients with severe SIRS</article-title>. <source>J Trauma</source><year>2006</year>;<volume>60</volume>:<fpage>126</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">16456446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ta.0000197374.99755.fe</pub-id></mixed-citation></ref><ref id="R284"><label>[284]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshmukh</surname><given-names>HS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Menkiti</surname><given-names>OR</given-names></name><etal/></person-group>. <article-title>The microbiota regulates neutrophil homeostasis and host resistance to <italic toggle="yes">Escherichia coli</italic> K1 sepsis in neonatal mice</article-title>. <source>Nat Med</source><year>2014</year>;<volume>20</volume>:<fpage>524</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">24747744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3542</pub-id><pub-id pub-id-type="pmcid">PMC4016187</pub-id></mixed-citation></ref><ref id="R285"><label>[285]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fay</surname><given-names>KT</given-names></name><name name-style="western"><surname>Klingensmith</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CW</given-names></name><etal/></person-group>. <article-title>The gut microbiome alters immunophenotype and survival from sepsis</article-title>. <source>FASEB J</source><year>2019</year>;<volume>33</volume>:<fpage>11258</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">31306584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201802188R</pub-id><pub-id pub-id-type="pmcid">PMC6766641</pub-id></mixed-citation></ref><ref id="R286"><label>[286]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Yan</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>SD</given-names></name><etal/></person-group>. <article-title>Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice</article-title>. <source>Eur Respir J</source><year>2023</year>:<volume>61</volume>:<fpage>2200840</fpage>.<pub-id pub-id-type="pmid">36229053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00840-2022</pub-id></mixed-citation></ref><ref id="R287"><label>[287]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>P</given-names></name></person-group>. <article-title>Gut microbiota&#8211;derived short-chain fatty acids and kidney diseases</article-title>. <source>Drug Des Devel Ther</source><year>2017</year>;<volume>11</volume>:<fpage>3531</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S150825</pub-id><pub-id pub-id-type="pmcid">PMC5729884</pub-id><pub-id pub-id-type="pmid">29270002</pub-id></mixed-citation></ref><ref id="R288"><label>[288]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sichler</surname><given-names>A</given-names></name><name name-style="western"><surname>Ecker</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis</article-title>. <source>J Hepatol</source><year>2023</year>;<volume>78</volume>:<fpage>820</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">36681162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2022.12.028</pub-id></mixed-citation></ref><ref id="R289"><label>[289]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Adeli</surname><given-names>K</given-names></name></person-group>. <article-title>Role of gut microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis</article-title>. <source>Microorganisms</source><year>2020</year>;<volume>8</volume>:<fpage>527</fpage>.<pub-id pub-id-type="pmid">32272588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms8040527</pub-id><pub-id pub-id-type="pmcid">PMC7232453</pub-id></mixed-citation></ref><ref id="R290"><label>[290]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Butyrate glycerides protect against intestinal inflammation and barrier dysfunction in mice</article-title>. <source>Nutrients</source><year>2022</year>:<volume>14</volume>:<fpage>3991</fpage>.<pub-id pub-id-type="pmid">36235644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu14193991</pub-id><pub-id pub-id-type="pmcid">PMC9570839</pub-id></mixed-citation></ref><ref id="R291"><label>[291]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name></person-group>. <article-title>Potential of gut-derived short-chain fatty acids to control enteric pathogens</article-title>. <source>Front Microbiol</source><year>2022</year>;<volume>13</volume>:<fpage>976406</fpage>.<pub-id pub-id-type="pmid">36204607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2022.976406</pub-id><pub-id pub-id-type="pmcid">PMC9530198</pub-id></mixed-citation></ref><ref id="R292"><label>[292]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>PV</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L</given-names></name><name name-style="western"><surname>Offermanns</surname><given-names>S</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2014</year>;<volume>111</volume>:<fpage>2247</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">24390544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1322269111</pub-id><pub-id pub-id-type="pmcid">PMC3926023</pub-id></mixed-citation></ref><ref id="R293"><label>[293]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Weng</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The inflammation induced by lipopolysaccharide can be mitigated by short-chain fatty acid, butyrate, through upregulation of IL-10 in septic shock</article-title>. <source>Scand J Immunol</source><year>2017</year>;<volume>85</volume>:<fpage>258</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">27943364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sji.12515</pub-id></mixed-citation></ref><ref id="R294"><label>[294]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balmer</surname><given-names>ML</given-names></name><name name-style="western"><surname>Ma</surname><given-names>EH</given-names></name><name name-style="western"><surname>Bantug</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Memory CD8(+) T cells require increased concentrations of acetate induced by stress for optimal function</article-title>. <source>Immunity</source><year>2016</year>;<volume>44</volume>:<fpage>1312</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">27212436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2016.03.016</pub-id></mixed-citation></ref><ref id="R295"><label>[295]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name></person-group>. <article-title>Current sepsis therapeutics</article-title>. <source>EBioMedicine</source><year>2022</year>;<volume>86</volume>:<fpage>104318</fpage>.<pub-id pub-id-type="pmid">36470828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104318</pub-id><pub-id pub-id-type="pmcid">PMC9782815</pub-id></mixed-citation></ref><ref id="R296"><label>[296]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaukonen</surname><given-names>K-M</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S</given-names></name><name name-style="western"><surname>Pilcher</surname><given-names>D</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></name></person-group>. <article-title>Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012</article-title>. <source>Jama</source><year>2014</year>;<volume>311</volume>:<fpage>1308</fpage>.<pub-id pub-id-type="pmid">24638143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.2637</pub-id></mixed-citation></ref><ref id="R297"><label>[297]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name><name name-style="western"><surname>Namendys-Silva</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit</article-title>. <source>Lancet Respir Med</source><year>2014</year>;<volume>2</volume>:<fpage>380</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">24740011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(14)70061-X</pub-id></mixed-citation></ref><ref id="R298"><label>[298]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name><name name-style="western"><surname>Opal</surname><given-names>SM</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JC</given-names></name><name name-style="western"><surname>Tracey</surname><given-names>KJ</given-names></name></person-group>. <article-title>Sepsis definitions: time for change</article-title>. <source>Lancet</source><year>2013</year>;<volume>381</volume>:<fpage>774</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">23472921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)61815-7</pub-id><pub-id pub-id-type="pmcid">PMC4535310</pub-id></mixed-citation></ref><ref id="R299"><label>[299]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Pascale</surname><given-names>G</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Deschepper</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis</article-title>. <source>Intens Care Med</source><year>2022</year>;<volume>48</volume>:<fpage>1593</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-022-06883-y</pub-id><pub-id pub-id-type="pmid">36151335</pub-id></mixed-citation></ref><ref id="R300"><label>[300]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartelli</surname><given-names>M</given-names></name></person-group>. <article-title>Evaluation and management of abdominal sepsis</article-title>. <source>Curr Opin Crit Care</source><year>2020</year>;<volume>26</volume>:<fpage>205</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">32004193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCC.0000000000000696</pub-id></mixed-citation></ref><ref id="R301"><label>[301]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coccolini</surname><given-names>F</given-names></name><name name-style="western"><surname>Sartelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Source control in emergency general surgery: WSES, GAIS, SIS-E, SIS-A guidelines</article-title>. <source>World J Emerg Surg</source><year>2023</year>;<volume>18</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">37480129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13017-023-00509-4</pub-id><pub-id pub-id-type="pmcid">PMC10362628</pub-id></mixed-citation></ref><ref id="R302"><label>[302]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallicelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Santandrea</surname><given-names>G</given-names></name><name name-style="western"><surname>Sartelli</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Sepsis team organizational model to decrease mortality for intra-abdominal infections: is antibiotic stewardship enough?</article-title><source>Antibiotics (Basel, Switzerland)</source><year>2022</year>:<volume>11</volume>:<fpage>1460</fpage>.<pub-id pub-id-type="pmid">36358115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics11111460</pub-id><pub-id pub-id-type="pmcid">PMC9687019</pub-id></mixed-citation></ref><ref id="R303"><label>[303]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>VX</given-names></name><name name-style="western"><surname>Fielding-Singh</surname><given-names>V</given-names></name><name name-style="western"><surname>Greene</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>The timing of early antibiotics and hospital mortality in sepsis</article-title>. <source>Am J Respir Crit Care Med</source><year>2017</year>;<volume>196</volume>:<fpage>856</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">28345952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201609-1848OC</pub-id><pub-id pub-id-type="pmcid">PMC5649973</pub-id></mixed-citation></ref><ref id="R304"><label>[304]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Im</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ko</surname><given-names>R-ER-E</given-names></name><etal/></person-group>. <article-title>Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study</article-title>. <source>Crit Care</source><year>2022</year>;<volume>26</volume>:<fpage>19</fpage>.<pub-id pub-id-type="pmid">35027073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03883-0</pub-id><pub-id pub-id-type="pmcid">PMC8756674</pub-id></mixed-citation></ref><ref id="R305"><label>[305]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooper</surname><given-names>GA</given-names></name><name name-style="western"><surname>Klippel</surname><given-names>CJ</given-names></name><name name-style="western"><surname>McLean</surname><given-names>SR</given-names></name><etal/></person-group>. <article-title>Concordance between initial presumptive and final adjudicated diagnoses of infection among patients meeting sepsis-3 criteria in the emergency department</article-title>. <source>Clinl Infect Dis</source><year>2023</year>;<volume>76</volume>:<fpage>2047</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciad101</pub-id><pub-id pub-id-type="pmcid">PMC10273369</pub-id><pub-id pub-id-type="pmid">36806551</pub-id></mixed-citation></ref><ref id="R306"><label>[306]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klompas</surname><given-names>M</given-names></name><name name-style="western"><surname>Calandra</surname><given-names>T</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name></person-group>. <article-title>Antibiotics for sepsis-finding the equilibrium</article-title>. <source>JAMA</source><year>2018</year>;<volume>320</volume>:<fpage>1433</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">30242350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.12179</pub-id></mixed-citation></ref><ref id="R307"><label>[307]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campion</surname><given-names>M</given-names></name><name name-style="western"><surname>Scully</surname><given-names>G</given-names></name></person-group>. <article-title>Antibiotic use in the intensive care unit: optimization and de-escalation</article-title>. <source>J Int Care Med</source><year>2018</year>;<volume>33</volume>:<fpage>647</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0885066618762747</pub-id><pub-id pub-id-type="pmid">29534630</pub-id></mixed-citation></ref><ref id="R308"><label>[308]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prout</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Talisa</surname><given-names>VB</given-names></name><name name-style="western"><surname>Carcillo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Decker</surname><given-names>BK</given-names></name><name name-style="western"><surname>Yende</surname><given-names>S</given-names></name></person-group>. <article-title>Bacterial and fungal etiology of sepsis in children in the United States: reconsidering empiric therapy</article-title>. <source>Crit Care Med</source><year>2020</year>;<volume>48</volume>:<fpage>e192</fpage>&#8211;<lpage>e9</lpage>.<pub-id pub-id-type="pmid">31789702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000004140</pub-id><pub-id pub-id-type="pmcid">PMC7875440</pub-id></mixed-citation></ref><ref id="R309"><label>[309]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zampieri</surname><given-names>FG</given-names></name><name name-style="western"><surname>Bagshaw</surname><given-names>SM</given-names></name><name name-style="western"><surname>Semler</surname><given-names>MW</given-names></name></person-group>. <article-title>Fluid therapy for critically ill adults with sepsis: a review</article-title>. <source>JAMA J Am Med Assoc</source><year>2023</year>;<volume>329</volume>:<fpage>1967</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.7560</pub-id><pub-id pub-id-type="pmid">37314271</pub-id></mixed-citation></ref><ref id="R310"><label>[310]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivers</surname><given-names>E</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B</given-names></name><name name-style="western"><surname>Havstad</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Early goal-directed therapy in the treatment of severe sepsis and septic shock</article-title>. <source>N Engl J Med</source><year>2001</year>;<volume>345</volume>:<fpage>1368</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">11794169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa010307</pub-id></mixed-citation></ref><ref id="R311"><label>[311]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>National Heart</surname><given-names>L</given-names></name><name name-style="western"><surname>Blood Institute</surname><given-names>P</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>NI</given-names></name></person-group><etal/>. <article-title>Early restrictive or liberal fluid management for sepsis-induced hypotension</article-title>. <source>N Engl J Med</source><year>2023</year>;<volume>388</volume>:<fpage>499</fpage>&#8211;<lpage>510</lpage>.<pub-id pub-id-type="pmid">36688507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212663</pub-id><pub-id pub-id-type="pmcid">PMC10685906</pub-id></mixed-citation></ref><ref id="R312"><label>[312]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pro</surname><given-names>CI</given-names></name><name name-style="western"><surname>Yealy</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kellum</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>A randomized trial of protocol-based care for early septic shock</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>370</volume>:<fpage>1683</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">24635773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1401602</pub-id><pub-id pub-id-type="pmcid">PMC4101700</pub-id></mixed-citation></ref><ref id="R313"><label>[313]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Investigators</surname><given-names>A</given-names></name><name name-style="western"><surname>Group</surname><given-names>ACT</given-names></name><name name-style="western"><surname>Peake</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Goal-directed resuscitation for patients with early septic shock</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>371</volume>:<fpage>1496</fpage>&#8211;<lpage>506</lpage>.<pub-id pub-id-type="pmid">25272316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1404380</pub-id></mixed-citation></ref><ref id="R314"><label>[314]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Evans</surname><given-names>LE</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name></person-group>. <article-title>The surviving sepsis campaign bundle: 2018 update</article-title>. <source>Intensive Care Med</source><year>2018</year>;<volume>44</volume>:<fpage>925</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">29675566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-018-5085-0</pub-id></mixed-citation></ref><ref id="R315"><label>[315]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Coston</surname><given-names>TD</given-names></name><etal/></person-group>. <article-title>Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial</article-title>. <source>Am J Respir Crit Care Med</source><year>2019</year>;<volume>200</volume>:<fpage>1487</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">31454263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201903-0557OC</pub-id><pub-id pub-id-type="pmcid">PMC6909845</pub-id></mixed-citation></ref><ref id="R316"><label>[316]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orbegozo Cort&#233;s</surname><given-names>D</given-names></name><name name-style="western"><surname>Gamarano Barros</surname><given-names>T</given-names></name><name name-style="western"><surname>Njimi</surname><given-names>H</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>J-L</given-names></name></person-group>. <article-title>Crystalloids versus colloids</article-title>. <source>Anesthesia Analg</source><year>2015</year>;<volume>120</volume>:<fpage>389</fpage>&#8211;<lpage>402</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000000564</pub-id><pub-id pub-id-type="pmid">25565318</pub-id></mixed-citation></ref><ref id="R317"><label>[317]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antal</surname><given-names>O</given-names></name><name name-style="western"><surname>Stefanescu</surname><given-names>E</given-names></name><name name-style="western"><surname>Mlesnite</surname><given-names>M</given-names></name><name name-style="western"><surname>Balan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hagau</surname><given-names>N</given-names></name></person-group>. <article-title>Initial fluid resuscitation following adjusted body weight dosing in sepsis and septic shock</article-title>. <source>J Crit Care Med (Targu Mures)</source><year>2019</year>;<volume>5</volume>:<fpage>130</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">31915718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2478/jccm-2019-0025</pub-id><pub-id pub-id-type="pmcid">PMC6942448</pub-id></mixed-citation></ref><ref id="R318"><label>[318]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>JN</given-names></name><name name-style="western"><surname>Reitz</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Time to treatment and mortality for clinical sepsis subtypes</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>236</fpage>.<pub-id pub-id-type="pmid">37322546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04507-5</pub-id><pub-id pub-id-type="pmcid">PMC10268363</pub-id></mixed-citation></ref><ref id="R319"><label>[319]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casserly</surname><given-names>B</given-names></name><name name-style="western"><surname>Read</surname><given-names>R</given-names></name><name name-style="western"><surname>Levy</surname><given-names>MM</given-names></name></person-group>. <article-title>Hemodynamic monitoring in sepsis</article-title>. <source>Critic Care Clin</source><year>2009</year>;<volume>25</volume>:<fpage>803</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccc.2009.08.006</pub-id><pub-id pub-id-type="pmid">19892254</pub-id></mixed-citation></ref><ref id="R320"><label>[320]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monnet</surname><given-names>X</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C</given-names></name><name name-style="western"><surname>Teboul</surname><given-names>J-LJ-L</given-names></name></person-group>. <article-title>How I personalize fluid therapy in septic shock?</article-title><source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>123</fpage>.<pub-id pub-id-type="pmid">36964573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04363-3</pub-id><pub-id pub-id-type="pmcid">PMC10039545</pub-id></mixed-citation></ref><ref id="R321"><label>[321]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouncey</surname><given-names>PR</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>TM</given-names></name><name name-style="western"><surname>Power</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Trial of early, goal-directed resuscitation for septic shock</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>372</volume>:<fpage>1301</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25776532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1500896</pub-id></mixed-citation></ref><ref id="R322"><label>[322]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early, goal-directed therapy for septic shock &#8211; a patient-level meta-analysis</article-title>. <source>N Engl J Med</source><year>2017</year>;<volume>376</volume>:<fpage>2223</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28320242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1701380</pub-id></mixed-citation></ref><ref id="R323"><label>[323]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>R</given-names></name><name name-style="western"><surname>Ram-Mohan</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group>. <article-title>Re-visiting humoral constitutive antibacterial heterogeneity in bloodstream infections</article-title>. <source>Lancet Infect Dis</source><year>2023</year>;<volume>24</volume>:<fpage>e245</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">37944543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(23)00494-2</pub-id></mixed-citation></ref><ref id="R324"><label>[324]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>FS</given-names></name><name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name></person-group>. <article-title>A new initiative on precision medicine</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>372</volume>:<fpage>793</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">25635347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp1500523</pub-id><pub-id pub-id-type="pmcid">PMC5101938</pub-id></mixed-citation></ref><ref id="R325"><label>[325]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankar-Hari</surname><given-names>M</given-names></name><name name-style="western"><surname>Rubenfeld</surname><given-names>GD</given-names></name></person-group>. <article-title>Population enrichment for critical care trials: phenotypes and differential outcomes</article-title>. <source>Curr Opin Crit Care</source><year>2019</year>;<volume>25</volume>:<fpage>489</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">31335383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCC.0000000000000641</pub-id></mixed-citation></ref><ref id="R326"><label>[326]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanski</surname><given-names>NL</given-names></name><name name-style="western"><surname>Wong</surname><given-names>HR</given-names></name></person-group>. <article-title>Prognostic and predictive enrichment in sepsis</article-title>. <source>Nat Rev Nephrol</source><year>2020</year>;<volume>16</volume>:<fpage>20</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">31511662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-019-0199-3</pub-id><pub-id pub-id-type="pmcid">PMC7097452</pub-id></mixed-citation></ref><ref id="R327"><label>[327]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knox</surname><given-names>DB</given-names></name><name name-style="western"><surname>Lanspa</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kuttler</surname><given-names>KG</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>SC</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SM</given-names></name></person-group>. <article-title>Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome</article-title>. <source>Intensive Care Med</source><year>2015</year>;<volume>41</volume>:<fpage>814</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25851384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-015-3764-7</pub-id><pub-id pub-id-type="pmcid">PMC4607311</pub-id></mixed-citation></ref><ref id="R328"><label>[328]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Identification of subphenotypes of sepsis-associated liver dysfunction using cluster ANALYSIS</article-title>. <source>Shock</source><year>2023</year>;<volume>59</volume>:<fpage>368</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">36562264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000002068</pub-id></mixed-citation></ref><ref id="R329"><label>[329]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>JN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis</article-title>. <source>JAMA</source><year>2019</year>;<volume>321</volume>:<fpage>2003</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">31104070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.5791</pub-id><pub-id pub-id-type="pmcid">PMC6537818</pub-id></mixed-citation></ref><ref id="R330"><label>[330]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>H</given-names></name><name name-style="western"><surname>Mo</surname><given-names>L</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y</given-names></name></person-group>. <article-title>Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis</article-title>. <source>Crit Care</source><year>2018</year>;<volume>22</volume>:<fpage>347</fpage>.<pub-id pub-id-type="pmid">30563548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-018-2279-3</pub-id><pub-id pub-id-type="pmcid">PMC6299613</pub-id></mixed-citation></ref><ref id="R331"><label>[331]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhavani</surname><given-names>SV</given-names></name><name name-style="western"><surname>Carey</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>ER</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>M</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>PA</given-names></name><name name-style="western"><surname>Churpek</surname><given-names>MM</given-names></name></person-group>. <article-title>Identifying novel sepsis subphenotypes using temperature trajectories</article-title>. <source>Am J Respir Crit Care Med</source><year>2019</year>;<volume>200</volume>:<fpage>327</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">30789749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201806-1197OC</pub-id><pub-id pub-id-type="pmcid">PMC6680307</pub-id></mixed-citation></ref><ref id="R332"><label>[332]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karakike</surname><given-names>E</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name></person-group>. <article-title>Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis</article-title>. <source>Front Immunol</source><year>2019</year>;<volume>10</volume>:<fpage>55</fpage>.<pub-id pub-id-type="pmid">30766533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00055</pub-id><pub-id pub-id-type="pmcid">PMC6365431</pub-id></mixed-citation></ref><ref id="R333"><label>[333]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leventogiannis</surname><given-names>K</given-names></name><name name-style="western"><surname>Kyriazopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Antonakos</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial</article-title>. <source>Cell Rep Med</source><year>2022</year>;<volume>3</volume>:<fpage>100817</fpage>.<pub-id pub-id-type="pmid">36384100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2022.100817</pub-id><pub-id pub-id-type="pmcid">PMC9729870</pub-id></mixed-citation></ref><ref id="R334"><label>[334]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>A targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<fpage>263</fpage>.<pub-id pub-id-type="pmid">37408042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-023-04552-0</pub-id><pub-id pub-id-type="pmcid">PMC10320874</pub-id></mixed-citation></ref><ref id="R335"><label>[335]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>HR</given-names></name><name name-style="western"><surname>Cvijanovich</surname><given-names>N</given-names></name><name name-style="western"><surname>Lin</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Identification of pediatric septic shock subclasses based on genome-wide expression profiling</article-title>. <source>BMC Med</source><year>2009</year>;<volume>7</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">19624809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1741-7015-7-34</pub-id><pub-id pub-id-type="pmcid">PMC2720987</pub-id></mixed-citation></ref><ref id="R336"><label>[336]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langley</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Tsalik</surname><given-names>EL</given-names></name><name name-style="western"><surname>van Velkinburgh</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>An integrated clinico-metabolomic model improves prediction of death in sepsis</article-title>. <source>Sci, Trans Med</source><year>2013</year>;<volume>5</volume>:<fpage>195ra95</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3005893</pub-id><pub-id pub-id-type="pmcid">PMC3924586</pub-id><pub-id pub-id-type="pmid">23884467</pub-id></mixed-citation></ref><ref id="R337"><label>[337]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davenport</surname><given-names>EE</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>KL</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study</article-title>. <source>Lancet Respir Med</source><year>2016</year>;<volume>4</volume>:<fpage>259</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26917434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(16)00046-1</pub-id><pub-id pub-id-type="pmcid">PMC4820667</pub-id></mixed-citation></ref><ref id="R338"><label>[338]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scicluna</surname><given-names>BP</given-names></name><name name-style="western"><surname>van Vught</surname><given-names>LA</given-names></name><name name-style="western"><surname>Zwinderman</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study</article-title>. <source>Lancet Respir Med</source><year>2017</year>;<volume>5</volume>:<fpage>816</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">28864056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(17)30294-1</pub-id></mixed-citation></ref><ref id="R339"><label>[339]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>TE</given-names></name><name name-style="western"><surname>Azad</surname><given-names>TD</given-names></name><name name-style="western"><surname>Donato</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters</article-title>. <source>Crit Care Med</source><year>2018</year>;<volume>46</volume>:<fpage>915</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">29537985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000003084</pub-id><pub-id pub-id-type="pmcid">PMC5953807</pub-id></mixed-citation></ref><ref id="R340"><label>[340]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodinier</surname><given-names>M</given-names></name><name name-style="western"><surname>Peronnet</surname><given-names>E</given-names></name><name name-style="western"><surname>Brengel-Pesce</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Monocyte trajectories endotypes are associated with worsening in septic patients</article-title>. <source>Front Immunol</source><year>2021</year>;<volume>12</volume>:<fpage>795052</fpage>.<pub-id pub-id-type="pmid">34912347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.795052</pub-id><pub-id pub-id-type="pmcid">PMC8667763</pub-id></mixed-citation></ref><ref id="R341"><label>[341]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shakoory</surname><given-names>B</given-names></name><name name-style="western"><surname>Carcillo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chatham</surname><given-names>WW</given-names></name><etal/></person-group>. <article-title>Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial</article-title>. <source>Crit Care Med</source><year>2016</year>;<volume>44</volume>:<fpage>275</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26584195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000001402</pub-id><pub-id pub-id-type="pmcid">PMC5378312</pub-id></mixed-citation></ref><ref id="R342"><label>[342]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coupet</surname><given-names>CA</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>C</given-names></name><name name-style="western"><surname>Evlachev</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Intravenous injection of a novel viral immunotherapy encoding human interleukin-7 in nonhuman primates is safe and increases absolute lymphocyte count</article-title>. <source>Hum Vaccin Immunother</source><year>2022</year>;<volume>18</volume>:<fpage>2133914</fpage>.<pub-id pub-id-type="pmid">36315906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2022.2133914</pub-id><pub-id pub-id-type="pmcid">PMC9746448</pub-id></mixed-citation></ref><ref id="R343"><label>[343]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnham</surname><given-names>KL</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>EE</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia</article-title>. <source>Am J Respir Crit Care Med</source><year>2017</year>;<volume>196</volume>:<fpage>328</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">28036233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201608-1685OC</pub-id><pub-id pub-id-type="pmcid">PMC5549866</pub-id></mixed-citation></ref><ref id="R344"><label>[344]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antcliffe</surname><given-names>DB</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>KL</given-names></name><name name-style="western"><surname>Al-Beidh</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial</article-title>. <source>Am J Respir Crit Care Med</source><year>2019</year>;<volume>199</volume>:<fpage>980</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">30365341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201807-1419OC</pub-id><pub-id pub-id-type="pmcid">PMC6467319</pub-id></mixed-citation></ref><ref id="R345"><label>[345]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>HR</given-names></name><name name-style="western"><surname>Hart</surname><given-names>KW</given-names></name><name name-style="western"><surname>Lindsell</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>TE</given-names></name></person-group>. <article-title>External corroboration that corticosteroids may be harmful to septic shock endotype a patients</article-title>. <source>Crit Care Med</source><year>2021</year>;<volume>49</volume>:<fpage>e98</fpage>&#8211;<lpage>e101</lpage>.<pub-id pub-id-type="pmid">33156120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000004709</pub-id><pub-id pub-id-type="pmcid">PMC7746624</pub-id></mixed-citation></ref><ref id="R346"><label>[346]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name></person-group>. <article-title>Deep learning-based clustering robustly identified two classes of sepsis with both prognostic and predictive values</article-title>. <source>EBioMedicine</source><year>2020</year>;<volume>62</volume>:<fpage>103081</fpage>.<pub-id pub-id-type="pmid">33181462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2020.103081</pub-id><pub-id pub-id-type="pmcid">PMC7658497</pub-id></mixed-citation></ref><ref id="R347"><label>[347]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meisel</surname><given-names>C</given-names></name><name name-style="western"><surname>Schefold</surname><given-names>JC</given-names></name><name name-style="western"><surname>Pschowski</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial</article-title>. <source>Am J Respir Crit Care Med</source><year>2009</year>;<volume>180</volume>:<fpage>640</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">19590022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.200903-0363OC</pub-id></mixed-citation></ref><ref id="R348"><label>[348]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacheron</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lepape</surname><given-names>A</given-names></name><name name-style="western"><surname>Venet</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: the GRID randomized controlled trial</article-title>. <source>J Crit Care</source><year>2023</year>;<volume>78</volume>:<fpage>154330</fpage>.<pub-id pub-id-type="pmid">37267804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2023.154330</pub-id></mixed-citation></ref><ref id="R349"><label>[349]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Ganzoury</surname><given-names>MM</given-names></name><name name-style="western"><surname>El-Farrash</surname><given-names>RA</given-names></name><name name-style="western"><surname>Saad</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>AG</given-names></name><name name-style="western"><surname>El-Sherbini</surname><given-names>IG</given-names></name></person-group>. <article-title>In vivo effect of recombinant human granulocyte colony-stimulating factor on neutrophilic expression of CD11b in septic neonates: a randomized controlled trial</article-title>. <source>Pediatr Hematol Oncol</source><year>2012</year>;<volume>29</volume>:<fpage>272</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">22475305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/08880018.2011.644880</pub-id></mixed-citation></ref><ref id="R350"><label>[350]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leentjens</surname><given-names>J</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M</given-names></name><name name-style="western"><surname>Koch</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study</article-title>. <source>Am J Respir Crit Care Med</source><year>2012</year>;<volume>186</volume>:<fpage>838</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">22822024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201204-0645OC</pub-id></mixed-citation></ref><ref id="R351"><label>[351]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial</article-title>. <source>Crit Care</source><year>2013</year>;<volume>17</volume>:<fpage>R8</fpage>.<pub-id pub-id-type="pmid">23327199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc11932</pub-id><pub-id pub-id-type="pmcid">PMC4056079</pub-id></mixed-citation></ref><ref id="R352"><label>[352]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Pei</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The efficacy and safety of thymosin &#945;1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial</article-title>. <source>Bmj</source><year>2025</year>;<volume>388</volume>:<fpage>e082583</fpage>.<pub-id pub-id-type="pmid">39814420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2024-082583</pub-id><pub-id pub-id-type="pmcid">PMC11780596</pub-id></mixed-citation></ref><ref id="R353"><label>[353]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francois</surname><given-names>B</given-names></name><name name-style="western"><surname>Jeannet</surname><given-names>R</given-names></name><name name-style="western"><surname>Daix</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial</article-title>. <source>JCI Insight</source><year>2018</year>:<volume>3</volume>:<fpage>e98960</fpage>.<pub-id pub-id-type="pmid">29515037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.98960</pub-id><pub-id pub-id-type="pmcid">PMC5922293</pub-id></mixed-citation></ref><ref id="R354"><label>[354]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotsaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>ImmunoSep (Personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol</article-title>. <source>BMJ Open</source><year>2022</year>;<volume>12</volume>:<fpage>e067251</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2022-067251</pub-id><pub-id pub-id-type="pmcid">PMC9772655</pub-id><pub-id pub-id-type="pmid">36600424</pub-id></mixed-citation></ref><ref id="R355"><label>[355]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>A phase II study of polyclonal anti-TNF-alpha (AZD9773) in Japanese patients with severe sepsis and/or septic shock</article-title>. <source>J Infect Chemother</source><year>2013</year>;<volume>19</volume>:<fpage>931</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">23681364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10156-013-0612-y</pub-id></mixed-citation></ref><ref id="R356"><label>[356]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leentjens</surname><given-names>J</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerretsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>. <article-title>The effects of orally administered beta-glucan on innate immune responses in humans, a randomized open-label intervention pilot-study</article-title>. <source>PLoS One</source><year>2014</year>;<volume>9</volume>:<fpage>e108794</fpage>.<pub-id pub-id-type="pmid">25268806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0108794</pub-id><pub-id pub-id-type="pmcid">PMC4182605</pub-id></mixed-citation></ref><ref id="R357"><label>[357]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlee</surname><given-names>D</given-names></name><name name-style="western"><surname>van Vught</surname><given-names>LA</given-names></name><name name-style="western"><surname>Scicluna</surname><given-names>BP</given-names></name><etal/></person-group>. <article-title>Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial</article-title>. <source>Stem Cells</source><year>2018</year>;<volume>36</volume>:<fpage>1778</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">30063804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/stem.2891</pub-id></mixed-citation></ref><ref id="R358"><label>[358]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntyre</surname><given-names>LA</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Mei</surname><given-names>SHJ</given-names></name><etal/></person-group>. <article-title>Cellular immunotherapy for septic shock. A phase i clinical trial</article-title>. <source>Am J Respir Crit Care Med</source><year>2018</year>;<volume>197</volume>:<fpage>337</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">28960096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201705-1006OC</pub-id></mixed-citation></ref><ref id="R359"><label>[359]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bengsch</surname><given-names>B</given-names></name><name name-style="western"><surname>Ohtani</surname><given-names>T</given-names></name><name name-style="western"><surname>Herati</surname><given-names>RS</given-names></name><name name-style="western"><surname>Bovenschen</surname><given-names>N</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K-M</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>EJ</given-names></name></person-group>. <article-title>Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns</article-title>. <source>J Immunol Methods</source><year>2018</year>;<volume>453</volume>:<fpage>3</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">28322863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jim.2017.03.009</pub-id><pub-id pub-id-type="pmcid">PMC5605401</pub-id></mixed-citation></ref><ref id="R360"><label>[360]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delano</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ward</surname><given-names>PA</given-names></name></person-group>. <article-title>Sepsis-induced immune dysfunction: can immune therapies reduce mortality?</article-title><source>J Clin Investig</source><year>2016</year>;<volume>126</volume>:<fpage>23</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">26727230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI82224</pub-id><pub-id pub-id-type="pmcid">PMC4701539</pub-id></mixed-citation></ref><ref id="R361"><label>[361]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fei</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Enhanced lactate accumulation upregulates PD-L1 expression to delay neutrophil apoptosis in sepsis</article-title>. <source>View</source><year>2023</year>:<volume>5</volume>:<fpage>20230053</fpage>.</mixed-citation></ref><ref id="R362"><label>[362]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The pathophysiology of sepsis and precision-medicine-based immunotherapy</article-title>. <source>Nat Immunol</source><year>2024</year>;<volume>25</volume>:<fpage>19</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">38168953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-023-01660-5</pub-id></mixed-citation></ref><ref id="R363"><label>[363]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>TREM2hi resident macrophages protect the septic heart by maintaining cardiomyocyte homeostasis</article-title>. <source>Nat Metab</source><year>2023</year>;<volume>5</volume>:<fpage>129</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">36635449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-022-00715-5</pub-id><pub-id pub-id-type="pmcid">PMC9886554</pub-id></mixed-citation></ref><ref id="R364"><label>[364]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Berghe</surname><given-names>G</given-names></name><name name-style="western"><surname>Teblick</surname><given-names>A</given-names></name><name name-style="western"><surname>Langouche</surname><given-names>L</given-names></name><name name-style="western"><surname>Gunst</surname><given-names>J</given-names></name></person-group>. <article-title>The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: gaps in current knowledge and future translational research directions</article-title>. <source>EBioMedicine</source><year>2022</year>;<volume>84</volume>:<fpage>104284</fpage>.<pub-id pub-id-type="pmid">36162206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104284</pub-id><pub-id pub-id-type="pmcid">PMC9519475</pub-id></mixed-citation></ref><ref id="R365"><label>[365]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandewalle</surname><given-names>J</given-names></name><name name-style="western"><surname>Timmermans</surname><given-names>S</given-names></name><name name-style="western"><surname>Paakinaho</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis</article-title>. <source>Cell Metab.</source><year>2021</year>;<volume>33</volume>:<fpage>1763</fpage>&#8211;<lpage>76.e5</lpage>.<pub-id pub-id-type="pmid">34302744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2021.07.002</pub-id></mixed-citation></ref><ref id="R366"><label>[366]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>PB</given-names></name><name name-style="western"><surname>Davis</surname><given-names>AM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J</given-names></name></person-group>. <article-title>Corticosteroids for sepsis, acute respiratory distress syndrome, or community-acquired pneumonia</article-title>. <source>JAMA J Am Med Assoc</source><year>2025</year>;<volume>333</volume>:<fpage>421</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.24537</pub-id><pub-id pub-id-type="pmid">39774599</pub-id></mixed-citation></ref><ref id="R367"><label>[367]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>B</given-names></name><name name-style="western"><surname>Finfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Adjunctive Glucocorticoid therapy in patients with septic shock</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>797</fpage>&#8211;<lpage>808</lpage>.<pub-id pub-id-type="pmid">29347874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1705835</pub-id></mixed-citation></ref><ref id="R368"><label>[368]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annane</surname><given-names>D</given-names></name><name name-style="western"><surname>Renault</surname><given-names>A</given-names></name><name name-style="western"><surname>Brun-Buisson</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Hydrocortisone plus fludrocortisone for adults with septic shock</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>809</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">29490185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1705716</pub-id></mixed-citation></ref><ref id="R369"><label>[369]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>T</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Belletti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: a systematic review and a component network meta-analysis</article-title>. <source>Intens Care Med</source><year>2022</year>;<volume>48</volume>:<fpage>16</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-021-06558-0</pub-id><pub-id pub-id-type="pmcid">PMC8724116</pub-id><pub-id pub-id-type="pmid">34750650</pub-id></mixed-citation></ref><ref id="R370"><label>[370]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis</article-title>. <source>JAMA Intern Med</source><year>2019</year>;<volume>179</volume>:<fpage>213</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">30575845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2018.5849</pub-id><pub-id pub-id-type="pmcid">PMC6439648</pub-id></mixed-citation></ref><ref id="R371"><label>[371]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uckun</surname><given-names>FM</given-names></name><name name-style="western"><surname>Orhan</surname><given-names>C</given-names></name><name name-style="western"><surname>Powell</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate rejuveinix (RJX)</article-title>. <source>Biomed Pharmacother</source><year>2021</year>;<volume>141</volume>:<fpage>111823</fpage>.<pub-id pub-id-type="pmid">34147902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111823</pub-id></mixed-citation></ref><ref id="R372"><label>[372]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: a randomized phase IIa trial</article-title>. <source>J Crit Care</source><year>2023</year>;<volume>76</volume>:<fpage>154294</fpage>.<pub-id pub-id-type="pmid">37116228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2023.154294</pub-id></mixed-citation></ref><ref id="R373"><label>[373]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Sulfide-modified nanoscale zero-valent iron as a novel therapeutic remedy for septic myocardial injury</article-title>. <source>J Adv Res</source><year>2024</year>;<volume>55</volume>:<fpage>145</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">36801383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2023.02.008</pub-id><pub-id pub-id-type="pmcid">PMC10770114</pub-id></mixed-citation></ref><ref id="R374"><label>[374]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xian</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of acupuncture as a complementary therapy for sepsis: a systematic review and meta-analysis</article-title>. <source>Acupuncture Med</source><year>2023</year>;<volume>41</volume>:<fpage>3</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/09645284221086288</pub-id><pub-id pub-id-type="pmid">35579024</pub-id></mixed-citation></ref><ref id="R375"><label>[375]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichacker</surname><given-names>PQ</given-names></name><name name-style="western"><surname>Parent</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalil</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis</article-title>. <source>Am J Respir Crit Care Med</source><year>2002</year>;<volume>166</volume>:<fpage>1197</fpage>&#8211;<lpage>205</lpage>.<pub-id pub-id-type="pmid">12403688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.200204-302OC</pub-id></mixed-citation></ref><ref id="R376"><label>[376]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Barochia</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Natanson</surname><given-names>C</given-names></name><name name-style="western"><surname>Eichacker</surname><given-names>PQ</given-names></name></person-group>. <article-title>The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death</article-title>. <source>Expert Opin Invest Drugs</source><year>2011</year>;<volume>20</volume>:<fpage>1555</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543784.2011.623125</pub-id><pub-id pub-id-type="pmcid">PMC3523300</pub-id><pub-id pub-id-type="pmid">21961576</pub-id></mixed-citation></ref><ref id="R377"><label>[377]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijlsma</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sadanandam</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>L</given-names></name></person-group>. <article-title>Molecular subtypes in cancers of the gastrointestinal tract</article-title>. <source>Nat Rev Gastroenterol Hepatol</source><year>2017</year>;<volume>14</volume>:<fpage>333</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">28400627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrgastro.2017.33</pub-id></mixed-citation></ref><ref id="R378"><label>[378]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Exploring disease axes as an alternative to distinct clusters for characterizing sepsis heterogeneity</article-title>. <source>Intensive Care Med</source><year>2023</year>;<volume>49</volume>:<fpage>1349</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">37792053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-023-07226-1</pub-id></mixed-citation></ref><ref id="R379"><label>[379]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Hao</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Relative adrenal insufficiency is a risk factor and endotype of sepsis &#8211; a proof-of-concept study to support a precision medicine approach to guide glucocorticoid therapy for sepsis</article-title>. <source>Front Immunol</source><year>2022</year>;<volume>13</volume>:<fpage>1110516</fpage>.<pub-id pub-id-type="pmid">36713379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1110516</pub-id><pub-id pub-id-type="pmcid">PMC9878847</pub-id></mixed-citation></ref><ref id="R380"><label>[380]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alp</surname><given-names>E</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Gundogan</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock: a promising therapy</article-title>. <source>Emerg Med Int</source><year>2022</year>;<volume>2022</volume>:<fpage>9222379</fpage>.<pub-id pub-id-type="pmid">35784641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/9222379</pub-id><pub-id pub-id-type="pmcid">PMC9249540</pub-id></mixed-citation></ref><ref id="R381"><label>[381]</label><mixed-citation publication-type="book"><article-title>Advanced mesenchymal enhanced cell therapy for SepTic patients</article-title><publisher-loc>(AMETHYST)</publisher-loc>: <publisher-name>ClinicalTrials.gov</publisher-name>; <year>2023</year><comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04961658?cond=%20sepsis%26intr=MSCs%20treatment%26aggFilters=studyType:int%26rank=3#collaborators-and-investigators" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04961658?cond=%20sepsis&amp;intr=MSCs%20treatment&amp;aggFilters=studyType:int&amp;rank=3#collaborators-and-investigators</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>